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Pre-mRNA splicing is catalyzed by the spliceosome, a highly dynamic, 
macromolecular RNP complex formed out of the U1, U2, U4, U5 and U6 snRNPs 
and multiple snRNP proteins. Spliceosomes are assembled stepwise on an intron 
and they can initially form across an exon, generating a cross exon A-like complex 
if the length of the intron separating the 5' and 3' splice sites is very long, or 
alternatively across an intron, yielding an A complex if this distance is short. During 
the early stages of spliceosome assembly, the 5’ splice site is first bound by the U1 
snRNP and subsequently, during A complex formation, the branch point sequence 
(BPS) of the intron is recognized and bound by the U2 snRNP. In the subsequent 
step the U4/U6.U5 tri-snRNP docks generating the pre-B complex and after its 
stable integration, the pre-catalytic B complex is formed. In the following steps, the 
spliceosome undergoes compositional and structural rearrangements leading to its 
catalytic activation and then catalysis of the pre-mRNA splicing reaction. SF3b is a 
heptameric subunit of the U2 snRNP that is required for the stable base pairing of 
the U2 snRNA with the BPS during A complex assembly, and it plays a key role in 
the recognition and selection of the branch site adenosine. The U2/BPS helix is 
clamped, and thereby stabilized, within the C-terminal HEAT domain of SF3b1, the 
largest protein of the SF3b complex. SF3b1, together with the SF3b subunit PHF5A, 
form the binding pocket for the branch site adenosine, the nucleophile for the first 
catalytic step of splicing. 
SF3b1 is a target of many natural pre-mRNA splicing inhibitors, including 
Pladienolide B (PlaB), that also exhibit anti-tumor activity and lead to changes in 
alternative splicing patterns. PlaB stalls spliceosome assembly prior to the formation 
of a pre-catalytic B complex but currently the exact mechanism responsible for this 
stalling and the effect of PlaB on the structure and composition of the spliceosome 
are unknown. To investigate this, I analyzed spliceosome assembly in HeLa nuclear 
extract in the presence of PlaB. I could show that PlaB does not affect the kinetics 
of cross-intron A complex formation, but prevents the subsequent docking of the tri-
snRNP and thus blocks the formation of a pre-B complex. I could also show that 
cross-exon A-like complexes form in the presence of PlaB, but that the subsequent 






complexes formed in the presence of PlaB are less stable, dissociating more readily 
in the presence of heparin. To investigate the basis for these changes, I affinity 
purified cross-intron A complexes stalled by PlaB and investigated their proteome 
by mass spectrometry. Compared to wild-type A complexes, the PlaB stalled 
complexes contained increased amounts of the helicase DDX42, which was 
proposed to play a role in the biogenesis of the 17S U2 snRNP, and reduced 
amounts of SPF30. As SPF30 was previously shown to be required for tri-snRNP 
incorporation into the spliceosome, its absence could contribute to the lack of tri-
snRNP recruitment to the PlaB stalled A complexes. Initial attempts to obtain a high 
resolution structure of the PlaB stalled A complex and, for comparison, the wild-type 
human A complex, by performing cryo-EM were not successful. Thus, future studies 
will be needed to determine what effect PlaB has on the structure of the 
spliceosome.  
Point mutations in the SF3b1 HEAT domain, including the exchange of the lysine at 
amino acid 700 with glutamic acid (K700E), are linked to various cancers and lead 
to the utilization of alternative branch sites and 3' splice sites in vivo. The exact 
mechanism responsible for these changes in alternative splicing is currently 
unknown. To investigate the consequences of cancer-linked SF3b1 mutations on 
splicing, I first analyzed their effects on the 17S U2 snRNP, using K562 cells 
expressing FLAG-tagged, wild-type (wt) SF3b1 or the SF3b1K700E mutant. 
Interestingly, affinity purification of human 17S U2 snRNPs containing SF3b1K700E, 
followed by mass spectrometry and immunoblotting, revealed the nearly complete 
absence of the U2-associated DEAD-box helicase hPrp5 and a significant reduction 
in the abundance of the hTAT-SF1 protein, compared to 17S U2 snRNPs containing 
wt SF3b1. Protein-protein crosslinking of 17S U2 snRNPs revealed crosslinks 
between the SF3b1 HEAT domain and hPrp5, consistent with the idea that 
conformational changes due to the K700E mutation may directly affect Prp5 binding 
to the U2 snRNP. As hPrp5 plays a key role in the stable binding of U2 during A 
complex formation, its absence may directly lead to alterations in BPS selection by 
U2 containing SF3b1K700E. Initial experiments also showed that the mutant, FLAG-
tagged 17S U2 snRNPs are incorporated into spliceosomal A complexes, indicating 
that they are still functional, and that it may be possible to isolate A complexes 






Finally, I set out to establish in vitro splicing conditions that recapitulate the use of 
alternative BPS and 3' splice sites in cells expressing SF3b1K700E that is observed 
in vivo, in order to study in detail the effect of this mutation on splice site selection. 
I first tested the splicing of ZDHHC16 pre-mRNA containing a cryptic branch site 
and 3' splice site in nuclear extract from wt and SF3b1K700E K562 cells; however, 
spliceosome assembly was stalled at the A complex stage. As an alternative to 
cross-intron splicing, I designed exon RNA substrates with regions of the introns of 
ZDHHC16, TMEM14C or ENOSF1 that contain cryptic branch sites and 3' splice 
sites that are used in the presence of SF3b1K700E in vivo. All tested RNAs supported 
cross-exon A-like formation in both HeLa and K562 nuclear extracts, albeit very 
inefficiently in K562 nuclear extract. Unexpectedly, exon complex formation on the 
cryptic branch sites of these substrates, upon mutation of the canonical BPS, was 
not dependent on the presence of SF3b1K700E. Nonetheless, these in vitro studies 
lay the groundwork for future investigation of the composition and structure of 
splicing complexes containing the SF3b1K700E mutation. Taken together, my studies 
provide new insights into the mechanism whereby the SF3b1 modulator PlaB 
potentially leads to a block in spliceosome assembly, and also into the effects of 
SF3b1 cancer-related mutations on the composition of the 17S U2 snRNP. They 
also pave the way for future in vitro studies to improve our understanding of how 
alternative branch site usage arises as a consequence of single amino acid 
substitutions in SF3b1, and thus potentially aid our understanding of how SF3b1 













The central dogma of molecular biology defines the flow of genetic information from 
DNA via messenger RNA (mRNA) to protein. First, the DNA is transcribed into RNA 
during the process called transcription; in the subsequent step, translation, the RNA 
is translated into a protein with the corresponding amino acid sequence. While this 
dogma holds true for prokaryotes, the genomic organization of eukaryotic organisms 
makes additional steps necessary to translate genetic information into proteins. 
Eukaryotic genes are discontinuous; the coding information (exons) is separated by 
non-coding elements, the introns. Transcription in eukaryotes produces a premature 
messenger RNA transcript (pre-mRNA) that must undergo multiple processing steps 
prior to translation. The most complicated maturation step is the removal of introns 
and joining of exons, which is known as pre-mRNA splicing. Pre-mRNA splicing is 
a complex process governed by a macromolecular ribonucleoprotein complex called 
the spliceosome. The spliceosome identifies the exon-intron boundaries and joins 
the two exons flanking an intron while simultaneously removing the intron.  
 
1.1 Pre-mRNA processing 
Eukaryotic RNA-polymerase II transcripts undergo extensive co- and post-
transcriptional modifications in addition to the removal of introns, before being 
exported into the cytoplasm for translation (Kelly and Corbett, 2009). The first 
modification is the addition of a N7-methylguanosine (m7G-cap) to the 5’ end of the 
growing transcript by formation of a 5’-5’ triphosphate bridge and 2’O-methylation of 
the first two pre-mRNA nucleotides. The capping of pre-mRNA is required for the 
nuclear export mechanism and to protect the RNA from degradation by 5’-3’ 
exonucleases. After transcription, the 3’ end of the pre-mRNA is cleaved, and a 
poly(A)-tail is added; it increases the stability of the pre-mRNA and later helps 
initiate the translation of the pre-mRNA into proteins (Jackson and Standart, 1990). 
In addition to these modifications at the 5’ and 3’ end of the RNA molecule, the 
intronic sequences of the transcribed gene are removed by pre-mRNA splicing. The 
process of pre-mRNA splicing takes place during and after transcription of the RNA 
molecule and has to be completed prior to nuclear export. Splicing of pre-mRNA 







1.2 Identification of splice sites 
The most important step to ensure a precise and reproducible outcome of intron 
removal is the correct identification of splice sites within the introns. The analysis of 
the pre-mRNA transcriptome of various organisms has led to the identification of 
short conserved cis-acting motives within the introns that are recognized by the 
spliceosome (Burge et al., 1999). These elements can be found near the exon-intron 
junctions and they are required for the identification of splice sites by the 
spliceosome. They are known as the 5’ splice site (5’SS), the branch point sequence 
(BPS) and the 3’ splice site (3’SS) (Figure 2.1). Unlike yeast, higher eukaryotes also 
contain a polypyrimidine tract located between the BPS and the 3’SS.  
 
Figure 1.1- Scheme of a human pre-mRNA. The 5’ exon is displayed in blue and the 3’ exon is in red. Indicated 
are the important recognition sites for spliceosome assembly with their respective consensus sequences: the 5’ 
splice site (5’SS), the 3’ splice site (3’SS), the branch point sequence (BPS) with the branch point (marked in 
blue) and the poly-pyrimidine tract between BPS and 3’SS. 
The 5’SS defines the border between the 5’ exon and the downstream intron and 
has a consensus sequence of AG|GURAGU (“|” marks the 3’ end of the exon) in 
Homo sapiens. The 3’SS defining the border between the intron and the 
downstream exon has a sequence of CAG| or UAG| (“|” marks the 5’ end of the 
exon). The consensus sequence for the branch point region in human pre-mRNAs 
is defined as YNYURAC (underlined adenosine nucleotide acts as a branch point). 
The branch point is commonly found between 18 and 40 nucleotides upstream of 
the designated 3’SS. As mentioned earlier, in humans, a polypyrimidine rich region 
known as the pY-tract is found between the branch point and the 3’SS; it is used as 
an additional interaction region for spliceosomal factors and aids in spliceosome 
assembly. 
The cis-acting elements required for splicing of pre-mRNAs show different degrees 
of sequence conservation (Table 2.1). While in Saccharomyces cerevisiae the 
sequences of the individual elements are precisely defined, these sequences in 






classical introns, which are spliced by the major spliceosome (U1/U2 type), higher 
eukaryotes also contain a small subset of introns (~1%) that possess different, more 
highly conserved consensus sequences (Table 2.1). These introns are recognized 
and spliced-out by a second, so-called minor spliceosome (U11/U12-type) (Hall and 
Padgett, 1994, 1996; Patel and Steitz, 2003). 
Table 1.1 – Splice site consensus sequences for yeast and higher eukaryotes.  
 Higher eukaryotes Yeast 
 U2-type U12-type U2-type 






YNYURAC UCCUUAAC UACUAAC 





1.3 Chemical mechanism of pre-mRNA splicing 
All pre-mRNA introns are removed via the same two-step transesterification 
reactions (Figure 2.2) (Moore and Sharp, 1993). The process of pre-mRNA splicing 
itself does not require any external energy input. However, the rearrangements of 
the spliceosomal components require energy in the form of ATP, making the overall 
process ATP-dependent. The first step of splicing is the nucleophilic attack of the 
branch point adenosine (BPA) 2’ hydroxyl-group on the phosphate of the terminal 
exonic nucleotide. This creates a free 5’ exon and an intron lariat. The intron lariat 
is formed due to the creation of 2’-5’ phosphodiester bond between the first intronic 
nucleotide (a guanine) and the BPA. During the second step, the now free 3’ OH 
group of the 5’ exon performs a nucleophilic attack on the phosphate group of the 
last intronic nucleotide. This creates a new phosphodiester bond between the last 
nucleotide of the 5’ exon and the first nucleotide of the 3’ exon while simultaneously 
releasing the intron lariat. The intron lariat is subsequently degraded while the 







Figure 1.2 – Schematic representation of the two-step splicing reaction. The chemical process of pre-
mRNA splicing is divided into two transesterification reactions in which the 5’ exon is first disconnected from the 
intron and then ligated with the 3’ exon while the intron lariat is removed. 
 
1.4 Stepwise assembly of the human spliceosome 
Spliceosome formation activation and catalytic action is a multistep process 
involving the assembly and disassembly of various complexes as well as precise 
RNP remodeling events. During these assembly events, multiple distinct 
spliceosomal complexes can be identified based on biochemical and structural data. 
The E, A, pre-B, B, Bact, B*, C, C* and P spliceosomal complexes are formed (in this 
order) during the splicing cycle (Will and Luhrmann, 2011). During the activation 
stage, the catalytic center of the spliceosome is formed and subsequently both 
transesterification reactions are carried out, as described above. After splicing 
catalysis, the individual components are recycled to be used in a new assembly 
cycle. The transitions between the various stages are mediated by energy-







Figure 1.3 – Stepwise assembly, catalytic activation and actalytic activity pathway of the spliceosome 
during splicing. The splicing of pre-mRNA begins with the association of U1 and U2 with the pre-mRNA. After 
formation of the A complex the tri-snRNP is bound and the B complex is formed. Then the U1 and U4 snRNAs 
and associated proteins are removed to form the activated B complex (Bact). Further structural rearrangements 
form the catalytically activated B* complex that can then complete the first step of splicing giving rise to the C 
complex. The C complex is then rearranged for the second step of splicing (C*). Once the second step is 
completed the spliceosome is disassembled and the individual components are recycled. 
The assembly of the spliceosome begins with the recognition of the 5’SS and the 
BPS/3’SS region. In the spliceosomal E complex the 5’SS is recognized by the U1 
snRNP (Figure 2.3). During this recognition process, the U1 snRNA base pairs with 
the intron nucleotides immediately downstream of the 5’SS. The U1/5’SS interaction 
is stabilized by the U1-70K protein and U1-C proteins (Heinrichs et al., 1990; Kohtz 
et al., 1994). In parallel, the BPS region is recognized by the branch point binding 
protein (BBP), whereas U2AF65 associates with the poly-pyrimidine tract and 
U2AF35 with the 3’SS. At this stage, the U2 snRNP is also loosely associated. 
During A complex formation the U2 snRNP displaces the BBP and now stably binds 
the branch point region. U2 snRNA base pairs with the pre-mRNA forming the 
U2/BPS helix. Additionally, multiple SF3a and SF3b proteins of the U2 snRNP make 
contacts with the pre-mRNA and stabilize the U2 binding (Gozani et al., 1996). For 






adenosine (Gozani et al., 1998). The branch point adenosine itself is contacted by 
the SF3b6 (SF3b14a) protein (Will et al., 2001). Besides interacting with the pre-
mRNA, SF3b1 also contacts the U2AF65 protein, which is bound to the 
polypyrimidine tract (Gozani et al., 1998). At this stage, multiple proteins interact 
with their binding sites on the pre-mRNA and/or other spliceosomal proteins, forming 
the aforementioned network of protein-RNA and protein-protein interactions 
necessary for the high fidelity of the splice site selection. 
The U5.U4/U6 tri-snRNP first binds loosely to the A complex and a pre-B complex 
results (Boesler et al., 2016). Upon stable association of the tri-snRNP with the 
spliceosome, the B complex is formed (Figure 2.3). During the association of the tri-
snRNP, the helicase Prp28 destabilizes the interactions between U1 and the 5’SS, 
thereby enabling the interaction of the U6 ACAGA box with the 5’SS (Staley and 
Guthrie, 1999). During this process, the kinase Prp4 phosphorylates the tri-snRNP-
associated factors Prp31 and Prp6, and the SF3b1 protein is hyper-phosphorylated 
by an unknown kinase. These phosphorylations are required for the splicing 
progression (Girard et al., 2012; Schneider et al., 2010a). During the next 
remodeling event of the spliceosome, catalyzed by Brr2 helicase, the U4 snRNP is 
removed from the B complex. In parallel, multiple Bact associated proteins are 
recruited and major structural remodeling events in the RNA-RNA network take 
place forming the activated B complex (Bact). Then Prp2 further remodels the 
spliceosome, creating the B* complex containing the catalytic center required for the 
first transesterification reaction. After completion of the first step of splicing, the C 
complex is formed, which contains the products of the first step of splicing, the free 
5’ exon and the intron lariat-3’exon. With the help of Prp16, the C complex can be 
rearranged into the C* complex that catalyzes the second step of splicing. During 
the second step of splicing, the 5’ and 3’ exons are ligated, and the intron lariat is 
excised. The second step of splicing results in the formation of the post-catalytic 
spliceosome, which is then disassembled by Prp22, resulting in the release of the 
mRNA and of the intron lariat bound to the remaining U snRNPs. The U snRNPs 







1.5 Exon definition 
Recent studies have shown that the average size of an intron is in the range of 5400 
nucleotides compared to the much smaller exons with an average size of 170 
nucleotides (Sakharkar et al., 2004). The initial assembly of spliceosomes across 
individual introns (Figure 2.4), a process known as intron definition, is limited to 
introns shorter than 300 nucleotides (Sterner et al., 1996). Pre-mRNA introns that 
exceed this length utilize an alternative pathway called exon definition, in which the 
first spliceosomal complex forms across a comparably short exon (Berget, 1995). 
The assembly of a cross-exon complex starts with the base pairing of the U1 snRNA 
to the 5’SS downstream of an exon, while the U2 snRNP interacts with the BPS and 
U2AF with the 3’SS located upstream of the exon (Figure 2.4). This process defines 
the 5’ and 3’ borders of an exon (hence the name exon definition) instead of an 
intron. Enhancer and silencing elements within the exon can also influence this 
recruitment process by allowing SR proteins and hnRNPs to interact with their 
respective ESE or ESS sequences. This regulation of spliceosome assembly at the 
stage of exon complex formation most likely has an impact on alternative splicing. 
 
 
Figure 1.4 – Splicing of pre-mRNAs after cross-intron or cross-exon assembly of the spliceosome. 
Spliceosome assembly can take place via formation of a cross-intron A complex or by assembling a cross-exon 
A-like complex. Both complexes then recruit the tri-snRNP and form the pre-B or cross-exon complex 
respectively. Once formed the cross-exon complex can interact with the upstream 5’SS and transition into the 






for the upstream exons and red for the downstream exon. The introns are indicated as black line and various U 
snRNPs are shown as colored circles. 
In order for a cross-exon complex to take part in pre-mRNA splicing, a transition into 
a cross-intron complex must take place because the catalytic steps of splicing can 
only occur in this complex. Previous studies indicate that the cross-exon complex 
can convert into the cross-intron complex by the recruitment of an upstream 5’SS, 
leading to the pairing of cross-intron splice sites (Schneider et al., 2010b). This 
means that the cross-intron and the cross-exon assembly of the spliceosome 
converge into one common pathway during the B complex stage (Figure 2.4). 
 
1.6 The spliceosome and its building blocks 
The precise identification of exon-intron borders and the correct ligation of individual 
exons is crucial for the cell viability to prevent the formation of aberrant gene 
products. Even small errors in splicing can have significant consequences for the 
cell by introducing frameshift mutations into the mRNA or by including/ excluding 
sequences in the spliced mRNA. The cis-acting sequences defining the exact 
position of splicing sites on pre-mRNAs are relatively short and only weakly 
conserved in higher eukaryotes. Therefore, these sequences are not sufficient to 
specify splice sites with the required fidelity on their own nor do they allow for the 
juxtapositioning of the reactive nucleotides for catalysis. Instead, additional trans-
acting components are needed to increase the overall fidelity of the splicing process 
by recognition of different cis-acting elements and to achieve the three dimensional 
RNA architecture required for splicing (Will and Luhrmann, 2011). These trans-
acting factors can be grouped into the U snRNPs and non-U snRNP proteins. 
1.6.1 Uridine-rich small nuclear ribonucleoproteins 
The spliceosome is a multi-megadalton RNA/protein (RNP) assembly that 
undergoes major structural changes during the splicing cycle, which are 
accompanied by significant changes in its protein and RNA composition. The major 
spliceosome consists of five U snRNPs (U1, U2, U4, U5 and U6) that interact with 
the pre-mRNA during the splicing cycle. Each snRNP contains a uridine-rich snRNA 
that acts as a binding platform for multiple different interacting proteins. The minor 






five U snRNPs; however, except for U5, it contains a different set of U snRNPs (U11, 
U12, U4atac, U5 and U6atac) with analogous functions to their counterparts found in 
the major spliceosome. The snRNA molecules of the snRNPs adopt defined three 
dimensional structures (Figure 2.5), which act as interaction sites for different RNA-
binding proteins and also base pair with nucleotides of the 5’ splice site and BPS 
(see below). The structures of the individual snRNAs are highly conserved but they 
undergo significant changes during the splicing process. The most notable 
secondary structure formed by the snRNAs is the U4/U6 snRNA duplex. U4 and U6 
snRNA share two regions of complementarity, the stem I and stem II, and thereby 
form a di-snRNP via base pairing (Brow and Guthrie, 1988). 
 
Figure 1.5- Sequence and structure of the human spliceosomal snRNAs. Sm protein binding sites are 






The U1, U2, U4 and U5 snRNAs all contain a so called Sm-site (Figure 2.5). These 
RNAs are synthesized by the RNA polymerase II and initially contain an m7G-cap. 
During maturation, they are exported to the cytoplasm. Here the Sm-proteins B, D1, 
D2, D3, E, F and G bind the uridine-rich Sm-site, forming a ring. Once the Sm-ring 
is formed, the m7G undergoes hypermethylation to the 2, 2, 7 tri-methyl-guanosine-
cap and the 3’ end of the RNA molecule is trimmed (Mattaj, 1986). The formation of 
the Sm-ring and the hypermethylation of the 5’-cap induce nuclear re-import of the 
snRNAs. In the nucleus, the remaining snRNA-associated proteins interact with their 
respective binding sites on the RNA and the mature snRNP is formed. The U6 
snRNA in contrast is transcribed by RNA polymerase III and does not contain a Sm-
site. Instead, the LSm proteins 2-8 assemble into a ring-like structure by binding to 
a uridine stretch at the 3’ end of the RNA (Achsel et al., 1999). The 5’ end of the U6 
snRNA contains a -monomethyl cap, as a result of the transcription by RNA 
polymerase III. The maturation of U6 snRNA is completed entirely within the nucleus 
of the cell (Mroczek and Dziembowski, 2013). 
 
Figure 1.6 – Protein composition of the human U snRNPs. Spliceosomal snRNPs are represented as colored 
circles with their sedimentation value (Svedberg units) indicated above. The snRNA structure and the individual 
associated protein composition is depicted underneath, with colored boxes indicating the origin of the proteins 






As mentioned above, each of the U snRNAs adopts a three-dimensional fold and 
interacts with a specific set of proteins in addition to the Sm-/LSm-ring proteins 
(Figure 2.6). For instance, the U1 snRNA interacts with three additional proteins, 
U1-70K, U1-A and U1-C. The 17S U2 snRNP is comprised of U2A’ and U2B’’ and 
the two heterologous protein complexes SF3a and SF3b. SF3a is comprised of 3 
proteins (SF3a1, SF3a2 and SF3a3) whereas SF3b contains seven proteins (Will 
and Lührmann, 2002). Proteins in both complexes help the U2 snRNP to recognize 
and select the correct BPS. Additional proteins associated with the 17S U2 particle 
are hPrp43, SPF45, SPF30, SR140, CHERP, PUF60, hPrp5, hTAT-SF1 and 
U2AF1/U2AF2 (Will and Lührmann, 2002). The U5 snRNP contains eight proteins 
(hPrp8, hBrr2, hSnu114, hPrp6, hPrp28, hLin1, 40K and hDib1) (Bach et al., 1989) 
and it is responsible for tethering of the 5’SS and the 3’SS after the first step of 
splicing, bringing the two exons into proximity for the second step of splicing 
(Newman, 1997). Prp8 is the largest snRNP protein of the spliceosome and acts as 
a scaffold for the catalytic RNA network in the spliceosome (Fica et al., 2017; Galej 
et al., 2016; Nguyen et al., 2015; Nguyen et al., 2016). hPrp28 and Brr2 are two 
DExD/H-helicase helicases that are required for the formation of the pre-catalytic 
spliceosome and the subsequent rearrangements leading to an activated 
spliceosome (see chapter 2.9) (Boesler et al., 2016; Mathew et al., 2008; Möhlmann 
et al., 2014; Price et al., 2014). The activity of hBrr2 is regulated by the U5-
associated proteins hPrp8 and hSnu114 (Mozaffari-Jovin et al., 2012; Mozaffari-
Jovin et al., 2014; Small et al., 2006). 
The U4 and U6 snRNP do not exist as individual snRNP particles but are found as 
parts of the U4/U6 di- or U4/U6.U5tri-snRNP. The U4/U6 di-snRNP contains five 
different proteins, hPrp3, hPrp31, hPrp4, CypH and 15.5K (Behrens and Luhrmann, 
1991; Lauber et al., 1997). The tri-snRNP is formed after association of the U5 
snRNP with the di-snRNP, and it contains all proteins previously associated with the 
di-snRNP, excluding hLin1. The tri-snRNP also recruits three additional proteins 
(hSnu66, hSad1, 27K) that were not part of either the di-snRNP or U5 snRNP 
(Behrens and Luhrmann, 1991). The U5 protein hPrp6 and the di-snRNP associated 
protein hPrp31 play an important role in the formation of the tri-snRNP, as depletions 
of either protein prevent its formation in vivo and in vitro (Makarova et al., 2004; 






in the mature tri-snRNP are exclusively based on protein-protein contacts, no 
interactions between the snRNA molecules are known. 
 
1.7 The RNA network of the spliceosome 
The pre-mRNA splicing is catalyzed by an active center of the spliceosome entirely 
comprised of RNA molecules. This active center remains largely unchanged for the 
first and second catalytic step of splicing. In order to form the active center, 
extensive re-organizations in the pre-mRNA-snRNA and snRNA-snRNA network of 
the spliceosome are required (Wahl et al., 2009; Will and Luhrmann, 2011). The first 
RNA-RNA interaction formed during the splicing reaction is the base pairing of the 
U1 snRNA with the 5’ splice site. During U2 binding, the so-called U2/branch point 
helix is formed, between the 5’ end of the U2 snRNA and the BPS of the intron, and 
the branch point adenosine is bulged out. The next step is the recruitment and 
integration of the tri-snRNP to form a pre-B complex. During integration of the tri-
snRNP, the 3’ end of U6 snRNA forms a short helical structure with the 5’ end of the 
U2 snRNA (U2/U6 helix II) (Nilsen, 1994). The U4/U6 RNA interactions remain 
largely unchanged at this stage; they still interact via the stem I and stem II regions 
of complementarity (Brow and Guthrie, 1988).  
The spliceosomal RNAs and group II self-splicing introns contain multiple shared 
structural motives and act via the same chemical reaction mechanism. Comparing 
the structure of the RNA in the catalytic center of the spliceosome with the group II 
self-splicing RNAs reveals that both form a similar catalytic center (Toor et al., 2008). 
However, the catalytic RNA structure of the spliceosome only forms in the presence 
of proteins that stabilize the RNA-RNA interactions required for catalysis. To form 
the active center of the spliceosome required for the first step of the splicing reaction 
to occur, major remodeling events within the RNA structure of the spliceosome must 
take place. The U1 snRNA/pre-mRNA interaction is disrupted and the U6 snRNA 
forms base pairs near the 5’SS via its ACAGAGA-box (Staley and Guthrie, 1999). 
After U6 base pairs with the 5’ SS, the U4/U6 duplex is disrupted by Brr2 and the 
U4 snRNP is displaced from the spliceosome. Once U4 is displaced, U2 and U6 
snRNA interact to form new base-paired helices (Ia and Ib). The interactions 






dimensional RNA structure crucial for catalysis (Fica et al., 2013). The U6 snRNA 
also forms a new internal stem-loop (ISL) upon dissociation of the U4/U6 snRNA 
dimer. The ISL is required to coordinate the two magnesium ions needed for 
catalysis (Yean et al., 2000). This formation of essential components of the catalytic 
center after removal of the U4 snRNA suggests a regulatory function for the U4 
snRNA; the U4/U6 RNA interactions could prevent premature formation of the active 
center. The U5 snRNA interacts with both the 5’ and the 3’ exons during catalysis 
and these interactions keep the two exons in close proximity for exon ligation during 
the second step of splicing (Sontheimer and Steitz, 1993).  
 
Figure 1.7 – Changes in the spliceosomal RNA network during pre-mRNA splicing. Schematic 
representation of the dynamic changes in the spliceosomal RNA network during splicing. In the A complex, the 
U1 snRNA base pairs with the 5’ splice site (light blue) and the U2 snRNA forms the branch point helix with the 






snRNP, the U2 snRNA and the U6 snRNA form contacts via base pairing in the helix II (green). After Prp28 
displaces U1 the U6 ACAGAG base pairs with the 5’SS (orange). To form the step I catalytically activated 
spliceosome, U4 is displaced; the base pairing between U4 and U6 is disrupted, allowing U6 snRNA to form an 
internal stem-loop (ISL). The removal of the U4 snRNA also allows additional interactions between U6 and the 
U2 snRNA in the form of helices Ia and Ib. In addition to interactions with the U6 snRNA, the U2 snRNA remains 
in contact with the branch point region of the pre-mRNA. After the completion of the first step of splicing, internal 
rearrangements reposition the 5’ and 3’ exon into the catalytic center for the second step. The pre-mRNA exons 
are depicted as black boxes and the intron is represented by a grey line. Relative distances and sizes are not 
to scale. 
1.8 Protein composition of the spliceosome 
Most of the spliceosome’s mass can be attributed to proteins. Spliceosomal proteins 
play crucial roles in the formation and maintenance of the catalytic RNA structure 
and facilitate all conformational and structural rearrangements of the spliceosome. 
The elucidation of the exact protein composition of the individual splicing complexes 
provides hints as to when a given protein functions. The ability to assemble 
spliceosomes in vitro and their purification made it possible to elucidate the 
individual protein composition of distinct stages (Wahl et al., 2009). Approximately 
170 proteins associate with human spliceosomes throughout splicing (Wahl et al., 
2009). Individual complexes like B, Bact and the C complex each contain around 120 
proteins. There is a large exchange of proteins are most steps of the spliceosomal 
cycle (Figure 2.8) (Agafonov et al., 2011). The ca. 170 proteins associated with the 
human spliceosome are grouped into U snRNP associated proteins, which were 
described in Chapter 2.6, and the non-U snRNP associated proteins. The non-U 
snRNP proteins interact with the spliceosome at distinct stages either as individual 
proteins or as a part of larger sub-complexes. Some are associated with the 
spliceosome only transiently for distinct steps of splicing, and others remain bound 
throughout the splicing cycle. Major non-U snRNP complexes that interact with the 
spliceosome are the Prp19/CDC5L complex, the RES complex, the intron binding 










Figure 1.8 - Spliceosomal protein dynamics during the splicing cycle. The protein composition of the human 
spliceosomal A, B and C complex assembled in vitro. The proteins are grouped based on their snRNP and 
complex association, or function. Taken from (Wahl et al., 2009) 
The Prp19/CDC5L complex is formed out of eight core proteins (PRP19, CDC5L, 
HSP73, β-catenin-like-1 CTNNBL1, PRL1, AD002 and SPF27) (Makarova et al., 
2004) and is not only involved in the splicing of pre-mRNAs but also in protein 






(Chanarat and Strasser, 2013). The Prp19/CDC5L complex is recruited during the 
formation of the B complex and is essential for the catalytic activation of the 
spliceosome (Chan et al., 2003). The RES complex associates with the human 
spliceosomes during the formation of the B, Bact and C complex (Bessonov et al., 
2010). It is required for splicing and plays a key role during spliceosome activation 
(Bao et al., 2017; Dziembowski et al., 2004). In addition, the RES complex functions 
in the nuclear export of mature mRNAs (Dziembowski et al., 2004). Another complex 
that binds the spliceosome during Bact formation is the pentameric Intron Binding 
Complex (IBC), which contains the helicase Aquarius (De et al., 2015). The EJC is 
a protein complex that assembles upstream of exon-exon junction during pre-mRNA 
splicing and consists of the proteins eIF4AII, Mago and Y14; the spliceosomal factor 
CWC22 is essential for EJC recruitment to the spliced RNA (Akhtar et al., 2019).  
Many individual proteins also associate with the spliceosome at defined stages of 
the splicing cycle. For example, proteins of the SR family (see chapter 2.10.1), which 
promote spliceosome assembly, hnRNP proteins, and DExD/H-box RNA helicases 
that catalyze structural changes (see below). Other spliceosomal proteins include, 
among others, so-called Prp19/CDC5L-related proteins, B-specific proteins, and 
step I and step II factors that are required for the catalytic steps of splicing. The 
human spliceosome has many proteins that are missing in yeast (Fabrizio et al., 
2009). These human-specific proteins bind at a particular stage (i.e. B-specific, C-
specific proteins) and include PPIases and additional helicases, like Aquarius, not 
found in the yeast spliceosome. 
 
1.9 The role of RNA helicases during splicing 
Al least eight RNA helicases are required for pre-mRNA splicing: UAP65, Prp5, 
Prp28, Brr2, Prp2, Prp16, Prp18, Prp22 and Prp43 (Cordin et al., 2012). Their 
sequential activity is directly involved in triggering the structural and proteomic 
rearrangements in the spliceosome during splicing. All helicases involved in splicing 
belong to the superfamily two (SF2) helicases (3 DEAD-box, 4 DEAH-box and 1 







Helicases UAP56 and Prp5 are involved in the selection of the branch point 
sequence. UAP56 is recruited to the branch site by its interaction with U2AF65; 
UAP56 binding triggers ATP hydrolysis leading to the dissociation of the dimer. 
Upon the dimer release, the U2 snRNP can access the branch site (Shen et al., 
2008). Prp5 is required for A complex formation and appears to remodel the 17S U2 
snRNP so that it can bind stably to the BPS (O'Day et al., 1996; Ruby et al., 1993; 
Will and Lührmann, 2002). In yeast Prp5 activity is also required for the proofreading 
of the U2 branch site interactions and for the displacement of specific proteins (e.g. 
Cus2, the yeast homolog of hTAT-SF1) prior to U2 association (Perriman et al., 
2003; Perriman and Ares, 2007). After initial tri-snRNP docking, Prp28 disturbs the 
interactions between the 5’ splice site and U1 snRNA by removing stabilizing protein 
factors. The removal of the U1/5’ SS interactions is directly connected to the 
establishment of the U6 snRNA/5’ SS interactions and might point towards a 
proofreading function for Prp28 (Chen et al., 2001; Staley and Guthrie, 1999). The 
helicase Brr2 is a part of the U5 snRNP and tri-snRNP. It unwinds the U4/U6 snRNA 
in the B complex and in this way starts the catalytic activation process of the 
spliceosome (Absmeier et al., 2016). During Bact complex formation, Prp2 is 
recruited together with GPKOW/Spp2, a cofactor that is required for the activity of 
Prp2 (Silverman et al., 2004). Prp2 action leads to the destabilization of the 
interactions between the SF3a and SF3b complex with the branch point sequence 
(Warkocki et al., 2009). As a result, Prp2 remodels the catalytic center of the 
spliceosome and liberates the reactants of the first splicing step from their protein 
scaffolds (Bao et al., 2017; Silverman et al., 2004; Warkocki et al., 2009). The 
helicase activity of Prp16 is required during the transition from the step one 
spliceosome (the C complex) to the step two activated spliceosome (C*). After the 
helicase Prp16 triggers the conformational rearrangements required for the second 
step of splicing, Slu7, Prp18 and Prp22 are recruited to the spliceosome (Aronova 
et al., 2007; Warkocki et al., 2009). Prp18 and Slu7 are involved in the catalysis of 
the second step of splicing by holding the exons in position for the transesterification 
reaction (Aronova et al., 2007). Prp22 joins the spliceosome during the second step 
of splicing and it is necessary for the release of the spliced mRNA and U5 proteins 
from the disassembling spliceosome (Company et al., 1991; Schneider et al., 2002). 






remaining post-splicing complex and releases the intron lariat (Martin et al., 2002; 
Tsai et al., 2007; Tsai et al., 2005). 
1.9.1 Proofreading of spliceosome assemblies 
As discussed above, the correct identification of splice sites is of crucial importance 
for cell viability. Therefore, the correct definition of splice sites is checked multiple 
times during spliceosome assembly. Interestingly, the helicases responsible for 
crucial structural rearrangements during splicing also appear to be responsible for 
fidelity control in some cases (Koodathingal and Staley, 2013). The identification of 
splice sites is directly connected to the ATPase activity of RNA helicases: correct 
splice site recognition increases the speed of ATP consumption, whereas incorrect 
splice site recognition decreases the ATPase activity of helicases (Egecioglu and 
Chanfreau, 2011), thus increasing the chance of the spliceosome being 
disassembled due to persistent stalling. In yeast, this phenomenon could be 
observed for multiple helicases at different stages of spliceosome assembly. For 
example, Prp5 appears to proofread the branch site selected during A complex 
assembly and Prp16 proofreads the U2/ BPS helix prior to catalytic step 2 (Burgess 
and Guthrie, 1993; Xu and Query, 2007).Taken together, the RNA helicases 
involved in splicing are not only involved in the structural rearrangements required 
to form the catalytic center and thereby complete RNA splicing, but they also have 
proofreading functions during these transitions. 
 
1.10 Alternative splicing 
The average pre-mRNA of a vertebrate is made up of multiple short exons 
separated by much larger introns. Exons are on average between 140 and 400 
nucleotides long while introns can be up to several hundred thousand bases long 
(Sakharkar et al., 2004). Alternative splicing is the process of generating multiple 
different mature mRNA molecules out of one pre-mRNA transcript. The function of 
alternative splicing is to increase the genome-coding capacity of higher eukaryotes 
without increasing the genome size. This finding is supported by the observation 
that the prevalence of alternative splicing increases with genome complexity of the 
organism (Bush et al., 2017). In yeast only 5% of genes contain introns and only 






whereas in humans almost all genes are spliced and 92-94% of them were shown 
to have one or more alternative splicing products (Wang et al., 2008).  
 
 
Figure 1.9 – Different forms of alternative splicing of pre-mRNA.  Scheme of different alternative splicing 
events found in humans. Exons are depicted as colored boxes, or in case of the mutually exclusive exons as 
black and white box while introns are depicted as thick black lines. Splice site pairings are indicated using thin 
lines. (A) Normal splicing of pre-mRNA without alternative splicing events. (B) Exon skipping, in which an entire 
exon is skipped during splicing and does not appear in the mature mRNA. (B) Mutually exclusive exons entail 
that either exon is included into the mature mRNA (mutually exclusive). (D) Intron retention, during which an 
entire intron is kept as a part of the mature mRNA. (E/F) Alternative 5’ and 3’ splice sites can be used to create 
new mRNAs from pre-mRNA molecules. This figure was adapted from (Keren et al., 2010). 
The most common mechanism of alternative splicing is exon skipping, during which 
an entire exon is not included into the mature mRNA (Fig. 2.9b). A rare special case 
of exon skipping is the presence of mutually exclusive exons in the pre-mRNA. Here 
only one of two exons can be present in the mature mRNA while the other one is 
skipped entirely (Fig 2.9c). In addition to excluding exons from the mRNA, it is also 






intron retention. Finally, along with omitting intended splice sites entirely, alternative 
5’ and 3’ splice sites also can be used. They are found in spatial proximity to the 
canonical exon borders and cause alterations in the exon/intron borders of the pre-
mRNA without including or removing exons completely (Figure 2.9e/f).   
1.10.1 Regulating alternative splicing 
Alternative splicing is tightly regulated by multiple different factors. First, splice sites 
in human cells are much less conserved than their counterparts in yeast suggesting 
that splice sites could show varying affinities to their respective splicing factors. 
Second, RNA secondary structures may shield splice sites making them unavailable 
for splicing under certain conditions (Keren et al., 2010). In addition, various 
regulatory proteins interact with short RNA sequences and influence the recruitment 
of spliceosomal factors (Figure 2.10). These proteins are known as SR-proteins and 
hnRNPs (Lin and Fu, 2007). SR proteins contain arginine-serine repeats in their RS 
domain. This domain can interact with the RS domains found in multiple splicing 
factors and enhance their recruitment and subsequent complex assembly by 
forming or stabilizing protein-protein interactions. SR proteins typically bind to 
intronic or exonic splice enhancers (ISE/ESE). The hnRNPs are antagonists of SR 
proteins, they bind to RNA silencing RNA elements known as the intronic and exonic 
splice silencers (ISS/ESS), and negatively influence spliceosome recruitment and 
assembly (Martinez-Contreras et al., 2007). The effect of both SR proteins and 
hnRNPs is confined to their surroundings and can thereby selectively enhance or 







Figure 1.10 – Regulation of alternative splicing. The presence of splicing regulators in form of exonic splice 
enhancers (ESE) and silencers (ESS) as well as their intronic counterpatrts (ISE/ ISS) can modulate the 
assembly of the spliceosme on the splice sites. SR proteins (light green triangles) enhance the recruitment of 
snRNPs and proteins and stablize splicesome assembly, while hnRNPs (pink octagons) interfere with snRNP 
recruitment and spliceosome assembly.The exon is represented as blue box while the flanking introns are 
shown as thick black lines. The spliceosomal snRNP particles are represented as circles (U1 – light blue, U2 – 
orange) and the poly-pyrimidine binding protein complex U2AF is shown in yellow. Fading of bound proteins in 
(B) is used to indicate decreased recruitment. 
In addition to the pre-mRNA internal regulatory elements, the transcription speed of 
RNA polymerase II is also thought to have a direct influence on alternative splicing. 
Transcription speed and pausing events impact the splice sites availability for 
spliceosome formation and thereby significantly influence the splice site pairing 
possibilities available during spliceosome formation. 
 
1.11 Structure of SF3b and the U2 snRNP 
The U2 snRNP plays a key role during A complex formation and the selection of the 
branch point. The 17S U2 particle is assembled in a stepwise process, which gives 
rise to two intermediate particles prior to the formation of the mature 17S U2 particle. 
The first assembly step is the formation of the Sm-ring at the Sm-site and the 
recruitment of the U2A’ and U2B’’ complexes to the stem-loop IV of the U2 snRNA, 
thus forming the 12S U2 particle (Lührmann et al., 1990). After the formation of the 
12S U2 particle, the SF3b protein complex binds and the 15S U2 particle is 
assembled, followed by the binding of the SF3a complex giving rise to the mature 






extensive network of protein-protein and protein-RNA interactions that are 
necessary for the stable integration of the U2 snRNP in the A complex.  
 
Figure 1.11 – Model of the U2 snRNP interaction with the intron and domain structure of human SF3b 
proteins. Schematic representation of the SF3a and SF3b proteins (grey) in the 17S U2 particle that contact 
the pre-mRNA (Gozani et al., 1996). The U2 snRNA (thick black line) and the 3’ end of the pre-mRNA (thin black 
line) are shown schematically. The 3’ exon is indicated as box and 3’ splice site (AG) and branch point adenosine 
(blue A) are shown as letters. The polypyrimidine tract is indicated as Yn. Adapted from (Will et al., 2001). (B) 
Domains of Sf3b proteins: Znf, Zinc finger; RRM, RNA recognition motif; pir, SF3b6 interacting region; ULM, 
U2AF ligand motif. The number at the C-terminus indicates the number of amino acids. 
Upon binding of U2 to the pre-mRNA, the SF3a and SF3b proteins interact with the 
RNA at the so-called anchoring site, roughly 25 nucleotides upstream of the branch 
point (Gozani et al., 1996). The SF3a proteins SF3a3 and SF3a2 contact the RNA 
directly via their zinc-finger domains and both interact with SF3a1 (Nesic and 
Kramer, 2001). The SF3b complex is a heptameric complex (SF3b1, SF3b2, SF3b3, 
SF3b4, SF3b5, PHF5A and SF3b6) (Figure 2.11b). Several SF3b proteins contact 
the pre-mRNA upstream of the branch site, while SF3b1 can be cross-liked to RNA 
nucleotides up- and downstream of the branch site (Gozani et al., 1996; Will et al., 
2001). SF3b1 also forms protein-protein interactions with U2AF65. In addition, the 






2001). Together, these interactions play an important role in the stabilization of the 
U2/BPS helix and tether the U2 snRNP to the BPS.  
Recently, the crystal structure of an isolated SF3b complex, which lacked SF3b2, 
SF3b4 and the N-terminal domain of SF3b1, was reported (Cretu et al., 2016). The 
C-terminal HEAT-domain of SF3b1 contains 20 tandem repeats that adopt a super 
helical structure (Cretu et al., 2016) (Figure 2.12a). The conformation of HEAT 
domain is directly influenced by its binding partners (Grinthal et al., 2010; Zachariae 
and Grubmuller, 2008). The HEAT repeats of SF3b1 are in direct contact with 
SF3b3, SF3b5 and PHF5A. PHF5A contacts the concave (inside) surface of the 
HEAT domain and bridges the N-terminal and C-terminal HEAT repeats (H2+H3). 
The WD-40 protein SF3b3 and SF3b5 also make multiple contacts with the SF3b1 
HEAT domain and influence its conformation. 
Advances in cryo-electron microscopy enabled the visualization of the near atomic 
structure of the spliceosome, making it possible to observe the structural changes 
accompanying the transition into different stages of assembly (Fica and Nagai, 
2017). High resolution cryo-EM models of the human pre-B, B, Bact, C, C* and P 
complexes have been obtained (Bertram et al., 2017a; Bertram et al., 2017b; 
Charenton et al., 2019; Haselbach et al., 2018; Zhang et al., 2017; Zhang et al., 
2018). At present no high-resolution structures of the human A complex or the 17S 
U2 snRNP are available. The cryo-EM structure of the human Bact complex reveals 
how the SF3b1 HEAT domain and other SF3b proteins interact with the U2/BPS 
helix and 3’ region of the intron (Figure 2.12). The U2/BPS helix is clamped between 
the N-terminal and C-terminal HEAT repeats and the BPS is bound in a pocket 
formed by PHF5A and the SF3b1 HEAT domain. Numerous other proteins interact 







Figure 1.12- Pseudo atomic model of SF3b interactions with the pre-mRNA in the human Bact complex. 
(A) Crystal structure of the SF3b core. Depicted are the HEAT-domain of SF3b1 and then bound SF3b10 and 
SF3b14 proteins. (B) Scheme of the SF3b1 HEAT domain as seen in the human Bact complex. The intronic RNA 
and the U2 snRNA form the U2/ BPS helix and is sequestered by the N- and C-terminal end of the HEAT domain. 
The intronic RNA downstream of the branch point adenosine then leaves the HEAT domain in the region 
between HEAT repeat 6 and 7. Image taken from (Cretu et al., 2016) and (Kastner et al., 2019). 
Comparison of the structure of the SF3b1 HEAT domain in the isolated complex 
with its structure in the human Bact complex revealed a major structural 
rearrangement within the HEAT-domain of SF3b1 (Figure 2.13). While the HEAT-
domain of SF3b1 adopts an open conformation in the isolated SF3b complex in the 
Bact complex the HEAT-domain is closed. The closed HEAT-domain, which also 






to stabilize the U2 interaction and to sequester the BPS adenosine to prevent 
premature splicing catalysis. 
 
Figure 1.13- Open and closed conformation of SF3b1 during splicing. Reconstruction of SF3b1 in an open 
conformation as found in the SF3b complex and in a closed conformation as seen in the Bact complex. The HEAT 
domain of SF3b1 is shown in blue, the U2 RNA in green and a part of the pre-mRNA involved in the formation 
of the branch point helix in red. Structures were extracted from the SF3b structure (Cretu et al., 2016) and the 
human Bact structure (Haselbach et al., 2018). 
 
1.12 Spliceosomal mutations in cancer 
Misregulated splicing of pre-mRNA is related to carcinogenesis and could be often 
observed in cancer cells (David and Manley, 2010). In addition, up to 50% of cancer-
causing mutations are found in genes whose products have splicing-related 
functions (Cartegni et al., 2002). With the emergence of affordable transcriptome 
sequencing, multiple mutational hotspots in splicing-associated proteins were 
discovered in samples obtained from patients with hematological malignancies 
(Yoshida and Ogawa, 2014). The mutational targets were spliceosomal proteins 
associated with the initial assembly steps of the spliceosome, for instance, U2AF1, 
SRSF2, ZRSR2 and SF3B1. All four of these proteins are directly involved in the 






occur in patients in a mutually exclusive manner, suggesting lethality of multiple 
mutations. 
SF3B1 is a common mutational target in hematopoietic cancers like myelodysplastic 
syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid 
leukemia (AML) (Yoshida and Ogawa, 2014). Up to 70% of cancer patients contain 
one of the hot-spot mutations. The SF3b1 protein can be divided into 3 structural 
domains. The N-terminal region of the protein is an unstructured stretch of 528 
amino acids, followed by a structured HEAT-domain (529-1201aa) comprised of 20 
HEAT repeats. The C-terminal end is also comprised of an unstructured stretch of 
102 amino acids (1202-1304aa). The mutations of SF3b1 associated with cancer 
mainly cluster within the HEAT-repeat domain of the protein with the most common 
mutations being K700E/Q699_K700del, K666N/T/E/R/Q/M and H662Q/D/Y 
(Yoshida and Ogawa, 2014) (Figure 2.14a). In the three-dimensional structure of 
the SF3b1 protein, most of its mutations could be seen clustered within a specific 
region that is in close proximity to the sixth HEAT-repeat where the intron exits the 
HEAT domain (Cretu et al., 2016) (Figure 2.14b). The nature of the amino acid 
substitutions suggests that the surface charge of the SF3b1 protein might change 







Figure 1.14 – Location of the cancer related mutations in the 3D-structure of SF3b1. (A) Schematic 
representation of SF3b1 domains, the unstructured N-terminal region containing the TP-repeats (transparent 
blue), the target region for phosphorylation and the structured HEAT-repeat domain (yellow). (B) The 3D-
structure of the HEAT-domain of SF3b1. Balls indicate the position of various cancer-associated mutations 
found in SF3b1. Taken from (Cretu et al., 2016). 
The presence of SF3b1K700E in the cell leads to the emergence of aberrantly spliced 
pre-mRNA molecules. The alterations of splicing mainly affect the selection of the 
3’ splice site, with cryptic 3’ splice sites being used only in the presence of the K700E 
mutation (Agrawal et al., 2017). These cryptic splice sites are found upstream of the 
canonical splice site and the poly-pyrimidine tract and are associated with their own 
distinct branch point sequence (Darman et al., 2015). Experimental evidence 
suggests that the usage of the cryptic splice site is directly coupled to the presence 
of a cryptic branch point, as removal of the latter results in the disappearance of 
cryptic splice products (Darman et al., 2015).  
Table 1.2 – Usage of cryptic splice sites is dependent on SF3b1K700E expression 
 SF3b1wt + SF3b1wt SF3b1wt + SF3b1K700E 
Canonical splice sites spliced spliced 






Bioinformatics analysis of total cellular RNA further identified that the cryptic branch 
points are located 12-18 nucleotides downstream of their respective branch point 
while the canonical AG dinucleotide is found more than 18 nucleotides downstream 
of the branch point adenosine (Deboever et al., 2015). However, the characteristic 
features of the cryptic branch point and 3’ splice site are poorly conserved and do 
not suffice to explain the changes in the splicing patterns of the affected cells. 
Cancer related mutations in SF3b1 have been proposed to alter the conformation 
of the HEAT domain and in this way destabilize the U2/BPS interaction, which could 
affect the usage of alternative BPS and 3’ splice sites. As an alternative, the 
mutations were proposed to alter the path of the 3’ end of the intron and in this way 
affect 3’ splice site usage (Jenkins and Kielkopf, 2017). 
 
1.13 Small molecule inhibitors of splicing that interact with SF3b1 
High-throughput screens have led to the identification of multiple compounds that 
can inhibit pre-mRNA splicing in vitro and/or in vivo. These compounds interfere 
with the normal function of the spliceosome causing general or gene specific 
changes in splicing. The mechanism used to inhibit pre-mRNA splicing is varied and 
ranges from interference during spliceosome assembly to steric modifications of the 
RNA. Many natural splicing inhibitors interfere with the assembly of the spliceosome 
and cause global changes in splicing patterns leading to cell-cycle arrest and 
apoptosis (Effenberger et al., 2014a; Effenberger et al., 2013; Folco et al., 2011; 
Hasegawa et al., 2011; Kaida et al., 2007; Kotake et al., 2007; Pawellek et al., 2014; 
Vigevani and Valcárcel). Interestingly these inhibitors all interact with the SF3b1 
protein and stop spliceosome assembly at an early assembly stage. The small 
molecule inhibitors targeting SF3b1 can be grouped into four classes based on their 
chemical structures (Bonnal et al., 2012; Effenberger et al., 2017). These are the 
pladienolides (A-G, E7107), spliceostatins (A-G, FR901464, thainlanstatins, 
meayamycin), herboxidiene (GEX1A), and sudemycins (C1, D6, E, F1). It was 
proposed that while chemically rather diverse, all inhibitors of SF3b1 share a 
common pharmacophore defined by a distinct set of functionally required groups 
(Lagisetti et al., 2008). Importantly, these compounds have been shown to 







Figure 1.15 – Structure of Pladienolide B. The Pladienolide B molecule is composed of a macrolide group 
connected to an aliphatic arm by a diene group acting as linker. 
The recent crystal structure of Pladienolide B bound to SF3b1 revealed the exact 
binding location of Pladienolide B and could show that the inhibitor binds to the open 
conformation of the protein (Cretu et al., 2018). To date it is still not known how 
exactly the presence of Pladienolide B influences the assembly of the spliceosome 
and which mechanism leads to the aforementioned changes in the cellular splicing 
pattern. A better understanding of the effects of Pladienolide B on the splicing 
machinery could help improve therapeutic approaches using these compounds. 
 
1.14 Aim of this thesis 
SF3b is a heptameric, U2 snRNP subunit that is essential for the stable interaction 
of the U2 particle with the branch point sequence of an intron during early 
spliceosome assembly and therefore aids in the recognition and selection of the 
branch site adenosine. SF3b1 is the largest protein of the SF3b complex and it is 
the target of several small molecule splicing inhibitors, including Pladienolide B, that 
have anti-tumor properties and alter alternative splicing patterns. At the same time, 
mutations in SF3b1 have been linked to a variety of cancers and cause changes in 
alternative splicing events that lead to malignancies. Thus, modulating the function 
of SF3b can have both positive and negative effects on modulating the onset or 
severity of a variety of human diseases. However, the molecular mechanisms how 






I wanted to address two major questions in my thesis regarding the function of 
Pladienolide B as an inhibitor of spliceosome assembly. First, what are the 
consequences of Pladienolide B binding on the assembly of the spliceosome? 
Secondly, what compositional and structural changes arise due to the presence of 
the inhibitor? To investigate this, I set out to affinity purify human spliceosomal 
complexes stalled by Pladienolide B and also wild-type complexes for comparison, 
and check for differences in their protein compositions using mass spectrometry. I 
also hoped to obtain a high resolution cryo-EM structure of the wild-type, human 
spliceosomal A complex, which is currently not available, and the Pladienolide B 
stalled A complex, that would reveal any structural differences especially in the 
conformation of the SF3b1 HEAT domain. These studies should clarify if indeed 
Pladienolide B prevents a conformational change in SF3B1 that was proposed to 
occur when U2 interacts during A complex assembly and leads to clamping down 
of the HEAT domain on the U2/BPS helix.  
In a second set of experiments, I also wanted to investigate how cancer-linked point 
mutations in SF3b1 lead to the recently observed changes in alternative splicing 
patterns in various cancers. To date the exact mechanism responsible for these 
changes could not be identified. I initially aimed to purify 17S U2 snRNPs containing 
the SF3b1 mutation K700E, one of the most common cancer-related mutants, and 
investigate its effect on the composition, structure and function of the U2 particle, 
and then to expand this to both cross-intron and cross-exon spliceosomal 
complexes containing the mutated SF3b1 protein. Another goal was to recapitulate 
in vitro, alternative splicing events dependent on SF3b1 mutations that were 
observed in vivo, in order to dissect the mechanisms that lead to the use of cryptic 
branch sites and 3' splice sites. These investigations will improve our understanding 
of how exactly the usage of cryptic branch points arises as a consequence of the 
single amino acid substitutions in SF3b1. These studies could provide valuable 
information concerning how changes in the function of SF3b1 due to single point 
mutations lead to cancer. Understanding the exact mechanism underlying these 










β-Mercaptoethanol       Roth, Germany 
Accutase        ThermoFischer, USA 
Acetic acid         Merck, Germany 
Agarose (low melting point)      ThermoFischer, USA 
Agarose         ThermoFischer, USA 
Ammonium peroxidisulphate (APS)      Merck, Germany 
Ampicillin         Sigma-Aldrich, Germany 
Anacardic acid       Alexis biochemical, USA 
Bromophenol blue        Merck, Germany 
Coomassie brilliant blue G-250      Serva, Germany 
Creatine phosphate        Sigma-Aldrich, Germany 
DMEM         ThermoFischer, USA 
Dimethylsulphoxide (DMSO)      Roth, Germany 
Dipotassiumhydrogenphosphate      Merck, Germany 
Dithioerythritol (DTE)       Roth, Germany 
Dithiothreitol (DTT)        Roth, Germany 
DNA-molecular weight marker      Gibco, New Zealand 
EDTA (Disodium salt dihydrate)      Roth, Germany 
Ethanol         Merck, Germany 
FBS         ThermoFischer, USA 
FLAG-peptide (3x)       Sigma-Aldrich, Germany 
Formaldehyde        Merck, Germany 
Formamide         Merck, Germany 
GlutaMax        ThermoFischer, USA 
Glycerol         Merck, Germany 
Glycine         Merck, Germany 
Glycoblue         Ambion, USA 
Heparin (sodium salt)       Roth, Karlsruhe  
HEPES (N-2-Hydroxyethylpiperazin-N-2-ethansulfonic acid)  Calbiochem, USA 
IMEM         ThermoFischer, USA 
Imidazole         Merck, Germany 
Maltose         Merck, Germany 
Methanol         Merck, Germany 
MOPS buffer         ThermoFischer, USA 
Milk powder         Roth, Germany 
Nonidet P-40 (Igepal CA-630)      Sigma-Aldrich, Germany 
Penicillin/Streptomycin      ThermoFischer, USA 
Pladienolide B       ChemCruz, USA 
Pluronic F-86        ThermoFischer, USA 
PMSF (Phenylmethylsulfonylfluoride)     Roche, Germany 
Potassium Chloride        Merck, Germany 
Potassiumdihydrogenphosphate      Merck, Germany 
Pre-stained protein-molecular weight marker    Bio-Rad, Germany 
Roti-Phenol-Chloroform-Isoamyl alcohol (PCI)    Roth, Germany 
Rotiphorese Gel 30 solution       Roth, Germany 
Rotiphorese Gel 40 solution       Roth, Germany 
Sodium Chloride       Merck, Germany 
Sodiumacetate        Merck, Germany  
Sodiumdodecylsulfate (SDS)      Serva, Germany 






TEMED (N, N, N’, N’-Tetramethylethylendiamine)    Sigma-Aldrich, Germany 
Tris-(hydroxymethyl)aminomethane (Tris)     Roth, Germany 
Triton X-100         Merck, Germany 
Tween 20         Sigma-Aldrich, Germany 
Urea          Merck, Germany 
Xylene cyanol        Fluka, Switzerland 
 
2.2 Chromatography materials and consumables 
Amylose resin       New England Biolabs, USA 
Cassettes for film exposure      Kodak, USA 
Centrifuge tubes       Beranek, Germany  
Chromatography columns      Bio-Rad, Germany 
Concentrator        Millipore, USA 
HisTrap HP, Ni-NTA-Sepharose (5 ml)    GE Healthcare, Germany 
NuPAGETM gels (1.5 mm, 4-12%)     ThermoFischer, USA 
Parafilm        Roth, Germany 
Poly-Prep columns       Bio-Rad, USA 
Protran BA 83 nitrocellulose      Whatman, UK 
ProbeQuantTM G-25/ G-50 micro columns    GE Healthcare, UK 
Slide-A-Lyzer dialysis units (MWCO 6 kDa)   Pierce, USA 
SnakeSkin dialyisis membranes (MWCO 6000-8000 Da)  Thermo Fischer Scientific, USA 
Sterile filters (0.2 Mm or 0.45 Mm)     Sarstedt, Germany 
Surgical blades       Martin, Germany 
Whatman 3MM Paper      Whatman, UK 
X-ray films (BioMax MR)      Kodak, USA 
 
2.3 Cell culture materials 
0.2l, 1l, 6l spinner flasks     Bellco, USA 
T-75 flasks       Sarstedt, Germany 
T-175 flasks       Sarstedt, Germany 
 
2.4 Machines 
ÄKTA Start        GE Healthcare, UK 
Amersham Imager 680     GE Healthcare, UK 
Autoclaves        H+P Labortechnik, Germany 
Axiovert 25       Zeiss, Germany 
Biofuge fresco       Kendro, USA 
Biofuge pico        Kendro, USA 
FLA-7000       Fuijfilm, Japan 
Gel documentation unit      Bio-Rad, Germany 
Gel electrophoresis apparatus     in-house 
Gel dryer Model 583       Bio-Rad, Germany 
Gradient Master Modell 106      BioComp Instruments 
Head-over-tail Rotor       Cole-Parmer, USA 
Heating blocks       Eppendorf, Germany 
HeraSafe       Kendro, USA 
Hybridization oven Hybaid      Biometra, Germany 
Incubator BD6220      Haraeus, Germany 






Megafuge 1.0R       Kendro, USA 
Milli-Q-water supply apparatus     Millipore, USA 
NanoDrop       ThermoFischer, USA 
PerfectBlue Semi-Dry Electro blotter    PeqLab, Germany 
pH-Meter        Mettler Toledo, Switzerland 
Phosphorimager Typhoon 8600     Amersham Pharmacia, UK 
Power supply EPS 2A200      Hoefer, USA 
Power supply EPS 3501/XL      Amersham Pharmacia, UK 
Q-ToF Ultima mass spectrometer     Waters, USA 
Scintillation counter LS 1701     Beckman/Packard, USA 
Sorvall HB-6 rotor       Kendro, USA  
Sorvall SA800 AT4 Rotor      Kendro, USA 
Sorvall SS-34 Rotor       Kendro, USA 
Sorvall TH660 Rotor       Kendro, USA 
Sorvall TST41.14 Rotor      Kendro, USA 
Speed Vac Konzentrator 5301     Eppendorf, Germany 
Spectrophotometer Nanodrop ND-1000    Thermo Scientific, USA 
Spectrophotometer Ultrospec 3000 pro   Amersham Pharmacia, USA 
SS-34 Rotor        Kendro, USA 
Tabletop centrifuge 5415D      Eppendorf, Germany 
Titan Krios       FEI, USA 
Trans-Blot Cell       Bio-Rad, USA 
Ultracentrifuge Discovery 90     Sorvall, Kendro 
Ultracentrifuge Discovery M150     Sorvall, Kendro 
Variomag Biomodul 40B     H + P Labortechnik, Germany 
Vortex        Janke & Kunkel, Germany 
X-ray film developer X-Omat 2000     Kodak, USA 
 
2.5 Nucleotides 
Nucleoside – 5’ – triphosphate (100 mM):   Pharmacia, Sweden 
ATP, CTP, UTP, GTP 
Deoxynucleoside – 5’ – triphsophate (100 mM):  Pharmacia, Sweden 
dATP, dCTP, dTTP, dGTP 
m7G(5’)ppp(5’)G-cap      Kedar, Poland 
(7-monomethyl-diguanosine triphosphate) 
 
2.5.1 Radiolabeled nucleotides 
α-32P-UTP [10 µCI/µl, 3000 Ci/mmol]    Perkin Elmer, USA 
 
2.5.2 Oligonucleotides  
2.5.2.1 Inserted tag DNA oligonucleotides for SF3b1    
Tag Sequence (5’-3’) 





















2.5.2.2 RNA oligonucleotides 
5’splice site RNA oligonucleotide    5’-CUGUUCAGGUAAGUAU 
2.6 Commercial kits 
BCA protein assay kit      Pierce, USA 
ECL Western Blot Detection Kit    GE Healthcare, USA 
Invitrogen® PureLink Maxiprep    Invitrogen, USA  
PCR & Gel Clean-Up Kit     Macherey-Nagel, Germany 
TMTduplex™ Isobaric Mass Tagging Kit   ThermoFischer, USA  
  
2.7 Enzymes 
cOmplete protease inhibitor, EDTA-free    Roche, Switzerland 
Proteinase K        Sigma-Aldrich, USA 
Restriction endonucleases      New England Biolabs, USA 
RNasin (RNase inhibitor) [40U/µl]     Promega, USA 
RQ1 DNase [1U/µl]      Promega, USA 
T4 Polynucletide kinase (PNK)     New England Biolabs, USA 
T7 RNA polymerase       New England Biolabs, USA 
YIPP [0.1U/µl]       New England Biolabs, USA 
2.8 Antibodies 
Anti-FLAG M2       Sigma-Aldrich, USA 
Anti-SF3b1.1       AG Lührmann 
Anti-SF3b1 (13E12)      AG Lührmann 
Anti-hPrp5       AG Lührmann 
Anti-hTAT SF1      AG Lührmann 
2.9 Plasmids 
pMINX Pre-mRNA construct (MINX) in pUC18-vector under control of a T7 
promoter, AmpR. (Zillmann et al., 1988) 
pMINX-exon MINX exon RNA construct in pSP65-vector under control of a T7 
promoter, AmpR. (Schneider et al., 2010b) 
pMINX-exon variants MINX exon RNA derivate synthesized externally into the pUC57 
vector under control of a T7 promoter, AmpR.  
pMS2-MBP-StrepII    Bacterial MS2-MBP-StrepII expression vector, AmpR. 
pWPI 2nd gen bicistronic lentiviral vector allows for simultaneous 
expression of a transgene and EGFP marker to facilitate tracking of 
transduced cells, AmpR. 






pMD2.G  VSV-G envelope expressing plasmid, AmpR. (Didier Trono) 
2.10 Cell lines 
2.10.1 Bacterial cell lines 
XL-10 gold        Agilent, USA 
2.10.2 Human cell lines 
HeLa S3        ATCC, USA 
HEK293T        ATCC, USA 
K562         ATCC, USA 
K562 FLAG-SF3b1wt       Dr. James Manley 
K562 FLAG-SF3b1K700E      Dr. James Manley 
2.11 Buffers and Media 
2.11.1 Media 
LB-Medium     
  Yeast extract 0.5% (w/v) 
  Tryptone 1% (w/v) 
  NaCl 1% (w/v) 
  pH 7.0 
 
SOC-medium     
  Tryptone 2% (w/v) 
  Yeast extract 0.5% (w/v) 
  NaCl 10 mM 
  KCl 2.5 mM 
  MgCl2 10 mM 
  Glucose 20 mM 
 
DMEM-medium complete     
  DMEM   
  Fetal bovine serum 10% (v/v) 
  L-glutamine 2 mM 
  Penicillin G 100 U/mL 









IMEM-medium complete     
  IMEM   
  Fetal bovine serum 10% (v/v) 
  Penicillin G 100 U/mL 
  Streptomycin 100 U/mL 




    
  IMEM   
  Fetal bovine serum 10% (v/v) 
  Penicillin G 100 U/mL 
  Streptomycin 100 U/mL 
  Pluronic F-86 1x 
  GlutaMAX 0.5x 
 
2.11.2 Buffers 
Coomassie staining solution     
  
Coomassie brilliant blue 
G250 100 µM 
  HCl 0.13 mM 
 
6x DNA loading buffer     
  glycerol 60% (v/v) 
  Tris-HCl, pH 7.5 10 mM 
  EDTA, pH 8.0 60 mM 
  bromphenol blue 0.05% (w/v) 
  xylene cyanol 0.05% (w/v) 
 
10x G-75     
  Hepes-KOH, pH 7.9 200 mM 
  NaCl 750 mM 









10x G-150     
  Hepes-KOH, pH 7.9 200 mM 
  NaCl 1.5 M 
  MgCl2 15 mM 
 
5x HTRO buffer     
  Hepes-KOH, pH 7.5 1 M 
  MgCl2 160 mM 
  Spermidin 10 mM 
 DTT 200 mM 
 
1x MOPS buffer     
  MOPS 40 mM 
  NaOAc 10 mM 
  EDTA, pH 8.0 1 mM 
 
5x native gel loading buffer     
  Tris 90 mM 
  boric acid 90 mM 
  EDTA, pH 8.0 2.5 mM 
  glycerol 30% (v/v) 
  bromphenol blue 0.05% (w/v) 
 
PBS     
  NaCl 137 mM 
  KCl  2.7 mM 
  Na2HPO4  10 mM 
  KH2PO4  1.8 mM 
  CaCl2  1 mM 
  MgCl2  0.5 mM 
 
2x PK buffer     
  Tris-HCl, pH 7.5 200 mM 
  EDTA, pH 8.0 25 mM 









2x RNA loading buffer     
  formamide 80%(v/v) 
  EDTA, pH 8.0 1 mM 
  bromphenol blue 0.05% (w/v) 
  xylene cyanol 0.05% (w/v) 
 
1x Röder C buffer     
  glycerol 25% (v/v) 
  Hepes-KOH, pH 7.9 20 mM 
  NaCl 420 mM 
  MgCl2 1.5 mM 
  EDTA, pH 8.0 0.2 mM 
  DTT 0.5 mM 
  PMSF 0.5 mM 
 
1x Röder D buffer     
  glycerol 10% (v/v) 
  Hepes-KOH, pH 7.9 20 mM 
  NaCl 100 mM 
  MgCl2 1.5 mM 
  EDTA, pH 8.0 0.2 mM 
  DTT 0.05 mM 
  PMSF 0.5 mM 
 
6x SDS-loading buffer     
  Tris-HCl, pH 6.8 25 mM 
  glycine 192 mM 
  SDS 1% (w/v) 
 
4x separating gel buffer     
  Tris 1.5 M 
  SDS 0.4% (w/v) 
  adjust to pH 6.8   
 
4x stacking gel buffer     
  Tris 0.5 M 
  SDS 0.4% (w/v) 







Stripping buffer     
  Tris-HCl, pH 6.7 62.5 mM 
  -mercaptoethanol 100 mM 
  SDS 2% (w/v) 
 
SLAB4     
  Tris 50 mM  
  Glycine 380 mM  
  SDS 3.5 mM  
 
10x TBE     
  Tris 0.89 M 
  boric acid 0.89 M 
  EDTA, pH 8.0 25 mM 
 
10x TBS     
  Tris 200 mM 
  NaCl 1.5 M 
  adjust to pH 7.5   
 
10x TBS-T     
  Tris 200 mM 
  NaCl 1.5 M 
  Tween-20 1% (v/v) 
  adjust to pH 7.5   
 
Western-Blot transfer buffer     
  SLAB4 50% (v/v) 












3.1 General Molecular Biology methods 
3.1.1 Quantification of nucleic acids solutions 
To quantify the concentration of nucleic acids in aqueous solutions spectrometry 
was used. The sample was applied to a NanoDrop® spectrophotometer and the 
extinction coefficient of the solution was measured. This was then compared to the 
extinction coefficient of the aqueous solution and OD at a wavelength of 260 nm 
could then be used to calculate the concentration of nucleic acid present in the 
solution. Due to variations in the optical properties the following equations were 
used to determine the concentration: 
1OD260 nm= 50 µg/ml double-stranded DNA 
1OD260 nm= 33 µg/ml single-stranded DNA 
1OD260 nm= 40 µg/ml single-stranded RNA 
The purity of the nucleotide solution could be evaluated by calculating the ratio of 
OD260 nm/OD280 nm. Values around 1.8 indicate pure DNA, while values close to 2.0 
indicate pure RNA. Lower than expected ratios indicate contamination of the sample 
with phenol and make further treatment of the sample necessary (e.g. an additional 
phenol-chloroform extraction). 
3.1.2 Phenol-Chloroform-Isoamyl extraction 
Phenol-Chloroform-Isoamyl alcohol extraction (PCI) was used to isolate nucleic 
acids from samples containing proteins. During PCI, if the sample volume was 
smaller than 200 µl water was added to obtain a final sample volume of 200 µl, then 
an equal amount of phenol-chloroform-isoamyl alcohol (25:24:1) was added to the 
sample and mixed by vigorous shaking for 5 to 10 min at room-temperature (RT). 
After shaking the organic and aqueous phase was separated by centrifugation (13 
krpm, 5 min, RT) in a tabletop centrifuge. After centrifugation, the aqueous upper 
phase is carefully removed, while avoiding to come into contact with the organic or 
interphase. The aqueous phase is then mixed with 0.1 volume of NaOAc (pH 5.2) 
and 2.5 volumes of 100% EtOH to precipitate the nucleic acids present in it. For 






centrifuged at 4°C, max. rpm for 1 h in a table top centrifuge. The resulting pellet is 
then carefully preserved, while the supernatant is aspirated, and washed once with 
70% (v/v) ethanol. After washing the pellet is dried and resuspended in the desired 
solution. 
3.1.3 Proteinase K digestion 
In order to recover RNA from samples containing high amounts of proteins, or to 
release RNA bound in stable protein complexes, a proteinase K (PK) digest is 
performed. To digest samples with proteinase K, the sample is incubated in 1x PK-
buffer containing 0.2 µg proteinase K per µl of sample for 45 min to 1 h at 45°C. 
After PK digest the RNA can be isolated using the aforementioned PCI protocol 
followed by resuspension in water and storage at -20°C. 
3.1.4 Protein precipitation 
To precipitate proteins from aqueous solutions two different approaches were used. 
For acetone precipitations the protein solution was combined with 5 volumes of ice 
cold acetone, mixed and then kept at -20°C overnight. Afterwards the proteins were 
precipitated from the solution by centrifugation (30 min, 4°C, 21000 rcf) and the 
supernatant was carefully aspirated. The pellet was then washed once with 80% 
(v/v) ethanol, and after removal of the supernatant, air dried for 10 min. The protein 
pellet could then be resuspended in protein sample buffer. Ethanol precipitation was 
used as an alternative to the precipitation of protein with acetone. For this approach, 
the protein containing solution was combined with 2.5 volumes of ethanol and 0.1 
volume of sodium acetate (pH 5.2). After mixing, the sample was kept at -20°C 
overnight and the proteins were precipitated by centrifugation (30 min, 4°C, 21000 
rcf). The pellet was again washed with 80% (v/v) ethanol and dried prior to 
resuspension in sample buffer. For both precipitation approaches, a small amount 
(1 µl) of GlycoBlue can be added to the sample prior to precipitation in order to 
increase the visibility of the pellet after precipitation. 
3.1.5 SDS-PAGE electrophoresis 
Proteins were resolved by SDS-PAGE electrophoresis using commercial 4-12% Bis-
Tris gels (lifeTechnologies). The samples were mixed with commercial 4x LDS-






1x MOPS buffer at 200 V for 55 min. Afterwards the proteins were visualized by 
Coomassie staining. 
3.1.6 Coomassie staining of proteins 
To stain SDS-PAGE gels with Coomassie blue, the gel was first fixated for 30 min 
in 40% (v/v) methanol; 10% (v/v) acetic acid and then washed twice for 15 min with 
ddH2O. To stain the proteins, heated sensitive Coomassie blue solution was added 
to the gel and kept overnight at RT. To destain the gel, it was washed multiple times 
with ddH2O, until the background staining reached an acceptable level. 
3.1.6.1 SPYRO Ruby staining of proteins 
To stain proteins with SPYRO Ruby the proteins were first separated on an SDS-
PAGE gel by gel electrophoresis. The gel was then fixated overnight using fixation 
solution [30% (v/v) ethanol, 10% (v/v) acetic acid] and after fixation the gel was 
equilibrated for staining by three incubations in 20% ethanol for 30 minutes each. In 
parallel, the dye stock solution was diluted in water to a final concentration of 1 µM 
and added to the gel. The gel was exposed to the dye for 6 hours, while being kept 
dark. After the staining was completed, the gel was equilibrated in water for 10 
minutes twice and then destained for a minimum of 16 h using a destaining solution 
[40% (v/v) ethanol, 10% (v/v) acetic acid]. Once destaining was completed, the 
stained proteins could be visualized by fluorescence measurements using the 
SPYRO Ruby filter on the FLA-7000. 
3.1.7 Western Blot 
To transfer proteins from a SDS-PAGE gel onto a nitrocellulose membrane (GE 
healthcare Amersham Protran 0.2 µM nitrocellulose) a tank-blot procedure was 
used. For blotting, a sandwich of a foam pad, three layers of Whatman 3 mm paper, 
SDS gel, nitrocellulose membrane, three additional layers of Whatman 3 mm paper 
and another foam pad was assembled in a gel holder cassette of the BioRad Trans-
Blot Cell system. The gel holder cassette was then submerged in blotting buffer. 
The transfer was facilitated by applying a constant voltage of 70 V for 2 h at 4°C. 
Once the transfer was completed the nitrocellulose membranes were removed and 
blocked by incubating in 5% (w/v) milk-TBST for 1 h at room temperature. Detection 
of bound proteins was then achieved by incubation with specific primary antibodies 






antibody the membrane was washed three times in TBST for 10 min at room 
temperature and to detect bound primary antibody the blot was exposed to 
secondary antibodies conjugated with horseradish peroxidase diluted 1:40000 in 
5% (w/v) milk-TBST for 1 h at room temperature. The secondary antibody was 
removed by three 10 min washing steps of TBST, followed by detection with the 
ECL Western Blot Detection Kit (GE Healthcare) according to the manufacturer’s 
instructions. Images were acquired by exposing to X-ray films or digitally with the 
Amersham imager 580 (GE). 
3.1.7.1 Striping of Western Blots 
If a western blot membrane was used for multiple different primary antibodies, it was 
necessary to remove any previously bound antibodies. For this, the membrane was 
incubated with stripping-buffer for 30 min at 50°C and then washed with TBST twice 
for 15 min at room temperature. The stripped membrane was then incubated with 
to primary antibody after blocking as described above. 
3.1.8 Restriction digest of plasmid DNA 
To digest plasmid DNA with restriction endonucleases plasmid DNA was incubated 
with the appropriate endonuclease/buffer combination. The exact reaction setup is 
described in the following table: 
Table 3.1 – General restriction digestion reaction 
Component Amount 
Plasmid DNA 1 µg 
Restriction enzyme 10 U 
10x buffer 1x buffer 
H2O Ad 50 µl 
 
The reaction was then incubated for 2 h at 37°C. After restriction digestion the DNA 
fragments can be separated by agarose gel electrophoresis and gel purified using 
a gel extraction kit. 
3.1.9 SYBR gold staining of RNA 
To stain RNA separated on SDS-PAGE gels, SYBRgold® (ThermoFischer) staining 






min and then washed with water once for 15 min followed by two 15 min washing 
steps with 1x TBE. After the final 1x TBE washing the SYBRgold dye was diluted in 
1x TBE 1:10000 and added to the gel. The gel was then protected from light and 
incubated with the staining solution for 1h. After the incubation period has passed, 
RNA can be visualized using the TAMRA-filter on a FLA-7000 machine. If desired 
the gel can now directly be stained with Coomassie blue to visualize proteins. 
3.1.10 Agarose gel electrophoresis 
To separate DNA fragments by size, agarose gel electrophoresis was performed. 
Depending on the desired resolution 0.5-2% (w/v) of agarose were dissolved in 1x 
TBE buffer, mixed with 1x SYBR Safe DNA stain, and used to cast a gel. The gel 
was then placed in an electrophoresis chamber and the sample, mixed with loading 
dye, were loaded into the wells. Gels were run for ~1 h at 150 V in 1x TBE buffer. 
After electrophoresis, the DNA was visualized using an Invitrogen Safe Imager Blue-
Light Transilluminator. 
3.1.11 Extraction of DNA from agarose gels 
To extract DNA fragments from agarose gels the DNA fragments were separated 
by size using agarose gel electrophoresis and the fragments were visualized using 
the Invitrogen Safe Imager Blue-Light Transilluminator. The bands corresponding to 
the desired fragment size were cut out of the gel using a sterile scalpel and placed 
in Eppendorf tubes. The commercial PCR& Gel extraction kit of Macherey-Nagel 
was then used according to the manufacturer’s instructions to extract the DNA. 
3.1.12 Ligation of DNA fragments 
To ligate DNA fragments ligation with T4 DNA ligase were performed. Fragments 
were mixed with a molar ratio of 3:1 for sticky-end ligations and 7:1 for blunt end 
ligations. In total 100 ng of plasmid fragments were combined with 1x T4 DNA-ligase 
buffer and 1 µl of T4 DNA ligase per 10 µl of ligation reaction. The assembled 
reaction was then incubated at 16°C overnight. After ligation the reaction containing 
the ligated fragments could be used for E.coli transformation directly. 
3.1.13 Generation of chemically competent E.coli 
To generate chemically competent E.coli cells, 3 ml LB-medium were inoculated 






37°C overnight. The starter culture was then added to 500 ml SOB medium and 
grown to an OD600nm between 0.4 and 0.6. After the desired OD was reached, the 
culture was placed on ice for 10 minutes and then the cells were pelleted by 
centrifugation (10 min, 5900 rpm, 4°C in F14-14 rotor). After centrifugation the pellet 
was resuspended in ice cold TB-buffer and incubated on ice for 10 minutes. 
Afterwards the cells were pelleted by centrifugation (10 min, 3400 rpm, 4°C in F14-
14 rotor) again and then resuspended in 18.6 ml TB and 1.4 ml DMSO. The cell 
suspension is then incubated on ice for another 10 min. Then the competent cells 
were aliquoted in to 50 µl aliquots and frozen in liquid nitrogen. The competent cells 
can then be stored at -80°C for several years. 
3.1.14 Transformation of chemically competent E.coli 
To transform chemically competent E.coli the cells were thawed on ice and then 100 
ng of plasmid DNA were added to 100 µl of competent bacterial cells. The DNA-
bacteria mixture was incubated on ice for 30 min followed by a 45 second heat-
shock at 42°C and a 2 minute regeneration period on ice. After the regeneration 
period, the transformed bacterial cells were combined with 2 ml of LB-medium 
without antibiotics and incubated in a shaker at 37°C for 1 hour prior to being plated 
onto LB-Agar plates containing the appropriate antibiotic selection marker. The 
plates were then placed in a 37°C incubator to grow the bacterial colonies. After 
single colonies formed, individual colonies were picked using a sterile toothpick and 
used to inoculate 2 ml cultures. 
3.1.15 Purification of plasmid DNA from E.coli 
To isolate plasmid DNA from E.coli culture two commercial kits were used. For small 
preparations (up to 2 ml culture volume), the Roche Plasmid Mini Kit was used 
according to the manufacturer’s instructions. For large scale preparations with up to 
500 ml culture volume the MaxiPrep Kit from lifeTechnologies was used according 
to the manual. The purified precipitated plasmid was resuspended in TE buffer. 
3.2 Construct design 
3.2.1 Design of the ZDHHC16-MS2 plasmid 
The ZDHHC16 pre-mRNA transcription plasmids were designed by extracting the 






control of a T7 RNA polymerase promoter. In addition, three MS2-loops were added 
to the 3’ end of the exon 10. The whole plasmid was then synthesized by GeneScript 
in a vector (pUC57) containing an ampicillin resistance.  
3.2.2 Design of MINX-exon complex plasmid and its derivatives 
The MINX exon plasmid was designed as a derivative of the original MINX-MS2 
plasmid. To generate the MINX exon plasmid, the 5’ exon of MINX and part of the 
adjacent intron were removed and replaced with a T7 promoter sequence. The 
remaining 3’ side of the intron and the 3’ exon were left unchanged. A 5’splice site 
was added to the 3’ end of the exon followed by a 15 nt spacer in between the 5’SS 
and the MS2-loops. The derivatives used for the analysis of the cross exon complex 
assembly on genes sensitive to the SF3b1K700E mutation were designed by replacing 
the region from 25 nt upstream of the cryptic branch point to the last most 3’ 
nucleotide with the same region from the affected intron of the gene of interest. The 
plasmids were then synthesized externally, by GeneScript, and subsequently used 
for transcriptions. 
3.2.3 Design of lentiviral plasmids and transient expression vectors 
3.2.3.1 Generation of a tagged SF3b1 plasmid 
To generate a tagged SF3b1 expression construct the cDNA sequence of SF3b1 
was synthesized (GeneScript) and ligated into an empty vector. The N- and C- 
terminal tags for SF3b1 were then added by restriction digestion and ligation. For 
this dsDNA oligomers, containing the appropriate restriction sites, were restriction 
digested and ligated into the similarly prepared vector. The ligated vector was then 
transformed into competent E.coli and integration of the tags was verified by DNA 
sequencing. 
3.2.3.2 Generation of lentiviral expression vectors 
The vectors used for the lentiviral expression of tagged SF3b1 were created by 
ligating a SF3b1 expression construct into the multiple cloning site of the respective 
vector. For lentiviral experiments and transient expressions, the pWPI backbone 
was used to create an expression vector. The SF3b1 cDNA was excised from its 
plasmid using Pac I and Pme I restriction enzymes and the pWPI vector was 






separated on an agarose gel and the correct fragment was isolated using agarose 
gel extraction. The resulting fragments were ligated using T4 DNA ligase and cloned 
into competent E.coli. 
3.2.4 Sequencing of plasmid DNA 
In order to obtain sequence information 1 µg of plasmid DNA was combined with 3 
µl of 10 µM sequencing primer and sent to MicroSynth® for Sanger sequencing. 
The resulting sequence files were aligned using the ClustalOmega tool for multiple 
sequence alignments. 
3.3 Cell culture 
3.3.1 General cell maintenance 
HeLa S3 cells (Computer Cell Culture Center, Belgium) were grown in suspension 
in S-MEM media supplemented with 5% (v/v) newborn calf serum, 50 µg/ml 
penicillin and 100 µg/ml streptomycin. Cultivation and harvesting of the cells was 
done as described in (Dignam et al., 1983). 
Adherent HEK293T cells were grown in DMEM (Gibco) supplemented with 10% 
(v/v) fetal bovine serum (Gibco) and 100 U/ml of both penicillin and streptomycin. 
The cells were maintained in a non-confluent monolayer and split at a confluence of 
~80%. To detach the cells from the cell culture flask/dish, the medium was aspirated 
and the cells were washed with 1xPBS, then Accutase (Gibco) was added and the 
cells were incubated for 5 min at room temperature. After incubation, the cells were 
carefully detached by carefully washing them off with culture medium. The cell 
suspension was then counted and could be used to seed new culture containers. 
The seeding density for new plates/flasks was kept at roughly 105 cells/cm². 
K562 suspension cells were cultivated in IMEM medium supplemented with 10% 
(v/v) heat inactivated fetal bovine serum (Gibco) and 100 U/ml of both penicillin and 
streptomycin. During culture in flasks, the cell density was kept between 3x105 and 
1.5x106 cells per ml. During cultivation in spinner flasks, the cells were constantly 
stirred at 40 rpm and 1x Pluronic F-86 (Gibco) was added to the medium in addition 
to the normal supplements used for culturing K562 cells in flasks. The cell density 
was maintained in the range of 3x105 to 1.2x106 cells per ml. To split K562 cells, the 






500 rcf at room temperature. After centrifugation the supernatant was aspirated and 
the cell pellet was carefully resuspended in preheated medium. Then the cell density 
was measured and an appropriate amount of cells was added to the new culture. 
For cells growing in large (3l and 6l) spinner flasks the cell density was kept in an 
acceptable range by increasing the culture volume without replacing the culture 
medium completely. This was done to minimize the risk of contamination. 
3.3.2 Cell counting 
To evaluate the cell density an improved Neubauer chamber was used. The 
Neubauer chamber allows the counting of cells in a defined volume, therefore the 
cell density can be calculated, based on the observed cell count and the used 
dilution-factor (d). 
𝑐𝑒𝑙𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 = 𝑑 × 
𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡
𝑛
 × 104 
3.3.3 Transfection of HEK293T cells 
Transient transfections of HEK293T cells were performed with polyethyleneimine 
(PEI). To transfect cells with PEI the plasmid DNA was mixed with the cationic 
compound to form particles that precipitate onto the cells and are taken up into the 
cell nucleus. To form these particles dissolved PEI was mixed with plasmid DNA. 
PEI and DNA were combined in a ratio of 3 µg of PEI with 1 µg of DNA in 25 µl of 
OPTI-MEM, commonly 1 µg DNA per 7.5 cm² of adherent cells were used. The PEI-
DNA mixture was then vortexed briefly and kept at room temperature for 15 to 30 
minutes. Once incubation is completed the PEI-DNA mixture is carefully added to 
the cells and kept on the cells for 24 h. After 24 h the medium containing the PEI-
DNA particles was carefully aspirated and replaced with normal preheated culture 
medium. To further increase the transfection efficiency the ratio of PEI to DNA can 
be increased up to 7 to 1. 
3.3.3.1 Preparation of PEI 
The PEI solution was prepared by dissolving 25 kDa polyethyleneimine to a final 
concentration of 1 µg/µl in water. To dissolve the PEI in water it is necessary to 
decrease the pH-value of the solution to approximately 2, at this pH the PEI will go 






hydroxide. The PEI solution can then be stored at 4°C for one month or at -20°C for 
a minimum of four years. 
3.3.4 Preparation of HeLa S10 nuclear extract 
To prepare splicing active nuclear extract from HeLa S10 cells, the protocol 
described in Dignam et al., 1983 was used with some modifications. Six to eight 
liters of cells were grown to a density of 5x 105 cells/ml and harvested by 
centrifugation in a Heraeus Cryofuge 6000i (10 min at 2000 rpm). The supernatant 
was aspirated and the cell pellet was washed thrice with 1x PBS pH 7.4. The pellet 
was then carefully resuspended in 1.25 volumes of 1x MC buffer containing 2 tablets 
of cOmplete EDTA-free protease inhibitor (Roche) per 50 ml of buffer. After 5 min 
incubation on ice the cells were transferred into 100ml douncers and while being 
kept on ice dounced 18-times. The cell suspension was then transferred to falcon 
tubes and the nuclei were pelleted by centrifugation in an SS34 rotor (13000 rcf, 5 
min and 4°C). After centrifugation the supernatant was removed and the nuclei pellet 
was resuspended in 1x RC buffer containing 0.5 mM DTE and 0.5 mM PMSF. To 
disrupt the nuclei they were again treated with 20 strokes of the dounce 
homogenizer while being kept on ice. The lysate was then stirred for        40 min at 
4°C and centrifuged in a SS34 rotor for 30 min at 16000 rpm at 4°C to remove 
debris. The recovered supernatant could then be frozen in liquid nitrogen for long-
term storage or dialyzed against 50 volumes of RD buffer. For dialysis, the 
supernatant was poured into pre-wetted SnakeSkin® dialysis tubing with a cut-off 
of 7000 Da and placed in RD for 5 h with an exchange of dialysis buffer after 2.5 h. 
Once the dialysis was completed, the resulting RD-nuclear extract was again 
centrifuged in the SS34 rotor (10 min, 16000 rpm, 4°C). After centrifugation the 
nuclear extract was aliquoted and frozen in liquid nitrogen prior to storage at -80°C. 
3.3.5 Preparation of small scale nuclear extracts from K562 cells 
To prepare small scale nuclear extracts from K562 cells the aforementioned large 
scale protocol was used with minor adjustments to accommodate the smaller pellet 
size. The main difference was using a smaller douncer. In addition, the final 
centrifugation step was carried out in 2 ml aliquots using a tabletop centrifuge (2 






3.4 In vitro splicing reactions 
3.4.1 Template generation for in vitro transcription 
To obtain specific RNA molecules for biochemical experiments, in vitro 
transcriptions were used. For this purpose, transcriptions plasmids encoding the 
different pre-mRNAs were isolated from XL-10 gold chemically competent E.coli 
using the Invitrogen® PureLink Maxiprep Kit according to the manufacturer’s 
instructions. Plasmid DNA was then resuspended in ddH2O and the sequence 
integrity was validated by sequencing. To generate a template for run-off 
transcription the plasmid DNA was linearized by restriction digestion with XbaI 
endonuclease (NEB). For this 25 µg of plasmid DNA were combined with 100 U 
enzyme and the appropriate buffer, and the reaction was then incubated overnight 
at 37°C. To isolate the digested plasmid DNA agarose gel-electrophoresis was 
performed to purify preparative amounts of linearized plasmid. The restriction 
digestion reactions were combined with 6x loading dye (supplied by NEB) and run 
on a 1% (w/v) agarose gel at 150 V for 30 min. 
The 1% agarose gel was prepared by melting an appropriate amount of agarose in 
1xTBE buffer and adding 1xSYBRsafe DNA stain after a short cooling period. The 
finished mixture was then used to pour a gel. After gel-electrophoresis, the DNA 
was visualized using blue light (wavelength of 470 nm). The desired bands were 
carefully cut out of the gel using a sterile scalpel and the DNA was extracted using 
the Macherey-Nagel Gel and PCR purification kit according to the manufacturer’s 
instructions. 
3.4.2 In vitro transcription 
RNA in vitro transcriptions were carried out using T7 RNA polymerase run-off 
transcription and Xba I-linearized DNA templates. Uniformly 32P labeled RNA was 
obtained by performing RNA synthesis in the presence of -32P-UTP. The 
composition of a transcription reaction is shown in the following table: 







The transcription reaction was performed at 37°C for 2.5 h. After completion of 
transcription, the DNA-template was removed by adding RQ1 DNase (1 U/µl, 
Promega) treatment for an additional 30 min at 37°C. To remove excess 
unincorporated NTPs from the reaction the sample was either run on a denaturing 
PAGE gel electrophoresis or applied to Illustra G-50 columns (GE healthcare) 
according to the manufacturer’s instructions. In case of purification via PAGE 
electrophoresis, the bands on the gel were visualized via autoradiography and then 
cut out of the gel with a sterile scalpel. To extract the RNA from the gel, excised gel 
pieces were submerged in gel extraction buffer [20 mM Tris, pH 7.5, 0.2 mM EDTA, 
pH 8.0, 150 mM NaCl, 0.5% SDS] and kept at 4°C overnight. Afterwards the RNA 
was isolated from the gel extraction buffer using PCI extraction. 
For all RNAs the concentration was determined using the NanoDrop and in case of 
32P-radiolabelled RNA molecules, the specific activity was determined by 
Cherenkov counting.  
3.4.3 In vitro splicing reactions 
To splice pre-mRNA in vitro radiolabeled RNA is added to a splice reaction. The 
splice reaction combines nuclear extract with energy substrates and salt. The 
reaction is set-up as follows, with the nuclear extract providing the entire potassium 
chloride and HEPES buffer required for the reaction: 
Table 3.3 - Röder D splice reaction 
Component Final concentration 
RD Nuclear extract 40% 
ATP 2 mM 
Creatine phosphate 20 mM 
Magnesium chloride 3 mM 
RNA 10 nM 
Component Stock Concentration
Final concentration Volume (µl) Final concentration Volume (µl) Final concentration Volume (µl) Final concentration Volume (µl)
HTRO buffer 5x 1x 1x 1x 1x
ATP 100mM 7.5mM 1.5 7.5mM 1.5 7.5mM 1.5 7.5mM 1.5
CTP 100mM 7.5mM 1.5 7.5mM 1.5 7.5mM 1.5 7.5mM 1.5
GTP 100mM 1.5mM 0.3 7.5mM 1.5 7.5mM 0.3 7.5mM 1.5
UTP 100mM 1.5mM 0.3 7.5mM 1.5 1.5mM 0.3 7.5mM 1.5
m7G(5')ppp(5')G-cap 174mM 5mM 0.6 5mM 0.6
linear template 0.5µg/µl 50ng/µl 1 50ng/µl 1 50ng/µl 1 50ng/µl 1
Rnasin 40U/µl 1U/µl 0.5 1U/µl 0.5 1U/µl 0.5 1U/µl 0.5
YIPP 40U/µl 0.5U/µl 0.25 0.5U/µl 0.25 0.5U/µl 0.25 0.5U/µl 0.25
T7 RNA polymerase 20U/µl 1U/µl 1 1U/µl 1 1U/µl 1 1U/µl 1
-32P-UTP 10mCi/µl; 3000 Ci/mmol 5 5
ddH2O 8.05 13.05 8.65 13.65
total 20 20 20 20







The splice reaction is then incubated at 30°C for the required time. 
Splice reactions that are performed using Röder C nuclear extract were carried out 
with the same general procedure; however the initial reaction setup changes slightly: 
Table 3.4- Röder C splice reaction 
Component Final concentration 
RC Nuclear extract 20% 
ATP 2 mM 
Creatine phosphate 20 mM 
Magnesium dichloride 3 mM 
Potassium chloride 60 mM 
HEPES-KOH (pH 7.9) 20 mM 
RNA 10 nM 
  
Additionally it is necessary that the RNA is pre-incubated with MS2-MBP in order to 
prevent premature RNA degradation. 
For experiments carried out in the presence of Pladienolide B, the reaction mixture 
without RNA was pre-incubated with Pladienolide B on ice for 10 minutes prior to 
the addition of the RNA. 
3.4.4 In vitro assembly of cross exon complexes 
The assembly of exon complexes was performed with exon RNA and RD nuclear 
extract under the same conditions that were used to perform in vitro splicing 
reactions outlined above, except the RNA concentration was reduced to 1 nM. 
3.4.5 Analysis of splicing complexes by native electrophoresis 
To visualize formation of spliceosomal complexes electrophoretic methods can be 
employed. Due to significant differences in migration speed, spliceosomal 
complexes can be separated on low percentage agarose gels and the respective 






To analyze complex formation on native gels, splice reactions were performed as 
described above and, after completion of the incubation time, the reaction was 
mixed with 0.15 µg/µl heparin and stored on ice to stop the reaction. The samples 
were then supplemented with an appropriate amount of native-gel loading-dye and 
loaded onto a 1-2% low melting agarose gel prepared with 0.5x TBE buffer. 
Electrophoresis was then carried out at 80 V for 5 h in 0.5x TBE buffer at 4°C. After 
electrophoresis, the gel was dried for 5 h at 60°C prior to visualization of complex 
formation via autoradiography or with a PhosphorImager. 
3.4.6 Denaturing polyacrylamide gel-electrophoresis 
Polyacrylamide gel-electrophoresis (PAGE) was used to separate RNA molecules 
by size. For the separation of the RNA-products of in vitro splicing denaturing PAGE 
with 8M urea was used. Depending on the size of the expected RNA-products the 
gels were prepared containing 6-15% (v/v) acrylamide solution (40:1), 1xTBE and 
8M urea. To initialize polymerization of the gels 300 µl of 20% (w/v) ammonium 
persulfate solution and 60 µl tetramethylethylenediamine (TEMED) were added to 
100 ml of gel solution. After polymerization the gel was prepared for the samples by 
washing the pockets with 1x TBE buffer and a 10 min pre-run, followed by another 
washing of the pockets. The RNA samples were dissolved in RNA-loading dye and 
briefly heated to 95°C for 5 min and chilled on ice prior to loading. The 
electrophoresis was performed at 16 W in 1x TBE. Afterwards the gel was fixed in 
40% (v/v) methanol; 10% (v/v) acetic acid, dried for 1 h at 80°C and the radioactive 
RNA was visualized by autoradiography or with a PhosphorImager. 
3.4.7 MS2-affinity selection of splicing complexes 
To isolate spliceosomal complexes from in vitro splicing reactions an MS2-affinity 
purification approach was used, as described in (Bessonov et al., 2010). The pre-
mRNA was incubated for 30 minutes on ice with a 5 to 10-fold molar excess of MS2-
MBP fusion protein in 20 mM HEPES-KOH, pH 7.9 buffer. Then the RNA was added 
to a splicing reaction of the desired size. After the reaction was completed, it was 
loaded onto an amylose affinity column. For analytical experiments, the reaction 
was passed through the column by gravity flow, while preparative experiments used 
commercial HiTrap MBP columns. Gravity flow columns were prepared with 






amount to a gravity flow column. The column was then washed with 10 bed-volumes 
of G-150 buffer. The splicing reaction was then added and passed through the 
column by gravity. After binding of the MS2-tagged complexes, the column was 
washed with 10 bed-volumes of G-150 buffer and then the bound complexes could 
be eluted using 10 mM maltose in G-150 buffer. The commercial HiTrap MBP 
columns were used according to the manufacturer’s instructions and the bound 
complexes were eluted using the same G-150 buffer containing 10mM that was 
used for the gravity columns. 
3.5 Other Complex and protein purifications 
3.5.1 Purification of MS2-MBP 
E.coli bacteria expressing the MS2-MBP-StrepII protein were grown in LB-medium 
at 37°C and harvested at an OD of 2. The cells were then harvested by 
centrifugation and the cell pellet was frozen in liquid nitrogen for storage. To isolate 
the MS2-MBP protein the pellet was thawed and resuspended in five volumes of 
buffer A [20 mM Tris-HCl, pH 7.4, 200 mM NaCl, 1 mM DTT, 1 mM MgCl2, 1x 
cOmplete protease inhibitor] and the cells were disrupted by harsh sonication (70% 
power, 15 min). The disrupted cell slurry was then clarified by centrifugation (30000 
rcf, 30 min at 4°C) and the supernatant was collected. The pooled supernatant was 
then applied to a Streptactin HiTrap 5 ml column to purify the MS2-MBP-StrepII 
protein. The columns were prepared for affinity purification according to the 
manufacturer’s protocol and pre-equilibrated with 10 column-volumes of buffer A. 
The clarified cell lysate was then applied over several hours with a loading speed of 
0.2 ml/ minute. After loading the column was washed with 10 column-volumes of 
buffer A (not containing protease inhibitor or MgCl2). Afterwards the column was 
washed with 10 column volumes of amylose matrix wash buffer [20 mM HEPES-
KOH, pH 7.9, 150 mM NaCl, 0.05% (v/v) NP-40]. The bound protein was then slowly 
(0.1ml/ min) eluted with heparin elution buffer      (20 mM HEPES-KOH, pH 7.9, 150 
mM NaCl, 15% glycerol (v/v) and 5 mM desthiobiotin). The elution fractions were 
quantified by a Bradford assay and the peak fractions were pooled. The pooled 
elution fractions were then concentrated using an equilibrated Amicron 10 MWCO 
column. After concentration the final protein concentration was measured on a 






StrepII: 55.4 kDa). The isolated protein was then aliquoted and frozen in liquid 
nitrogen. For long term storage the aliquots were kept at -80°C. 
3.5.2 Anti-FLAG purification of 17S U2 particles 
The anti-FLAG affinity column was prepared with Sigma M2 anti-FLAG beads. Prior 
to application of the pooled gradient fractions, the beads were washed twice with 5 
bed-volumes of G-150 buffer containing 2% (w/v) sucrose (denoted washing buffer). 
After the initial washing step to remove the storage buffer potentially bound 
contaminants were removed by washing the column with 2.5 bed volumes of 0.1 M 
glycine (pH 3.5) followed 20 bed-volumes of washing buffer. 
To purify 17S U2 particles via the N-terminal FLAG-tag of SF3b1, nuclear extract 
containing the tagged protein was prepared using the small scale nuclear extract 
protocol outlined above. The nuclear extract was then dialyzed against Röder D 
buffer and the resulting dialyzed extract was applied to SureSpin gradients. The 
gradients were prepared as linear 5-20% (w/w) sucrose gradients containing G-150 
buffer. In order to accommodate a larger amount of extract per gradient, 3.3 ml of 
the nuclear extract were applied to each gradient. The gradients were then 
centrifuged for 18:15 h at 4°C and 29500 rpm. After centrifugation, the gradient was 
fractionated into 1.5 ml fractions and aliquots of each fraction were analyzed by 
PAGE, followed by SYBR gold staining to visualize the distribution of snRNA across 
the gradient. Fractions in the 17S region of the gradient containing the U2 snRNA 
were pooled and mixed with an equal volume of G-0 buffer, to reduce sucrose 
content and salt concentration. The diluted gradient fractions were then applied to 
the anti-FLAG affinity column and incubated on the column for 2h by rotating head-
over-tail. 
The column was washed with 5 bed-volumes of wash buffer twice. To elute the 
bound complexes, 0.5 bed-volumes of elution buffer (0.1 mg/ml 3xFLAG-peptide in 
wash-buffer) were added to the column and drained by gravity flow. The column 
was then capped and 1 bed-volume of elution buffer was added and incubated on 
the beads for 15 minutes. The elution buffer was drained by gravity flow and was 
collected in an Eppendorf tube. Afterwards four to nine additional elution fractions 






then analyzed for their snRNA and protein content, frozen in liquid nitrogen and 
stored at -80°C. 
3.5.3 Crosslinking of 17S U2 snRNPs and crosslink identification  
Affinity-purified 17S U2 snRNPs were cross-linked with 75 µM BS3 for 30 min at 20 
°C. The reaction was stopped by adding Tris-HCl, pH 7.9 to 10 nM and crosslinked 
U2 was further purified further by centrifugation on 10-25% (w/v) glycerol gradients 
in G150 buffer. Crosslinked 17S U2 particles sedimenting in the 17S region of the 
gradient were pelleted by ultracentrifugation and then analyzed as described by 
(Leitner et al., 2014), with some modifications as follows: pelleted material was 
dissolved in 4 M urea- 50 mM ammonium bicarbonate, reduced with DTT, alkylated 
with iodoacetamide, and the mixture was diluted to an end concentration of 1 M urea 
before digesting with trypsin (1:20 w/w).  Peptides were reverse-phase extracted, 
fractionated by gel filtration on a Superdex Peptide PC3.2/30 column (GE 
Healthcare) and analyzed on a Thermo Scientific Q Exactive HF mass 
spectrometer. Protein-protein crosslinks were identified by pLink 1.23 search engine 
(pfind.ict.ac.cn/software/pLink) and filtered at FDR 1% according to the 
recommendations of the developer (Yang et al., 2012). 
3.5.4 Affinity purification of 17S U2 from HeLa nuclear extract 
HeLa nuclear extract was prepared essentially as described by Bertram et al. 
(2017b), except that the nuclei were extracted with a modified buffer Roeder C buffer 
containing 250 mM KCl and 8.5 mM MgCl2. After centrifugation to remove non-
soluble material, the extract was fractionated on a 17-30% (w/v) sucrose gradient 
containing 1X GK5M buffer [20 mM Hepes-KOH, pH 7.9, 150 mM KCl, 5 mM MgCl2, 
0.2 mM EDTA, pH 8.0]. Peak fractions containing 17S U2 were pooled, loaded onto 
an anti-SF3B1 affinity column and bound 17S U2 snRNPs were eluted with 0.2 
mg/ml SF3B1 peptide (EQYDPFAEHRPPKIAC) in 1X GK5M + 1.5% sucrose. 
3.5.5 Anti-FLAG affinity purification of exon complexes 
To purify exon complexes from the K562 nuclear extract the complexes were 
assembled on radiolabeled RNA as described in “In vitro exon complex assembly”. 
The assembled complex was first isolated from the nuclear extract by MS2-selection 
and then eluted using maltose containing elution buffer. The eluates were pooled 






column was then washed twice with 5 bed-volumes of wash buffer. To elute the 
bound complexes, 0.5 bed-volumes of elution buffer (0.1 mg/ml 3xFLAG-peptide in 
wash-buffer) were added to the column and drained by gravity flow. The column 
was then capped and 1 bed-volume of elution buffer was added and incubated on 
the beads for 15 minutes. The elution buffer was drained by gravity flow and was 
collected in an Eppendorf tube. The proteins were then precipitated and analyzed 
by mass spectrometry. 
3.6 Mass spectrometry 
3.6.1 Protein identification by MS 
To identify protein by mass-spectrometry, the sample containing the proteins of 
interest were first separated by 1-D gel electrophoresis (see chapter 4.1.5). The gel 
was then cut into pieces and the proteins were digested in-gel with trypsin and 
extracted as described in (Shevchenko et al., 1996). The extracted peptides were 
identified in a liquid-chromatography coupled electrospray ionization quadrupole 
time of flight (Q-ToF) or Orbitrap mass spectrometer. Proteins were identified by 
searching fragment spectra against the UniProt reference database using Mascot 
as a search engine. 
3.6.2 Proteome analysis by MS 
To analyze the proteome of K562 cells tandem mass tag-labeling (TMT-labeling) 
was performed (Thompson et al., 2003). Equal amounts of K562 cells expressing 
wild-type SF3b1 and K700E SF3b1 were harvested by centrifugation (5 min, 500 
rcf, RT) and washed with PBS twice. The washed pellet was then lyzed by adding 
5 pellet volumes of lysis buffer (1% SDS in 100 mM TEAB). The lysate was then 
clarified using centrifugation (10 min, 16000 rcf, 4°C) and the supernatant was 
transferred into a new Eppendorf tube. The clarified lysate was then precipitated by 
adding six volumes of acetone and chilling the sample overnight at -20°C followed 
by centrifugation (8000 rcf, 10 min at 4°C). The protein pellet was resuspended in 
100 mM TEAB. RapiGest (in 50 mM TEAB) and DTT were added to a final 
concentration of 0.1% (RapiGest) and 10mM (DTT) and incubated for 1 h at 55°C. 
After incubation, the sample was cooled to RT and iodoacetamide was added to a 
final concentration of 20 mM and incubated at RT (in the dark) for 1 h. Afterwards 






of 50 mM TEAB and 1x of the 50x trypsin stock solution was added. The sample 
was then kept at 37°C overnight to digest the proteins.  
To prepare the TMT-labels 41 µl of anhydrous acetonitrile were added to 0.8 mg of 
labeling reagent and the reagent was dissolved for 5 min with occasional vortexing. 
The dissolved TMT-reagent (TMT 126 for SF3b1wt and TMT 127 for SF3b1K700E) 
was then added to 100µl of the trypsin digested protein sample and incubated for    
1 h at RT. After the incubation, 8 µl 5% hydroxylamine were added to each reaction 
and incubated for 15 min to quench the reaction. At this stage, the sample could be 
stored at -80°C if desired. Prior to mass spectrometry the samples were cleaned 
with C18 spin tips. To clean the sample the C18 tip was pre-washed with 400 µl 
100% acetonitrile twice, followed by one wash step with 50% acetonitrile, 0.1% 
formamide in water and three wash steps with 0.1% formamide in water. The sample 
was then passed over the column twice followed by two wash steps with 0.1% 
formamide in water. The bound peptides were then eluted in 200µl 0.1% formamide, 
50% acetonitrile in water. The eluted peptides were dried in a vacuum centrifuge 
and stored at -80°C. 
3.7 Electron microscopy 
Structural analysis of isolated complexes was done by negative stain and cryo-EM. 
All EM experiments were done in collaboration with Dr. Norbert Rigo. For EM 
investigations complexes were purified using the outlined MS2-affinity purification 
approach. Due to the concentration requirements of cryo-EM preparation reactions 
were scaled up (up to 400 ml), so that a post-gradient yield of 10-20 pmol of 
spliceosomes in the peak fractions could be expected. The eluate of the MS2 
selection was applied to linear 5-20% (w/v) sucrose gradients (TST41.14 rotor, 
27500 rpm, 18 h and 4°C). Post centrifugation the gradient was fractionated by hand 
and the presence of radioactive pre-mRNA was detected by Cherenkov counting. 
Peak fractions corresponding to the desired A complex were then pooled and buffer-
exchanged on Amicron 50 kDa MWCO columns. Afterwards the sample was used 
to prepare grids for negative stain or cryo-EM microscopy. 
For negative stain, the sample was adsorbed to a thin carbon film for 10-30 min and 
then transferred to a staining solution [2% (w/v) uranyl formate)] and stained for 2 






Images were acquired on a CM200 FEG electron microscope (Philips, Netherlands) 
equipped with a 4k x 4k charge coupled CCD camera at 88000 fold magnification. 
For each data set, images containing approximately 75000 particles were collected. 
The particles were then picked using the Warp software package and classified 
using Relion. Cryo-EM grids were prepared by adsorbing particles to a carbon film 
followed by removal of excess liquid with a VitroBot (ThermoScientific) prior to 
freezing in liquid ethane. The frozen grids were then stored under liquid nitrogen. 
For gold grids, the sample was applied directly to the grid, excess liquid was 
immediately blotted away, and the grid was plunge frozen in liquid ethane. The gold 
grids were then also stored in liquid nitrogen until image acquisition took place. 
Images were acquired using a Titan Krios (FEI) equipped with a K2 camera (Gatan) 
at a magnification of 110000x. Acquired images were then processed with Warp and 


















4.1 Splicing inhibition by Pladienolide B 
4.1.1 Stalling of splicing in the presence of Pladienolide B 
Pladienolide B (Pladienolide B) leads to an inhibition of splicing both in vitro and in 
vivo (Effenberger et al., 2014a; Kotake et al., 2007). Separate studies have also 
shown that Pladienolide B can interact with the SF3b1 subunit of the SF3b complex 
(Yokoi et al., 2011). Here the compound occupies the SF3b1 pocket that normally 
binds the branch point adenosine and interferes with its normal recognition (Cretu 
et al., 2018; Cretu et al., 2016). In vitro studies indicated that spliceosome assembly 
is stalled by Pladienolide B at an early stage, at either the A or subsequent pre-B 
complex stage (Effenberger et al., 2014a). However, it is not clear how Pladienolide 
B inhibits the spliceosome assembly, in particular whether it alters the composition 
and/or structure of the spliceosome after binding. 
 
 
Figure 4.1- Schematic representation of the MINX pre-mRNA transcript. The pre-mRNA contains two exons 
separated by a 120nt intron. The 5’ exon has a length of 58nt and the 3’ exon is 40nt long. The branch point (A) 
is located 34 nucleotides upstream of the 3’ splice site. In between the branch point and the 3’ splice site a poly-
pyrimidine tract (Yn) can be found. At the 3’ end of the transcript, there are three MS2-loops for affinity 
purification. 
To investigate in more detail the inhibitory effect of Pladienolide B on pre-mRNA 
splicing in vitro, I transcribed 32P-UTP labeled MINX pre-mRNA in vitro and purified 
it. This pre-mRNA contains two adenovirus derived exons and a single intron, in 
which a branch site and poly-pyrimidine (Yn) tract suitable for splicing in human 
nuclear extracts can be found (Figure 5.1). After the 3’ exon three stem-loops that 
bind the MS2 protein have been added to enable the purification of complexes 
assembled on the pre-mRNA. Incubation of this RNA under splicing conditions leads 
to the robust formation of a mature MINX mRNA. I then performed splicing essays 






mRNA. The nuclear extract was pre-treated with Pladienolide B, in the absence of 
the pre-mRNA, by incubating the reaction on ice for 10 minutes. 
 
Figure 4.2 – Effects of increasing concentrations of Pladienolide B on the splicing of 32P-labled MINX-
MS2 pre-mRNA in vitro. Splicing was performed in the presence of various concentrations of Pladienolide B 
in HeLa nuclear extract for one hour. RNA was analyzed by denaturing PAGE (A). Spliceosomal complex 
formation was analyzed on a native agarose gel (B). The position of intron-lariat/3’exon, intron-lariat, pre-mRNA, 
mRNA and the positions of the spliceosomal complexes H/E, A and B are indicated next to the respective gel. 
Bands were visualized by autoradiography. DMSO, control reaction with the compound solvent. 
In the presence of DMSO, the Pladienolide B solvent, the splicing products (mRNA 
and excised intron) and intermediate products (cleaved 5’exon and intron-






concentrations of Pladienolide B shows that splicing is inhibited starting at a 
concentration of 50 nM (Figure 5.2). At 200 nM, both steps of splicing are completely 
inhibited. That is, not only the mature mRNA is no longer formed in the presence of 
Pladienolide B, but also no intermediate products of the splicing of MINX pre-mRNA 
cannot be detected (Figure 5.2a). This leads to the conclusion that the stalling of the 
splicing reaction takes place prior to the first step of splicing, consistent with 
previous studies (Effenberger et al., 2014a). In order to investigate the exact point 
in the splicing cycle at which Pladienolide B inhibits the progression of splicing, in 
vitro splicing reactions were incubated with increasing concentrations of 
Pladienolide B and analyzed by native gel electrophoresis, which allows analysis of 
the formation of spliceosomal complexes. In the presence of DMSO, A complexes 
were seen after two minutes and B complexes after 10 minutes (Figure 5.2b). With 
Pladienolide B, complex assembly was stalled at the stage of an A complex, already 
at 50 nM and further increases in the concentration did not impact the formation or 
the stability of the stalled complex.  
To further investigate the exact nature of the stalled complex I performed less 
stringent gradient centrifugation experiments. The presence of heparin during the 
native gel electrophoresis disrupts weak interactions. For example, the tri-snRNP 
could potentially be loosely bound and thus a pre-B complex might form, but would 
be disrupted by the presence of heparin and not detected on the native gel. For this 
purpose a normal splicing reaction (3 minutes incubation time) and a reaction stalled 
by the addition of 250 nM Pladienolide B (10 minutes incubation time) were 
performed and subjected to linear 10-30% glycerol gradient centrifugation. The 
gradient profiles show that in the absence of Pladienolide B, complexes peak in 
fractions 14-17 and 20-24 (Figure 5.3a). Analysis of the RNA present in these 
fractions indicates they are A and pre-B/ B complexes, respectively. The complexes 
assembled in the presence of Pladienolide B on MINX pre-mRNA peak at the 
position of an A complex. The snRNA profile confirms that the peak observed in the 
gradient of the Pladienolide B stalled splicing reaction indeed corresponds to an A 
complex, indicated by the presence of both the U1 and the U2 snRNA, as well as 
MINX pre-mRNA (Figure 5.3c). No U4, U5 or U6 snRNA can be detected and the 
appearance of a second peak cannot be observed with the Pladienolide B treated 






incubation time is three times as long. We conclude that the presence of 
Pladienolide B in the nuclear extract interferes with the association of the tri-snRNP 
with the A complex, blocking assembly before the formation of the pre-B complex. 
 
 
Figure 4.3 – Glycerol sedimentation profiles of splicing complexes formed in the presence of 250nM 
Pladienolide B or DMSO. In vitro splicing was performed in the presence of DMSO for 3 minutes or 250nM 






separated on a linear 10-30% (w/v) glycerol gradient containing 150mM sodium chloride (1x G-150 buffer), and 
fractionated from the top (A). The radioactivity of each gradient fraction is measured by Cherenkov counting and 
plotted. Peaks corresponding to the A and B spliceosomal complexes are indicated. Splicing extract plus DMSO 
(B) or Pladienolide B (C) were subjected to 10-30% (w/v) gradient centrifugation. RNAs were isolated from 
gradient fractions, separated by PAGE and visualized by SYBR gold staining. RNA identities are indicated at 
the left. 
 
4.1.2 A complexes formed in the presence of Pladienolide B are unstable 
The presence of Pladienolide B in the SF3b core was proposed to lock the HEAT-
domain of the SF3b1 protein in an open conformation (Cretu et al., 2018). However 
cryo-EM structures of the human and yeast spliceosome show that during later 
stages of the splicing cycle SF3b1 adopts a “closed” conformation, tightly grabbing 
the U2 snRNA/branch point helix (Haselbach et al., 2018; Rauhut et al., 2016; Yan 
et al., 2016; Zhang et al., 2018). Since the presence of Pladienolide B potentially 
leads to the arrest of SF3b1 in an open conformation this could impact the stability 
of the assembled complex. In order to evaluate the stability of Pladienolide B stalled 
A complexes compared to kinetically assembled A complexes, I performed a 
heparin titration. Heparin dissociates protein complexes in a concentration 
dependent manner and therefore can be used to analyze complex stability. 
 
Figure 4.4 - Stability of A complexes in the presence of increasing concentrations of heparin. Splicing 
complexes were assembled in splicing extracts +/- 250 nM Pladienolide B and analyzed on native agarose gels 
after addition of increasing amounts of heparin. Bands were visulaized using a PhosphorImager and their 
identity is shown on the left. The comparison of the uninhibited and the Pladienolide B treated A complexes 
shows that the presence of Pladienolide B leads to a significant increase in the heparin sensitivity of the complex, 
starting at concentrations of 0.2 µg/µl. 
The titration of heparin shows that the kinetic A complex is stable in the presence of 
heparin with a final concentration in excess of 0.6 µg/µl (Figure 5.4). The 






heparin concentration exceeds 0.1 µg/µl. Thus it can be concluded, that the A 
complex formed in the presence of Pladienolide B is less stable than the kinetic A 
complex assembled in HeLa nuclear extract. The failure to adopt a closed 
conformation of the HEAT-domain of SF3b1 could negatively impact the association 
of the U2 snRNP with the pre-mRNA. The presence of Pladienolide B could lead to 
changes in the binding of proteins needed for the stable A complex formation or 
could impair the structural rearrangement needed for a more stable A complex 
conformation. Taken together, these results suggest that while the presence of 
Pladienolide B does not impact the initial assembly it does have an influence on the 
A complex itself, since the complex is much less stable in the presence of heparin 
than its kinetic counterpart. 
4.1.3 Affinity purification of Pladienolide B stalled A complexes 
Stalling of spliceosome assembly by Pladienolide B can be the result of changes in 
the composition of the spliceosome or in its structure that prevent the tri-snRNP 
recruitment and stable integration. However, the exact consequences of the binding 
of Pladienolide B to SF3b1 on the structure and composition of spliceosomal 
complexes are currently unknown. I therefore affinity purified Pladienolide B stalled 
A complexes to check if their composition or structure was affected. For comparison 
I also purified kinetically stalled A complexes.  
MS2-tagged MINX pre-mRNA was pre-incubated with an excess of MS2-MBP and 
then incubated under splicing conditions either without Pladienolide B or after 
adding 250 nM Pladienolide B (Figure 5.5a). The splicing reaction was loaded onto 
amylose beads and bound complexes were eluted with an excess of maltose (5 mM 
maltose). To separate the A complex from other complexes, the eluted complexes 
were separated by centrifugation on a 5-20% (w/v) sucrose gradient. Complexes in 
the A complex peak (Figure 5.5b) which contained only the MINX pre-mRNA plus 








Figure 4.5 – Purification of human A complexes under kinetically stalled conditions or stalled with 
Pladienolide B. (A) Schematic of purification approach used for complex isolation from large in vitro splicing 
reactions. MS2-tagged MINX pre-mRNA substrate was pre-incubated with MS2-MBP fusion protein and then 
used for in vitro splicing. After splicing, the complexes were affinity-selected using amylose beads and the eluted 
complexes were separated by gradient centrifugation (5-20% (w/v) sucrose). The distribution of splicing 
complexes was detected by Cherenkov counting; peak fractions were pooled and used for further analysis. (B) 
Gradient sedimentation profile after bottom to top fractionation of kinetic and Pladienolide B stalled splicing 
reactions. (C) snRNA distribution across the gradients shown in B. RNA was analyzed by PAGE, visualized by 
SYBR gold and their identities are shown on the left. 
 
4.1.4 Chase experiments with Pladienolide B stalled complexes 
To check if Pladienolide B remains present within the spliceosome during the 
formation of spliceosomal complexes and their subsequent purification a chase 
experiment was performed. In a chase experiment spliceosomal complexes are 
assembled on radiolabeled MINX pre-mRNA in nuclear extract treated with 
Pladienolide B and then the A complexes are isolated using MS2-affinity selection. 
The isolated complexes can be added to nuclear extract to start the splicing process 
from a defined starting point. Initial experiments showed that stalled A complexes 






pre-mRNA (data not shown). However, U2 particles present in the nuclear extract 
could replace the U2 particles containing SF3B bound to Pladienolide B if the stalled 
A complexes dissociate. Thus with this kind of experiment it is impossible to 
distinguish if splicing occurs because Pladienolide B is no longer bound to the 
complex or if there is an exchange of U2 particles in the A complex that re-enables 
splicing. 
4.1.4.1 Depletion of SF3b from nuclear extract 
For chase experiments involving the A complex the reassembly of the A complex 
has to be prevented, in order to determine if Pladienolide B is still present and 
inhibiting splicing. Since our department had an established protocol for the 
depletion of SF3b, a core component of the 17S U2 particle, I chose this approach 
to create a nuclear extract that cannot reform A complexes. Antibodies targeting an 
N-terminal epitope in SF3b1 were used to deplete HeLa S10 nuclear extract of the 
SF3b complex. This creates a nuclear extract without functional 17S U2 particles 
and it is therefore splicing deficient. To test for sufficient SF3B depletion the 
depleted extract was tested in splicing assays and the abundance of SF3b1 protein, 
as a marker for the abundance of SF3b complex, was analyzed by western-blots. 
To control for non-specific effects, mock-depleted extract (treated in the same way 







Figure 4.6 – Immunodepletion of SF3b from HeLa nuclear extract. (A) Scheme of the SF3b depletion 
process. (B) In vitro splicing of 32P-MINX pre-mRNA using different concentrations of mock versus SF3b1 
depleted extract. RNA was analyzed by denaturing PAGE and visualized with a PhosphorImager. The position 
of the splicing intermediates and products plus unspliced pre-mRNA is shown on the right. (NE cntrl = untreated 
nuclear extract). 
Western blot analysis showed that greater than 95% of SF3b1 was removed from 
the nuclear extract (data not shown). The analysis of MINX pre-mRNA splicing 
confirmed that the depletion of SF3b inhibits splicing. A clear reduction in mRNA 
and spliced-out intron, and in the splicing intermediates, was seen in SF3b extract 
compared to the mock-depleted extract at all extract concentrations tested. The 
mock-depletion compared to untreated extract shows that the experimental 
procedure itself causes only moderate reduction in the splicing efficiency of MINX 
pre-mRNA. 
4.1.4.2 Complementation experiments 
To investigate if Pladienolide B remains bound to the SF3b1 protein during A 
complex purification, I affinity purified A complexes stalled by Pladienolide B, or for 
comparison stalled with Anacardic Acid (AA), which disassembles tri-snRNPs but 
does not prevent A complexes from being chased into catalytically active 







Figure 4.7- Pladienolide B stalled A complexes are not chased into active spliceosomes. (A) Scheme of 
the Pladienolide B chase experiment. (B) In vitro splicing of 32P-labled MINX pre-mRNA in untreated nuclear 
extract (NE) or mock-depleted or SF3b nuclear extract after addition of purified A complexes stalled with 250 
nM Pladienolide B (Pladienolide B) or 0.3 mM anacardic acid (AA) as indicated. MINX pre-mRNA (RNA) was 
also added as a negative control. RNA was analyzed by denaturing PAGE and visualized with a 
PhosphorImager. 
The gel in figure 5.7b shows the result of the chase experiment. Pladienolide B 
stalled A complexes can only be chased into splicing active spliceosomes, if they 
are incubated with nuclear extract containing intact 17S U2 particles, as is the case 
when the A complex is added to untreated or mock-depleted nuclear extract (lanes 
2 and 4). If the isolated A complex is added to buffer (lane 1) splicing fails due to the 






added to nuclear extract that has been depleted of SF3b, and therefore of functional 
U2 particles, splicing does not take place (lane 3). In contrast, A complexes stalled 
by addition of AA, which only disrupts the tri-snRNP, can be chased into active 
complexes not only in untreated and mock treated extract, but also in the SF3b 
extract (lanes 7-12). The second control, addition of RNA to the nuclear extracts, 
confirms the previous result that SF3b depleted nuclear extract is not capable of 
efficiently splicing MINX pre-mRNA, while the normal and the mock depleted nuclear 
extract are, again confirming the necessity of functional U2 snRNPs for splicing of 
pre-mRNA. These results indicate that the Pladienolide B compound likely remains 
present within the complex during the purification of the A complex. It also indicates 
that the presence of Pladienolide B within the A complex is sufficient to prevent the 
progression of pre-mRNA splicing. 
4.1.5 Characterization of Pladienolide B stalled A complex 
4.1.5.1 Protein composition of the Pladienolide B stalled A-complex 
I first determined whether the presence of Pladienolide B causes changes in the 
protein composition of the stalled A complex. For this purpose affinity-purified A 
complexes, either kinetically stalled or stalled by Pladienolide B, were investigated 
by LC-MS/MS mass-spectrometry. Mass spectrometry was performed in 















Table 4.1- Proteins identified by LC-MS/MS in kinetic and Pladienolide B stalled human A complexes. 
Total peptide counts for each individual protein is shown for two independent preparations. The proteins are 
gouped according to function or association within the spliceosome. Common contaminants such as ribosomal 
proteins are omitted. 
 
In both A complexes all proteins commonly found at the A complex stage of 
spliceosome assembly could be identified by mass spectrometry, such as the U1 
and U2 snRNP associated proteins, as well as various U2-related and A complex 
associated proteins (Table 5.1). In the case of the kinetic A complex, some proteins 
associated with the U5 snRNP could also be found. These proteins are observed in 
the spliceosome at later stages of splicing, after the recruitment of the tri-snRNP 
complex. The comparison of the kinetic human A complex and the Pladienolide B 
stalled human A complex reveals a similar protein composition for both complexes 
with only minor changes. Two very interesting differences between the kinetic A 
complex and the Pladienolide B stalled A complex are seen. The kinetic A complex 
lacks DDX42 compared to the Pladienolide B treated complex. DDX42 is a RNA-
helicase that normally dissociates upon formation of the mature 17S U2 particle (Will 
and Lührmann, 2002). Another protein that appears to be absent in the Pladienolide 
B treated A complex, is SMNDC1 (SPF30). SMNDC1 is a factor required for the 
kDa
human                         
gene name
kinetic A #1 kinetic A #2 PlaB #1 PlaB #2
kDa
human                         
gene name
kinetic A #1 kinetic A #2 PlaB #1 PlaB #2
Sm proteins U5
B/B' 24,6 SNRPB 7 8 11 9 220K / hPrp8 273,6 PRPF8 32 39
D1 13,3 SNRPD1 3 7 6 6 200K / hBrr2 244,5 SNRNP200 85 69 2 0
D2 13,5 SNRPD2 7 13 14 8 116K / hSnu114 109,4  EFTUD2 24 31 0 2
D3 13,9 SNRPD3 14 24 23 19 102K / hPrp6 106,9 PRPF6 8 14
E 10,8 SNRPE 100K / hPrp28 95,6 DDX23 12 17
F 9,7 SNRPF
G 8,5 SNRPG A/B proteins
RBM39 (RNPC2, CAPER) 58,5 RBM39 2 2 15 37
U1 snRNP
U1-70K 51,6 SNRNP70 4 8 8 14 cap binding complex
U1-A 31,3 SNRPA 2 2 CBP20 18 NCBP2
U1-C 17,4 SNRPC CBP80 91,8 NCBP1 14 35
U1 snRNP associated hnRNP
FBP11 108,8 PRPF40A hnRNP H1 49,2 HNRNPH1 4
S164 (fSAP94) 100,2 RBM25 hnRNP K 51 HNRNPK 2
hnRNP L 64,1 HNRNPL 2
17S U2 snRNP hnRNP M 77,5 HNRNPM 9 0
U2A' 28,4 SNRPA1 16 28 27 26 hnRNP U 90,5 HNRNPU 3 0
U2B'' 25,5 SNRPB2 2 3 1 2
SF3a120 88,9 SF3A1 72 106 98 122
SF3a66 49,3 SF3A2 9 15 13 17
SF3a60 58,9 SF3A3 59 60 73 117
SF3b155 145,8 SF3B1 259 224 284 364
SF3b145 100,2 SF3B2 88 99 123 158
SF3b130 135,6 SF3B3 292 283 314 426
SF3b49 44,4 SF3B4 12 15 14 16
SF3b14a/p14 14,6  SF3B6 6 13 10 16
SF3b14b 12,4 PHF5A 5 4
SF3b10 10,1 SF3B5
17S U2 related
tat SF1 85,9 HTATSF1
hPRP43 90,9 DHX15 6 19 2 21
SPF45 45,0 RBM17
SPF30 26,7  SMNDC1 10 11
U2AF65 53,5 U2AF2 2 3 7 12
U2AF35 27,9 U2AF1 1 1 1 2
SPF31 29,8 DNAJC8 1 0
hPRP5 (DDX46) 117,4 Prp5
SR140 118,3 U2SURP 0 2
CHERP 103,7 CHERP
PUF60 59,9 PUF60
SF3b125 103 DDX42 19 49
A proteins
RBM10 103,5 RBM10 5 5 4 9






docking of the tri-snRNP to the spliceosome (Meister et al., 2001; Rappsilber et al., 
2001) and thus its absence could be significant for the lack of tri-snRNP binding 
seen after Pladienolide B treatment (see discussion). 
4.1.6 Electron microscopic investigations of the Pladienolide B stalled A-complex 
To determine if Pladienolide B affects the structure of the A complex, I set out to 
obtain high resolution structures of the spliceosomal A complex using cryo-electron 
microscopy, in collaboration with Dr. Norbert Rigo in our department. For this 
purpose, I first evaluated different purification conditions for both kinetic and 
Pladienolide B stalled A complexes to optimize yield and stability of the complexes, 
especially since the Pladienolide B stalled complexes are less stable. The 
complexes were assembled in HeLa S10 nuclear extract, and for the stalled 
complex in the presence of 250 nM Pladienolide B, and purified by MS2-selection. 
They were then subjected to gradient centrifugation and fixated using in-gradient 
glutaraldehyde crosslinking (GraFix) (Kastner et al., 2008). After gradient 
centrifugation, the A-complex peak was isolated and buffer-exchanged to reduce 
the sucrose concentration below 0.08% and then analyzed by negative stain EM 
and cyro-EM grids were prepared as well. 
 
Figure 4.8 – Electron microscopy of the Pladienolide B stalled human A complex and of the kinetic 
human A complex. Complexes were formed on MINX-MS2 pre-mRNA in HeLa nuclear extract by MS2 affinity 
selection and then separated on a sucrose gradient (5-20% (w/v)) and cross-linked by GraFix. The peak 
fractions were pooled, buffer-exchanged and adsorbed onto a carbon film support for negative staining. Images 
were acquired in a CM200 microscope at 63000x magnification (A) Overview of raw images of the kinetic or 






Negative stain experiments with isolated human A complexes showed that intact 
particles could be isolated under the chosen conditions and that 2D classes could 
be calculated for both, the Pladienolide B stalled and the kinetic A complex (Figure 
5.8). The A complex images have a maximum dimension of ca. 25nm and appear 
similar to previous A complex images from our lab (Behzadnia et al., 2007). The 
classes look similar for both A complexes, with elongated and more compact 
classes appearing in a roughly 1:1 ratio. Overall the presence of Pladienolide B does 
not cause major structural changes in the A complex, at least not any that would be 
visible in negative stain EM. The calculation of initial 3D models failed for both 
obtained datasets; however the manual selection of only compact classes from the 
Pladienolide B stalled data set led to an initial 3D model of the particle. The prepared 
cryo-grids however, did not allow us to calculate initial 2D classes. This was 
independent of the quenching method and time used or if the gold or carbon grids 
were prepared. Further investigations into the potential reasons for this behavior will 
be conducted in the future. 
4.1.7 Pladienolide B and the cross-exon complex 
In previous work, it was shown that when introns are very long the spliceosome first 
assembles across an exon. In this case, U2 binds to the branch site and U1 to the 
downstream 5’ splice site (Figure 5.9a), forming an A-like complex. The U5.U4/U6 
tri-snRNP can also interact loosely with the A-like complex to form a 37S exon 
complex (Schneider et al., 2010b). This complex can be converted into a stable B-
like complex by adding an oligonucleotide with a 5’SS consensus sequence 
(Schneider et al., 2010b). This dissociates the U1 snRNP and binds to the U6 
snRNA. During these rearrangements the tri-snRNP is stably integrated into the 
complex. As it is not known if Pladienolide B inhibits the assembly of the cross-exon 
complex, I next investigated the effect of Pladienolide B on the assembly of these 
complexes formed on MINX exon RNA in HeLa nuclear extract. The MINX exon 
RNA contains an exon and part of the preceding intron with the BPS plus a 







Figure 4.9- Pladienolide B inhibits the formation of a cross-exon B-like complex. (A) Complex transitions 
between the A-like and the B-like complex. (B) Scheme of the MINX exon RNA. (C) Cross-exon complexes 
were assembled in the presence of different concentrations of Pladienolide B or DMSO. Complex formation was 
analyzed on native agarose gels in the presence of 0.15 µg/µl heparin. Bands were visualized with a 
PhosphorImager and are indicated on the left. None of the tested concentrations had a negative impact on the 
assembly of the cross-exon A-like complex. (D) Cross-exon complexes were allowed to form for 2.5 minutes 
and then the reaction was incubated for an additional 2.5 minutes with or without an 100-fold molar excess of 
5’ splice site oligonucleotide (OL). Complex formation was analyzed on native agarose gels in the presence of 






Native gel electrophoresis of the assembled cross-exon complexes shows that the 
presence of Pladienolide B in the nuclear extract has no impact on the A-like cross-
exon complex formation. At all Pladienolide B concentrations tested the A-like cross 
exon complex forms efficiently in less than 2.5 minutes and remains stable over the 
duration of the experiment (Figure 5.9c). Similar results are seen with the DMSO 
control. Thus, Pladienolide B does not hinder the binding of U2 to the branch site 
region of the exon RNA. Due to the presence of heparin, loosely associated tri-
snRNP does not survive the native gel analysis. 
Exon complexes with loosely associated tri-snRNP can be converted into a B-like 
complex upon addition of a small RNA oligomer that contains a 5’ splice site 
sequence. This transition is characterized by the stable, heparin-resistant binding of 
the tri-snRNP, as described in previous publications (Schneider et al., 2010b). Since 
the Pladienolide B compound prevents the association of the tri-snRNP with cross-
intron A complexes I next investigated if a similar effect is observed for the cross-
exon complexes. To examine if this is the case, cross-exon complexes were 
assembled in the presence of Pladienolide B and then a 100-fold molar excess of 
the 5’SS oligo was added to the reaction, in order to trigger the transition into a 
stable B-like complex. The DMSO control in figure 5.9d shows that the addition of 
the 5’SS oligo after allowing A-like complexes to form for 2.5 minutes, leads to the 
formation of a B-like complex migrating higher than the A-like complex on a native 
agarose gel (Figure 5.9d). Pladienolide B does not affect the formation of the exon 
complex, but addition of the 5’SS oligonucleotide no longer induces the formation of 
a B-like complex. These results are very similar to the observations made in the 
context of the cross-intron A complex. In both cases, Pladienolide B prevents the 











4.2 Cancer associated mutations in SF3b1 
With the emergence of global transcriptomic analysis of cancer patient samples, 
spliceosome associated proteins have been identified as mutational targets in 
multiple different types of cancers (Yoshida and Ogawa, 2014). A number of cancer-
linked mutations have been identified in the U2-associated, SF3b subunit, SF3b1 
(Figure 2.14). The most common ones (i.e. hot-spot mutations) are clustered in the 
HEAT domain of human SF3b1 (Figure 2.14). The K700E mutation is found most 
frequently and is often found in myeloid malignancies (Boultwood et al., 2014; 
Yoshida and Ogawa, 2014). SF3b1 mutations lead to changes in alternative splicing 
patterns and appear to affect branch site selection (see Introduction). SF3b1 
mutations have yet to be found as homozygous mutations in patient samples and 
the generation of homozygous mutated human cell lines in the laboratory setting 
has not been successful. This indicates that a change in both alleles of the SF3b1 
gene is lethal for the effected cell. This circumstance greatly complicates the 
investigation of these mutations, both in vitro and in vivo, since the effects are 
always observed in the presence of the wild-type protein, which might mask or make 
the effects of the mutant protein milder. This makes it necessary to develop 
strategies that can be used to clearly distinguish the effects of the mutated and wild-
type protein in all in vitro experiments. 
4.2.1 Lentivirus experiments to generate mutant SF3b1 cell lines 
During my thesis, I wanted to generate a cell line that expressed a tagged SF3b1 
from an artificial gene that was introduced stably into the host-cell genome. Then I 
could use the affinity-tag to selectively purify my protein of interest or any potential 
complexes that it was a part of. Initially I chose a lentiviral transduction system to 
integrate the artificial gene into the host-cell genome without disrupting the 
endogenous SF3b1 expression. For this a 3 plasmid system was employed to 
produce lentiviral particles, which could infect the target cells. The plasmids used 
were obtained via Addgene (Trono Laboratory) and allowed for stable expression of 
the gene of interest (GOI) under control of a human EF1-alpha promoter. 
4.2.1.1 Initial experiments 
After generating the appropriate expression plasmids (see methods) I wanted to test 






transduction leads to the creation of a stable cell line expressing my gene of interest 
(SF3b1 tagged with C-terminal His tag, or N-terminal SBP-tag and a C-terminal His-
tag). To evaluate this, I created lentiviral particles containing only pWPI-GFP and 
transduced HEK293 and HeLa S3cells. The results of the initial transformation tests 
confirmed that the system of lentiviral transduction is capable of creating cells that 
stably express the gene located on the pWPI vector. The transduction efficiency for 
HEK293 cells was close to 100% under optimized conditions and in the range of 
85% for the transduction of HeLa cells. As soon as the SF3b1 is inserted into the 
pWPI vector the transduction efficiency decreased to 90% for HEK293 cells and 
75% for the harder to transduce HeLa S10 cells. This sudden decrease in the 
transduction efficiency raised the question whether the presence of the SF3b1 gene 
interferes with the expression of the GFP marker present on the vector, or if the 
SF3b1 gene itself cannot be expressed from the vector used. To evaluate this 
question the pWPI-SF3b1 vector was transfected transiently into HEK293 cells and 
the expression of GFP, as well as the GOI expression, was evaluated. The result of 
the transient expression experiments confirm that the pWPI vector containing the 
GOI is, capable of expressing both GFP and the GOI. The transduced cells were 
then sorted based on the presence of GFP expression, which is directly coupled to 
the expression of the GOI. After sorting, the cell population expressing GFP was 
expanded and retested for GOI expression after fixed time intervals. However, the 
expression of tagged SF3b1 could only be confirmed for short periods after 
transduction. Afterwards the sorted population of cells failed to express tagged 
protein, be it tagged wild-type SF3b1 or mutated SF3b1 protein. This loss of 
expression indicates a potential selective disadvantage for artificial SF3b1 
expression, leading to the slow loss of the artificial gene inserted via lentiviral 
transduction. 
4.2.1.2 Large scale transient transfections and SBP-purification 
The establishment of lentiviral transduction protocols also created the alternative 
option of performing large scale transient transfection with the aforementioned 
expression constructs. These expression constructs were then used to transiently 
transfect large amounts of cells with a PEI-based transient transfection method. The 








Figure 4.10 – Tagged SF3b1 purification from transiently transfected HEK293T nuclear extract. HEK293T 
cell derived nuclear containing N- and C-terminally tagged SF3b1 was used to purify SF3b1 using streptavidin 
beads (left) or Talon beads (right). The bound proteins were eluted using biotin for the streptavidin beads and 
with 0.1 M imidazole for the Talon beads. The Input, wash and eluate fractions were then analyzed on western 
blots. The blots were then developed with antibodies targeting the SBP- or the histidine-tag and visualized using 
HRP based chemiluminescence. 
The construct expressing N- and C-terminally tagged SF3b1 (SBP-SF3b1-HIS) did 
lead to the expression of tagged protein. However, the input lane in figure 5.10 
shows that at least some of the tagged protein is cleaved, evidenced by the 
degradation bands appearing on the western blot. Furthermore, the binding 
efficiency to streptavidin beads or Talon beads was very poor as evidenced by 
similar band intensities of the input and column flow-through. The purification of 
tagged SF3b1 using the N-terminal SBP-tag fails to purify full-length protein (a 
truncated version can be eluted). The N-terminal His-tag, however, can be used to 
purify low amounts of the tagged protein. However, significant amounts of unspecific 
contaminants are co-eluted (data not shown). In summary, the tested N- and C-
terminally tagged SF3b1 protein is expressed in human cells, but is not suitable for 
the purification of SF3b1-containing complexes. 
4.2.2 Characterization of K562 cell line 
4.2.2.1 Introduction 
To study the effect of mutations in SF3b1, I instead used a K562 cell line expressing 
a FLAG-tagged version of SF3b1 that was generated during my thesis by the 






using the CRISPR/Cas9 system to trigger a homologous recombination event that 
led to the replacement of one SF3b1 allele with an artificial SF3b1 gene encoding a 
protein with a 6xHIS-FLAG tag at the N-terminal end plus a substitution of lysine 
700 with glutamate (K700E). As a control, a second cell line containing the same 
tag added to the N-terminal end of a wild-type SF3B1 allele was created. 
4.2.2.2 Validation of FLAG-tagged SF3b1 expression 
To validate expression of the target wild-type or mutant SF3b1, nuclear extracts of 
the K562 cell lines were prepared using the small scale nuclear extract protocols 
described in the method section. The nuclear extract of both cell lines was then 
tested for expression of FLAG-tagged proteins by western blot, using antibodies 
specifically recognizing SF3b1 or the FLAG tag. 
 
Figure 4.11 – Both K562 cell lines express FLAG-tagged SF3b1 protein. Western blot of nuclear extract 
obtained from K562 cells. Membranes was incubated in primary antibodies against SF3b1, FLAG-tag and 
SF3b4. Signal was detected by chemiluminescence using HRP-conjugated secondary antibodies. 
As shown in figure 5.11, both cell lines express a FLAG-tagged protein with a size 
of approximately 155kDa and the relative expression of tagged protein is nearly 
identical in the two cell lines. This result confirms that the tagging of SF3b1 was 
successful and that both cell lines express the N-terminally tagged protein. A 
comparison of the western-blot signals, suggests that the ratio of endogenous 






4.2.2.3 Presence of the K700E mutation causes an increased doubling time in K562 
cells 
After confirming that both cell lines express tagged SF3b1, I characterized the cell 
line in more detail. The physical appearance of the K562 cells did not show any 
irregularities as a consequence of the introduction of the K700E mutation; cell size, 
granularity and visual appearance remained identical. To analyze the growth 
characteristics the number of cells generated with both cell lines was determined 
over a period of 72 h, and the average doubling time of both cell lines was calculated 
(Figure 5.12).  






























Figure 4.12 – Determination of the doubling times of K562 cells expressing a FLAG-tagged SF3b1wt or 
SF3b1K700E protein. Cell density was determined by manual counting with six biological and two technical 
replicates for each time point and is plotted as a function of time. 
Interestingly the introduction of the K700E amino acid substitution in SF3b1 cells 
causes an increase in the doubling time by roughly 2 h or 10%, from ~20 h to 22 h. 
Although the doubling-time is increased after the introduction of the mutation, a 
negative effect on population vitality could not be observed. The absence of an 
increased cell mortality could be an indicator that while the presence of the mutation 
decreases the rate of cell growth, it does not cause an increased incidence of 
apoptotic events. The observation that the K700E mutation also has an impact on 







4.2.2.4 Splicing of MINX pre-mRNA in the presence of SF3b1K700E 
I next checked if the K700E mutation had an impact on the efficiency of in vitro 
splicing. To test this radiolabeled MINX pre-mRNA was added to the nuclear extract 
under splicing conditions, and the intermediates and products of the splicing 
reaction were separated on a denaturing polyacrylamide gel. 
 
Figure 4.13 – MINX pre-mRNA splicing in nuclear extract obtained from K562 cells expressing wild-type 
and tagged SF3b1. Splicing reactions were incubated for the indicated times and RNA was isolated and 
analyzed on a 10% PA gel. The positions of the splicing intermediates, products and unspliced pre-mRNA are 






As shown in figure 5.13a MINX-MS2 pre-mRNA is efficiently spliced into mature 
mRNA in both nuclear extracts. However, quantification of the band intensities 
demonstrates that the rate at which the different steps of splicing occurs is different. 
The wild-type nuclear extract splices MINX pre-mRNA faster than the extract 
containing SF3b1K700E. This is evident when comparing the rate of increase in the 
signal for the mature mRNA (Figure 5.13b). The splicing reaction in the wild-type 
nuclear extract reaches a plateau in the amount of mRNA formed after 30 minutes, 
while in the K700E nuclear extract a similar % of mRNA is reached first after 60 
minutes. In addition, the splice reaction containing SF3b1K700E accumulates more 
intron-lariat-3’ exon intermediates at the early time points than the wild-type 
reaction. These results confirm that the nuclear extract obtained from K562 cells is 
capable of splicing MINX pre-mRNA. In addition, the experiments confirm that the 
expression of SF3b1K700E does not substantially inhibit the splicing of MINX pre-
mRNA. However, the quantification of the rate of mRNA formation shows that the 
presence of SF3b1K700E leads to a slowdown of the splicing reaction. 
4.2.2.5 Preparation and characterization of nuclear extract containing SF3b1K700E 
SF3b1 is a major component of the heptameric SF3b complex, which is a major 
subunit of the 17S U2 snRNP. I therefore next checked if the mutated protein affects 
the formation of the 17S U2 particle. To investigate this nuclear extract of both cell 
lines was prepared using the small scale nuclear extract protocol and then 







Figure 4.14 – Sedimentation behavior of U1, U2, U5 and U4/U6 snRNPs in the presence of SF3b1K700E. 
Gradient centrifugation of nuclear extract obtained from K562 cells expressing (A) wild-type SF3b1 or (B) 
SF3b1K700E. Gradients were fractionated by hand from the top. RNA was isolated, separated by PAGE and 
visualized by staining with SYBR gold. The position of the snRNAs is indicated on the right. The abundant small 
RNA directly below U1 is likely 5.8 rRNA. 
The U snRNA distribution in the gradient is nearly identical in both nuclear extracts. 
The U1 snRNP peaks in fractions 11-14, corresponding to the 12S region of the 
gradient. The larger 17S U2 snRNP peaks in fractions 19-21. Most of the U5 and 
U4/U6 snRNPs, which form the tri-snRNP, can be found in the heavy fractions 22-
26 of the gradients. Thus, the SF3b1K700E mutation does not substantially alter the 
distribution of the U2 snRNP. This is an indication that the presence of SF3b1K700E 
does not interfere with the formation of the 17S U2 snRNP to a degree that causes 
a significant change in particle size and/or geometry, since this would lead to a 
change in the sedimentation behavior of 17S U2. 
4.2.3 Isolation and characterization of 17S U2 particles 
A major goal of my studies is to determine what effect cancer related mutations in 
SF3b1 have on the structure and composition of the 17S U2 snRNP. To investigate 
these potential consequences, I isolated 17S U2 snRNPs and compared the 
particles assembled with SF3b1wt with the particles assembled in presence of 






expressed in cells that still contain one allele expressing the wild-type protein. Thus, 
to isolate only the wild-type or mutant U2 snRNPs I performed affinity selection with 
antibodies against the N-terminal FLAG-tag of SF3b1. 
 
Figure 4.15- Isolation of 17S U2 particles via the N-terminal FLAG-tag. (A) Scheme of the experimental 
approach used for the purification of 17S U2 particles from K562 nuclear extract. (B) Protein composition of anti-
FLAG purified complexes in comparison with 17S U2 snRNPs isolated from nuclear extract with an antibody 
against SF3b1. The RNA composition of the eluted complexes is shown in (C). RNA was isolated from the 
indicated anti-FLAG column eluates, separated by PAGE and visualized by SYBRgold staining. 
The 17S U2 purification procedure is summarized in figure 5.15a. Nuclear extract 
from wild-type cells or from cells containing mutated SF3b1 was prepared using 
manual douncing (as described in chapter 4.3.5). The nuclear extract was then 
subjected to glycerol gradient centrifugation. Fractions corresponding to the 17S 
region of the gradient were then pooled, diluted with G-150 buffer and applied to 
beads containing covalently bound anti-FLAG antibodies. Using only the 17S region 
of the gradient ensures that little or no free SF3b complexes or SF3b1 are co-
purified. After extensive washing, complexes were eluted in native form by 
competitive elution with a triple-FLAG peptide. 
The eluted complexes were analyzed for their protein and RNA content. The RNA 






staining, which shows that solely that U2 snRNA is present in the eluates, with no 
contamination of other snRNAs. The protein composition is shown in panel C. The 
FLAG-tagged U2 snRNP contain nearly identical proteins as the purified 
endogenous 17S U2 snRNPs. Importantly, bands corresponding to high molecular 
weight SF3b proteins (SF3b1, SF3b2, SF3b3) and SF3a proteins are clearly visible, 
confirming the presence of 17S U2 snRNPs. 
Thus, the purification approach outlined above is suitable to isolate native 17S U2 
particles containing 6xHIS-FLAG-tagged SF3b1 protein. 
4.2.3.1 Mass-spectrometry confirms the presence of solely SF3b1K700E in the 
purified 17S U2 snRNPs 
I next checked whether the 17S U2 snRNPs purified from the SF3b1K700E K562 
nuclear extract contained exclusively the mutated SF3b1 protein. The substitution 
of the lysine at position 700 with a glutamate changes the fragmentation pattern 
after trypsin digestion (which cleaves after lysines or argenines) of the protein, as is 
shown in figure 5.16a, making the identification of the mutated protein possible. The 
MS-analysis of the SF3b1 protein present in the purified 17S U2 particle shows that 
the peptide obtained only upon K700E substitution is found solely in particles 
isolated from cells expressing the SF3b1 mutant, and that the peptides generated 
by tryptic digestion of the wild-type SF3b1 protein are absent in this sample. This 
confirms that the purification strategy using an N-terminal FLAG tag on SF3b1 is 
capable of selectively isolating 17S U2 snRNPs containing the tagged wild-type or 







Figure 4.16- Fragmentation scheme of SF3b1K700E. The normal digestion pattern after trypsin-digestion is 
shown in (A). The introduction of the K700E amino-acid substitution leads to the removal of a cleavage site and 
changes the fragmentation pattern. (B) The MS-analysis shows that the sample isolated from the nuclear extract 
containing SF3b1K700E contains only peptides associated with the changed fragmentation pattern. Numbers 
shown correspond to the number of peptides sequenced. 
4.2.3.2 MS-analysis of the protein composition of the 17S U2 complex 
To gain detailed information about their exact protein composition, affinity purified 
17S U2 particles containing wild-type SF3b1 and particles containing SF3b1 with 















Table 4.2 - Proteins identified by LC-MS/MS in 17S U2 particles containing wild-type SF3b1 or SF3b1K700E. 
Total peptide counts for each individual protein are shown for two/ three independent preparations. The proteins 
are gouped according to function or association within the spliceosome.  
 
The comparison of the U2 snRNPs containing wild-type and SF3b1K700E showed a 
similar protein composition for both complexes. All major 17S U2 associated 
proteins, including all SF3b and SF3a subunits, could be detected in both complexes 
with apparently similar stoichiometry based on the number of peptides sequenced. 
However, two significant differences are apparent. First, the complex containing 
wild-type SF3b1 appears to contain significantly more hTAT-SF1 protein than the 
17S U2 snRNP containing SF3b1 with the K700E amino acid substitution. Secondly, 
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B/B' 24,6 SNRPB 42 34 40 24 21 19
D1 13,3 SNRPD1 9 11 8 3 3 6
D2 13,5 SNRPD2 26 24 28 15 11 23
D3 13,9 SNRPD3 30 40 29 12 9 16
E 10,8 SNRPE 16 18 13 4 13
F 9,7 SNRPF 7 3 6 5 2 8
G 8,5 SNRPG 5 6 3 3 2
17S U2 snRNP
U2A' 28,4 SNRPA1 67 96 51 39 36 35
U2B'' 25,5 SNRPB2 25 16 20 15 7 12
SF3a120 88,9 SF3A1 142 288 140 78 147 78
SF3a66 49,3 SF3A2 65 27 55 57 17 49
SF3a60 58,9 SF3A3 26 180 19 13 70 15
SF3b155 145,8 SF3B1 333 528 271 198 254 270
SF3b145 100,2 SF3B2 180 293 189 138 177 128
SF3b130 135,6 SF3B3 425 609 483 289 304 255
SF3b49 44,4 SF3B4 16 46 11 3 9 12
SF3b14a/p14 14,6  SF3B6 31 37 30 14 21 18
SF3b14b 12,4 PHF5A 24 18 19 13 12 13
SF3b10 10,1 SF3B5 4 6 10 5 2 8
17S U2 related
tat SF1 85,9 HTATSF1 194 269 177 34 40 30
hPRP43 90,9 DHX15 113 298 114 123 154 148
SPF45 45,0 RBM17 34 80 33 32 47 35
SPF30 26,7  SMNDC1 3 2 1 3 2
U2AF65 53,5 U2AF2 4 36 3 0 10 8
U2AF35 27,9 U2AF1 1 3 2 1 3 2
SPF31 29,8 DNAJC8 7 11 1 4 2 2
hPRP5 / DDX46 117,4 DDX46 175 310 117 0 18 0
SR140 118,3 U2SURP 102 219 87 99 127 112
CHERP 103,7 CHERP 63 160 38 68 100 76
PUF60 59,9 PUF60 6 5
SF3b125 103 DDX42 23
A proteins
RBM10 103,5 RBM10 152 29 40 62
SF1 68,3 SF1 3 6
RBM5/LUCA15 92,2 RBM5 22 34 15 28 40 25






containing SF3B1K700E, while significant amounts of it can be found in the complexes 
containing wild-type SF3b1. These findings are of potential significance, because 
Prp5 is required for A complex formation and the stable recognition of the branch 
point by the 17S U2 snRNP (Will and Lührmann, 2002). 
4.2.3.3 hPrp5 is underrepresented in 17S U2 particles containing SF3b1K700E 
The mass spectrometry data indicated that the presence of SF3b1K700E in the 17S 
U2 particle leads to decreased levels of hPrp5 and hTAT-SF1 being found. To 
validate these data, the abundance of the two proteins was evaluated via western 
blot using polyclonal antibodies against the two proteins of interest, and SF3b4 as 
a loading control. The signal for Prp5 was substantially lower in the SF3b1K700E 
containing particle versus the wild-type tagged SF3b1, confirming the mass 
spectrometry results. A much smaller difference was, however observed for hTAT-
SF1, where quantification of the bands suggested only a 40% drop in signal intensity 
in the K700E versus wild-type particles. 
 
Figure 4.17- Western blot analysis of hPrp5 and hTAT-SF1 levels in purified U2 snRNPs. Purified 17S U2 
snRNPs were analyzed by western blot after PAGE. Membranes were incubated with primary antibodies 
targeting hPrp5, hTAT-SF1 and SF3b4. Bound antibody was detected by chemiluminescence using HRP-
conjugated secondary antibodies. 
4.2.3.4 Cross-linking of 17S U2 particles 
The lower amounts of hPrp5 and hTAT-SF1 observed in the 17S U2 particles 
containing SF3b1K700E could be due to the K700E mutation directly affecting their 
interactions with U2 particles or due to changes in the SF3B1 HEAT domain 
structure. The SF3B1 HEAT domain is a scaffold for the binding of several other 
SF3b proteins (Cretu et al., 2016). Nevertheless, it is not known if human Prp5 and 






therefore carried out protein-protein crosslinking of 17S U2 particles in collaboration 
with Dr. Cindy Will and Dr. Olexandr Dybkov in our department. Large amounts of 
17S U2 were affinity purified from HeLa nuclear extract using anti-peptide antibodies 
against SF3B1 (Will and Lührmann, 2002). After concentrating the purified particles, 
the crosslinking reagent BS3 (bis(sulfosuccinimidyl)suberate), which is an amine-
to-amine crosslinker, reacting with primary amines as found on lysines, was added 
and a titration was performed to find the optimal concentration of BS3 where 
individual particles were still present. In the next step, crosslinked U2 particles were 
centrifuged on a gradient to separate individual crosslinked 17S particles from 
particles crosslinked to each other, which would have a higher S value. Crosslinked 
amino acids were afterwards identified by mass spectrometry.  
 
Figure 4.18 – Cross-linking of 17S U2 snRNPs. 17S U2 particles were affinity purified from HeLa nuclear 






particle. Proteins are shown as nodes on the graph. Only proteins cross-linked hPrp5 or hTAT-SF1 are shown. 
Observed cross-links are shown as lines and high numbers of cross-links are indicated with grey shading. (B) 
Graphical representation of cross-links observed between SF3b1 and hPrp5 or hTAT-SF1. The HEAT-domain 
of SF3b1 is shown in yellow. (FDR = 1%, unfiltered). 
hPrp5 and hTAT-SF1 could be cross-linked to multiple proteins of the 17S U2 
particle (Figure 5.18a). The observed number of cross-links between SF3b1 and 
hPrp5 is especially high. The location of the cross-links found between SF3b1 and 
hPrp5, and between SF3b1 and hTAT-SF1 is shown in figure 5.18b. The cross-links 
between SF3b1 and hTAT-SF1 are mainly found in the N-terminal region of both 
proteins, with no cross-links involving residues of the HEAT-domain of SF3b1. 
hPrp5 and SF3b1 on the other hand form significantly more cross-links. Several 
lysines of SF3b1s N-terminal region could be cross-linked to hPrp5, but there were 
also crosslinks with lysines in the N-terminal HEAT repeats of the protein (but not 
K700). This is consistent with the idea that the K700E mutation might directly affect 
the binding of hPrp5 because it might change the structure of the HEAT domain. 
However, this structural change could also change the binding of proteins like 
SF3b2 and SF3b3 and indirectly alter the binding of hPrp5 or hTAT-SF1. 
4.2.4 Does 17S U2 containing SF3b1K700E function in A complex formation 
I next checked if 17S U2 snRNP containing SF3b1K700E can take part in 
spliceosomal A complex formation. In order to investigate this, I performed splicing 
in K562 nuclear extract containing either FLAG-tagged SF3b1wt or FLAG-tagged 
SF3b1K700E. Afterwards the reaction was applied to a linear glycerol gradient and 
the complexes in the A complex peak were isolated using MS2-affinity selection. 
Equal amounts of the peaks were loaded onto a 4-12% commercial protein gel and 
analyzed by western-blot. The blot was then developed using antibodies against the 
FLAG-tag and against SF3b4 as a loading control. The resulting signal could be 
correlated with the amount of tagged protein present in the A complex, which 







Figure 4.19 – SF3b1K700E is less abundant than SF3b1wt in A complexes assembled on MINX pre-mRNA. 
(A) Gradient centrifugation of A complexes assembled in K562 nuclear extract containing either FLAG-tagged 
SF3b1wt or tagged SF3b1K700E. Gradients were prepared with 10-30% (v/v) glycerol in G150 buffer and 
fractionated top to bottom. (B) Western blot of the pooled and precipitated peak fractions of the gradients. 
Proteins were detected with primary antibodies against the FLAG tag and SF3b4, which was used as loading 
control. (C) Relative abundance of FLAG-tagged SF3b1 in the A complex peaks. 
As shown in figure 5.19a the extract containing a mixture of SF3b1wt and SF3b1K700E 
forms slightly less A complex than the extract containing only wild-type SF3b1 
protein. However, both A complexes contain FLAG-tagged protein as shown by 
western blot with anti-FLAG antibodies, indicating that the K700E mutation in SF3b1 
does not prevent 17S U2 from binding to the MINX pre-mRNA branch point region. 
The quantification of the western-blot (Figure 5.19b) shows that the SF3b1K700E 
protein is less abundant (~75% of the wild-type FLAG-tagged protein) in the purified 
A complex relative to the amount of SF3b4 present, which serves as a loading 






the FLAG-tag does not prevent the wild-type or the mutant U2 particle from binding 
the pre-mRNA. 
These results also show that the 17S U2 containing the SF3b1 K700E mutation 
retains its ability to bind the branch point region of the pre-mRNA. However, the 
reduced occupancy when compared to the tagged wild-type protein suggests that 
the amino acid substitution might have a negative effect on the ability of the 17S U2 
particle containing SF3b1K700E to stably bind to the BPS. This could be a direct effect 
of the mutation on the SF3b1 structure or an indirect effect due to the changed, 
apparently less stable, interaction of Prp5 with 17S U2 containing the K700E 
mutation. 
Initial attempts to purify A complexes containing solely the 17S U2 with mutated 
SF3b1 via anti-FLAG affinity purification allowed only small amounts of A complexes 
to be purified, suggesting that the FLAG-tag was not accessible for antibody binding. 
Purification of A complexes containing the mutation could reveal whether its stability, 
composition or even structure are altered by the K700E mutation. In the future, I will 
also examine if the mutant 17S U2 is incorporated into the spliceosomal B complex. 
This would mean that the A complex containing the mutant supports tri-snRNP 
binding and probably is not structurally or compositionally substantially different from 
the wild-type A complex. 
4.2.5 Investigating the effect of SF3b1 mutations on alternative splice site selection 
in vitro 
As mentioned in the introduction of this chapter, the mutations of SF3b1 in cancer 
patients and in cell lines are associated with a change in the cellular splicing 
patterns. RNAseq analysis of cells affected by the K700E mutation revealed 
significant changes in the 3’SS usage and the emergence of novel cryptic splice 
products. The exact cause for the emergence of cryptic splice products in the 
presence of SF3b1 mutations is currently unknown, but is thought to be due to a 
switch in branch site selection due to the less stable association of U2 containing 
mutated SF3b1 (Darman et al., 2015). Therefore, I wanted to investigate the effect 
of the SF3b1 K700E mutation using the controlled environment of an in vitro splicing 
system. Previous studies have identified certain introns, with which the splicing 






et al., 2017; Darman et al., 2015). In addition, investigation of the K700E mutation 
in an in vitro setting would allow me to separate spliceosomes containing the 
mutation from their wild-type counterparts. Based on this information I designed 
constructs for in vitro splicing experiments. 
4.2.5.1.1 Splicing complex formation on ZDHHC16 pre-mRNA 
ZDHHC16 is one of the genes that has been identified utilize a cryptic 3’SS during 
splicing in the presence of SF3b1K700E (Agrawal et al., 2017; Darman et al., 2015). 
In order to investigate the events leading to the emergence of cryptic splicing, I 
designed an in vitro splicing substrate based on the published mini-gene used for in 
vivo experiments. The artificial ZDHHC16 pre-mRNA contains two exons (exon 9 
and 10) separated by an 860 nt intron derived from the ZDHHC16 intron 9 (Figure 
5.20a). The 5’exon has a length of 58 nt and the 3’exon is 72 nt long. The ZDHHC16 
pre-mRNA contains one 5’ splice site and two branch points and 3’ splice sites. The 
canonical branch point is located 30 nt upstream of the canonical 3’SS. The cryptic 
branch point (green A) is located 34 nt upstream of the intron-3’exon boundary. The 
cryptic 3’SS (3’cSS) can be found 20 nt upstream of the canonical splice site and 
14 nt downstream of the cryptic branch point adenosine. In the ZDHHC16 -30 A>G 
pre-mRNA, the canonical branch point adenosine at position -30 (relative to the 
3’SS) has been changed to a G, which should lead to usage of the cryptic branch 








Figure 4.20 - Schematic representation of the ZDHHC16 pre-mRNA transcript. (A) The stretch spanning 
exon 9, intron 9 and exon 10 of the human ZDHHC16 gene was placed behind a T7 promoter and MS2-loops 
were added to the 3’ end of the transcript. Exons are indicated as colored boxes and the connecting intron is 
depicted as thick black line. Branch point adenosine nucleotides are indicated as “A” (blue for canonical branch 
point and green for cryptic branch point) and the relative location of the 3’ splice sites are indicated by arrows. 
The poly-pyrimidine tract is abbreviated as Yn. All distances between relevant structures of the pre-mRNA 
template are indicated. (B) Exact sequence comparison of the 3’ region of the intron 9 of ZDHHC16. The location 
of the cryptic and canonical BPA is indicated and the 3’ splice sites are underlined. The exon 10 is shown as 
semi-transparent red box. 
The ZDHHC16 construct was then transcribed into radiolabeled RNA and an in vitro 
splicing reaction using HeLa S10 nuclear extract was performed. For initial tests the 
ZDHHC16_wt pre-mRNA was used exclusively, since the RNA containing the A>G 
substitution at the canonical branch point was previously shown to be incompatible 







Figure 4.21- In vitro splicing of the ZDHHC16_wt pre-mRNA. MINX or ZDHHC16 pre-mRNA were incubated 
under splicing conditions using Röder C nuclear extract (A) or Röder D nuclear extract (B). RNA was isolated 
and analyzed on a 4-12% PA gel and visualized by PhosphorImager. The products of MINX splicing are 
indicated on the left. For ZDHHC16_wt only pre-mRNA can be found on the RNA gel. The additional smaller 
band observed with ZDHHC16_wt is most likely the result of RNA degradation. Gradient centrifugation of 
splicing complexes formed on MINX pre-mRNA (C) or ZDHHC16_wt pre-mRNA (D) after 30’, 60’ and 90’ 
incubation at 30°C. 
The results of the splicing tests are presented in figure 5.21. The RNA analysis 
shows that the ZDHHC16_wt pre-mRNA cannot be spliced in HeLa S10 RC or RD 
nuclear extract, while the MINX pre-mRNA is efficiently spliced to mRNA under both 
conditions. The faster migrating band in the ZDHHC16_wt samples is most likely 
the result of RNA degradation and cannot be attributed to splicing because it can 
already be seen at the zero time point. The analysis of splicing complex formation 
by gradient centrifugation shows (Figure 5.21c,d) that, while with MINX pre-mRNA 
a normal gradient profile consisting of A and B/Bact complexes is observed after 30 
minutes, with the ZDHHC16_wt pre-mRNA only one peak is observed in fractions 
11-14. The increased size of the ZDHHC16 pre-mRNA compared to MINX pre-
mRNA (860bp vs 120bp) should result in a shift to heavier gradient fractions. Thus, 
it is not clear what this peak is. To clarify this, I affinity purified complexes formed 






ZDHHC16_wt and ZDHHC16_-30 shows no difference in complex assembly and 
sedimentation behavior on gradients (data not shown).   
4.2.5.1.2 Mass-Spectrometry of the stalled ZDHHC16 A complexes 
Since no splicing of the ZDHHC16 pre-mRNA was observed, but a complex similar 
to the A complex was formed, I next determined the RNA and protein composition 
of this complex, to determine if it is indeed an A complex. For this purpose, I 
assembled complexes on three different pre-mRNAs (MINX, ZDHHC16_wild-type 
and ZDHHC16_-30) in HeLa S10 nuclear extract. Complexes assembled on the pre-
mRNAs were isolated using MS2 affinity selection. Analysis of their RNA 
composition indicates that the complexes formed on ZDHHC16 pre-mRNA are 
indeed A complexes due to the presence of the pre-mRNA and mainly U1 and U2. 
However, with ZDHHC16_-30 there appears to be less U2 present, which may 
indicate that it is less stably bound and lost during affinity purification. The affinity 
purified complexes also seem to contain small amounts of U4 and U5 snRNA, and 
thus could contain some pre-B or B complexes. 
 
Figure 4.22 –RNA (A) and Protein (B) composition of the MS2-selected particles. The MS2-MBP used for 
binding to the MS2-loops and the amylose resin is marked (red arrow). The MS2-tagged pre-mRNA used for 
complex assembly is labeled in the RNA-gel.  
The isolated complexes display major differences when analyzed by SDS-PAGE. 






control. However, two additional bands appear at an approximate size of 110 kDa 
and 37 kDa.  
Table 4.3 - Proteins identified by LC-MS/MS in human A complexes isolated on MINX or ZDHHC16 pre-
mRNA. Total peptide counts for each individual protein is shown. The proteins are gouped according to function 
or association within the spliceosome. Common contaminants such as ribosomal proteins are omitted. 
 
kDa
human                         
gene name hA MINX hA Z16_wt hA Z16_-30
kDa
human                         
gene name hA MINX hA Z16_wt hA Z16_-30
Sm proteins hPRP19/CDC5L related
B/B' 24,6 SNRPB 15 9 8 hSYF1 (XAB2) 100 XAB2 0 16 24
D1 13,3 SNRPD1 8 3 4 KIAA0560 (fSAP164) 171,3 AQR 6 14 11
D2 13,5 SNRPD2 18 6 8
D3 13,9 SNRPD3 18 6 8 A/B proteins
E 10,8 SNRPE 2 2 4 TCERG1 (CA150) 123,9 TCERG1
F 9,7 SNRPF 4 1 2 RBM39 (RNPC2, CAPER) 58,5 RBM39 38 26
G 8,5 SNRPG 1 2 2 TLS/FUS 53,4 FUS 6 4 4
ELAV (HuR) 36,1 ELAVL1 6 14 13
U1 snRNP PPP1CA 37,5 PPP1CA 1 1 2
U1-70K 51,6 SNRNP70 21 14 8 p72/DDX17 80,3 DDX17 16 22 24
U1-A 31,3 SNRPA 16 5 6 DDX9, DHX9 141 DHX9 77 85 82
U1-C 17,4 SNRPC 1 0 0 NFAR 95,4 ILF3 30 25 30
NF45 43,1 ILF2 12 21 14
U1 snRNP associated LOC124245 (NHN1) 106,4 ZC3H18 8 0 0
FBP11 108,8 PRPF40A 7 10 4 ASR2B 100 SRRT 13 10 6
S164 (fSAP94) 100,2 RBM25 14 7 10 p68 (DDX5) 69,2 DDX5 18 26 31
17S U2 snRNP Recruited prior to Bact
U2A' 28,4 SNRPA1 17 12 11 hsp27 22,8 HSPB1 0 2 1
U2B'' 25,5 SNRPB2 6 2 5 SKIV2L2 (KIAA0052, fSAP118) 117,8 SKIV2L2 8 18 19
SF3a120 88,9 SF3A1 46 24 18 Detected in Bact
SF3a66 49,3 SF3A2 5 4 1 p30 DBC (KIAA1967) 102,9 CCAR2 0 22 20
SF3a60 58,9 SF3A3 18 12 8
Detected in C complex
SF3b155 145,8 SF3B1 98 75 53 matrin 3 94,6 MATR3 14 122 96
SF3b145 100,2 SF3B2 42 26 20
SF3b130 135,6 SF3B3 151 91 78 EJC/mRNP
SF3b49 44,4 SF3B4 2 2 2 Acinus (fSAP152) 151,9 ACIN1 17 0 4
SF3b14a/p14 14,6  SF3B6 10 5 6 UAP56 49 DDX39B 29 25 33
SF3b14b 12,4 PHF5A 9 5 4 ELG 70,6 NCBP3 5 3 0
SF3b10 10,1 SF3B5 DDX3 73,2 DDX3X 15 17 15
17S U2 related mRNA binding proteins
tat SF1 85,9 HTATSF1 11 5 2 PABP1 70,7 PABPC1 8 8 9
hPRP43 90,9 DHX15 67 27 31
SPF45 45,0 RBM17 7 5 2 cap binding complex
SPF30 26,7  SMNDC1 2 1 0 CBP80 91,8 NCBP1 18 19 11
U2AF65 53,5 U2AF2 7 6 6
U2AF35 27,9 U2AF1 22 15 23
SPF31 29,8 DNAJC8 5 5 5 SR proteins
hPRP5 (DDX46) 117,4 Prp5 16 15 18 SF2/ASF 27,8 SRSF1 39 18 24
SR140 118,3 U2SURP 12 7 12 9G8 27,4 SRSF7 17 7 12
CHERP 103,7 CHERP 8 5 5 SRp20 19,3 SFRS3 6 5 2
PUF60 59,9 PUF60 32 19 23 SRp30c 25,5 SRSF9 6 1 2
SF3b125 103 DDX42 35 13 11 SRp40 31,3 SFRS5 16 5 2
SRp46 32,3 SRSF8 17 8 4
A proteins SRp55 39,6 SRSF6 31 17 12
THRAP3 (TRAP150) 108,7 THRAP3 13 9 8 SRp75 56,7 SRSF4 11 5 2
BUB3 37,2 BUB3 19 7 11 SC35 25,5 SFRS2 7 4 4
FLJ10839, CCAR1 132,8 CCAR1 39 17 25 SFRS12 59,4 SREK1 13 7 5
RBM10 103,5 RBM10 7 2 0 SRSF11 53,5 SRSF11 5 4 4
SF1 68,3 SF1 12 4 8 hTra-2 beta/SFRS10 33,7 SRSF10 0 3 2
RBM5/LUCA15 92,2 RBM5 14 6 7
SF4 (F23858) 72,5 SUGP1 7 5 0 hnRNP
hnRNP A0 30,9 HNRNPA0 6 15 19
U5 hnRNP A1 38,7 HNRNPA1 34 115 145
220K / hPrp8 273,6 PRPF8 50 19 13 hnRNP A3 39,6 HNRNPA3 8 28 32
200K / hBrr2 244,5 SNRNP200 88 44 25 hnRNP AB 36,2 HNRPAB 7 15 20
116K / hSnu114 109,4  EFTUD2 30 20 18 hnRNP A2/B1 37,4 HNRPA2B1 30 121 134
40K 39,3 SNRNP40 hnRNP C 33,7 HNRNPC 12 6 10
102K / hPrp6 106,9 PRPF6 25 6 6 hnRNP D 38,4 HNRNPD 6 9 25
15K / hDib1 16,8 TXNL4A 3 0 0 hnRNP F 45,7 HNRNPF 10 17 19
100K / hPrp28 95,6 DDX23 30 8 7 hnRNP G 42,3 RBMX 1 7 6
52K / hLin1 37,6 CD2BP2 4 0 0 hnRNP H1 49,2 HNRNPH1 14 30 29
hnRNP H2 49,3 HNRNPH2 10 18 20
U4/U6 hnRNP H3 36,9 HNRNPH3 0 4 6
90K / hPrp3 77,6 PRPF3 8 4 1 hnRNP K 51 HNRNPK 20 52 59
60K / hPrp4 58,5 PRPF4 11 2 0 hnRNP L 64,1 HNRNPL 11 27 27
20K 19,2 PPIH 2 0 0 hnRNP L-like HNRNPLL 0 6 8
61K / hPrp31 55,5 PRPF31 7 4 2 hnRNP M 77,5 HNRNPM 14 9 10
15.5K (NHP2L1) 14,2 SNU13 hnRNP Q 69,6 SYNCRIP 14 30 34
hnRNP R 70,9 HNRNPR 13 13 20
U4/U6.U5 hnRNP U 90,5 HNRNPU 6 36 40
110K / hSnu66 90,3 SART1 15 4 1 hnRNP UL2 (SAF-A2) 85,1 HNRPUL2 5 15 17
65K / hSad1 65,4 USP39 6 1 4 PCBP1 37,5 PCBP1 17 21 30
PCBP2 38,1 PCBP2 9 11 13
B proteins RALY 32,4 RALY 5 0 1
hSmu-1 (fSAP57) 57,5 SMU1 20 4 5 E1B-AP5 95,7 HNRPUL1 5 10 8
RED 65,6 IK 9 2 3
Miscellaneous proteins
hPRP19/CDC5L complex IGF2BP3 (Koc1) 63,7 KOC1 7 7 17
hPRP19 55,2 PRPF19 6 5 2 Luc7-like 2 46,5 LUC7L2 14 5 4
CDC5L 92,2 CDC5L 6 3 2 PTBP1 57,2 PTBP1 5 39 32






Mass spectrometry of isolated spliceosomal complexes shows that with all three 
pre-mRNAs predominantly A complexes were isolated, with minor contaminations 
of B-complex and some Bact associated proteins (Table 5.3). The individual complex 
proteomes show only small differences in the A complex associated proteins, which 
include U1, U2 snRNP proteins. The most significant difference in the mass-
spectrometry data is observed for the matrin-3 protein. The number of peptides for 
matrin-3 in the ZDHHC16 complexes vastly exceed the observed peptide count for 
the MINX pre-mRNA complexes (14 vs. 122/96). The protein CCAR2, a core 
component of the DBIRD complex, is also substantially more abundant in the 
complex formed on ZDHHC16 pre-mRNA. The DBIRD complex binds to RNA 
polymerase II and has been linked to alternative splicing (Close et al., 2012) and 
could be uniquely associated with the ZDHCC16 A complex. Another group of 
proteins where a significant difference can be detected are the hnRNP proteins. 
While the positive splice regulators, the SR proteins, can be found with a similar 
incidence on all three pre-mRNAs, higher peptide counts are seen for the hnRNPs 
for the ZDHHC16 pre-mRNAs. HnRNP A1, A2/B1 and K are much more abundant 
on the ZDHHC16 pre-mRNA and other hnRNP proteins are also found at elevated 
levels.  This may be due to the much longer RNA sequence of the ZDHHC16 pre-
mRNA compared to MINX. Potential differences between Z16_wt and Z16_-30 
include the apparent absence of RBM39 and SF4 (SUGP1). 
4.2.5.2 Cross exon constructs 
After the initial experiments had shown that splicing of the complete ZDHHC16 
construct is not possible under in vitro splicing conditions, I redesigned the 
constructs to be used to study the effects of SF3b1 mutations on BS/ 3’ SS selection. 
The very long intron of ZDHHC16 makes these studies more difficult with cross-
intron splicing complexes. Thus, one goal was to shorten the intron. Another was to 
simplify the analysis of BS/3’SS usage. For this reason, I switched to the cross-exon 
assembly pathway (see above). This enables the removal of most of the intronic 
sequence, since only the immediate surrounding area of the branch site and 3’ SS 
are needed for complex assembly. 
The cross exon RNA constructs were designed by inserting the 3’ end of the 






encompassing 25nt upstream of the cryptic branch point to the canonical 3’SS AG 
dinucleotide was inserted into the similarly defined region of the original MINX exon 
RNA construct, after removing the MINX BS/3’SS nucleotides. Such hybrid 
constructs were not only designed for ZDHHC16, but also for TMEM14C and 
ENOSF1. Like ZDHHC16, TMEM14C intron 1 and ENOSF1 intron 7 have both a 
canonical and a cryptic 3’SS and branch site and in vivo it was shown that after 
mutation of the canonical branch site, splicing required the presence of the mutated 
SF3b1. These mutations theoretically would allow isolation of in vitro complexes 
containing only the mutated protein, even if the nuclear extract contains wild-type 
and mutated protein in a one to one ratio. 
 
Figure 4.23- Comparison of the TMEM14C, ZDHHC16 and ENOSF1 exon RNA constructs. Scheme of the 
MINX exon RNA (A), the TMEM14C/ ZDHHC16/ ENOSF1 exon constructs (B). For the three new variants of 






3’ SS and the cryptic branch point (Xc) as well as the distance between the two 3’ splice sites (Z) is indicated in 
the table Y. (C) Sequence alignment of the relevant areas on the MINX exon construct replaced by gene specific 
sequences. Green indicates the cryptic branch point nucleotides. 
Table 4.4 – Distances between different structural elements in the various exon RNA constructs. 
 X Xc Z 
TMEM14C exon 20 nt 29 nt 14 nt 
ZDHHC16 exon 30 nt 34 nt 21 nt 
ENOSF1 exon 15 nt 29 nt 17 nt 
4.2.5.2.1 Complex assembly on the ZDHHC16, ENOSF1 and TMEM14C cross 
exon constructs 
The various exon RNAs were then used to analyze the initial assembly steps of 
cross exon complex formation. I first checked if the assembly of cross exon 
complexes is possible at all. For this, the RNAs were added to HeLa S10 nuclear 
extract and exon complex assembly was evaluated by native gel electrophoresis. 
 
Figure 4.24 - Native gel electrophoresis of cross exon complexes assembled on different RNAs in HeLa 
nuclear extract. 32P RNAs shown above were incubated in HeLa nuclear extract for the indicated times and, 
after addition of heparin to 0.15µg/µl, separated on a 1.5% agarose gel. Bands were visualized with a 
PhosphorImager and their identity is indicated on the left. The MINX exon RNA was used as a positive control. 
The native gel electrophoresis shows that all exon RNAs are capable of forming 
exon complexes in HeLa nuclear extract (Figure 5.24). However, the efficiency of 
A-like complex formation on the ZDHHC16_wt, ENOSF1_wt and TMEM14C_wt 
RNAs is significantly reduced when compared to the MINX exon construct. In 
addition the gel also reveals that the substitution of the canonical branch point 
adenosine has no impact for ZDHHC16 (Z16_-30), or even a positive one for 
TMEM14C (TMEM14C_-6) on the amount of A-like complex formed. The 






canonical branch point is unexpected. Published results, based on in vivo data, 
show that the removal of the canonical branch point abolishes splicing of the 
affected pre-mRNA in absence of the SF3b1K700E mutation (Darman et al., 2015). 
The substitution of the cryptic branch point (ZDHHC_-33/35) appeared to cause a 
slight decrease in the amount of exon complex formed. These results are 
unexpected, since previously published work could show that the removal of the 
cryptic branch point has no impact on the formation of splice products in vivo in the 
absence of SF3b1K700E (Darman et al., 2015). 
4.2.6 Assembly of cross exon complexes in K562 nuclear extract 
4.2.6.1 Comparison of MINX exon complexes assembled in K562 nuclear extract 
I next wanted to investigate if the presence of SF3b1K700E has an impact on the 
formation of cross exon complexes. To do this, I first analyzed MINX exon 
complexes that were assembled in K562 nuclear extract containing FLAG-tagged 
wild-type SF3b1 or tagged SF3b1K700E. 
 
Figure 4.25 - Native gel electrophoresis of MINX exon complexes assembled in different nuclear extracts. 
32P-MINX exon RNA was incubated in HeLa S10 (S10) nuclear extract and K562 nuclear extract containing only 
wild-type SF3b1 (K562wt) or wild-type and K700E SF3b1 (K562K700E). For the indicated times and, after addition 
of heparin to 0.15µg/µl, separated on an 1.5% agarose gel. Bands were visualized with a PhosphorImager and 
their identity is indicated on the left. 
The analysis of the complex formation shows that the MINX A-like exon complex 
forms in all three nuclear extracts tested. The efficiency of complex formation is 






mutant K562 extract. To investigate if the presence of the SF3b1 mutation leads to 
the assembly of abnormal exon complexes on MINX exon RNA, I isolated MINX 
exon complexes containing only tagged SF3b1 and analyzed the complex by mass-
spectrometry. 
To separate the tagged from untagged complexes, the exon complexes formed on 
MS2-tagged exon RNA were purified by MS2-affinity selection, and then those exon 
complexes containing FLAG-tagged SF3b1 were separated from the remaining 
complexes by anti-FLAG affinity chromatography. The purification of MINX exon 
complexes using the aforementioned double-affinity purification approach allowed 
the purification of only very small amounts of A-like exon complex (<100 fmol from 
a 10 ml reaction) which equals ~1% of the input RNA. However, the total yield of the 
purification was very low for both nuclear extracts used, indicating limited availability 





















Table 4.5- Proteins identified by LC-MS/MS in human A-like exon complexes assembled on MINX pre-
mRNA and isolated from different K562 nuclear extracts. Total peptide counts for each individual protein 
are shown. The proteins are gouped according to function or association within the spliceosome. Common 
contaminants such as ribosomal proteins are omitted. 
 
The evaluation of the MS results for the MINX exon complexes assembled in the 
SF3b1wt and SF3b1K700E K562 nuclear extract shows that both complexes have a 
similar protein composition (Table 5.5). The amount of tri-snRNP associated 
proteins present in the exon complexes formed in the SF3b1K700E extract versus the 
SF3b1wt containing extract appears generally lower, suggesting less tri-snRNP 
association. One other interesting protein that is less abundant, based on the 
number of peptides sequenced, in the exon complexes assembled in SF3b1K700E 
extract is DDX17, an RNA helicase shown to be involved in the process of splice 
site selection (Dardenne et al., 2014). Taken together these results suggest, that 
while the presence of SF3b1K700E does not cause major changes in the proteome of 
kDa
human                         
gene name WT-NE K700E-NE
kDa
human                         
gene name WT-NE K700E-NE
Sm proteins U5
B/B' 24,6 SNRPB 17 14 220K / hPrp8 273,6 PRPF8 26 15
D1 13,3 SNRPD1 0 2 200K / hBrr2 244,5 SNRNP200 20 25
D2 13,5 SNRPD2 8 13 116K / hSnu114 109,4  EFTUD2 35 11
D3 13,9 SNRPD3 10 8 102K / hPrp6 106,9 PRPF6 25 6
E 10,8 SNRPE 7 4 100K / hPrp28 95,6 DDX23 11 6
U1 snRNP U4/U6
U1-70K 51,6 SNRNP70 17 19 90K / hPrp3 77,6 PRPF3 16 5
U1-A 31,3 SNRPA 4 4 60K / hPrp4 58,5 PRPF4 13 6
U1-C 17,4 SNRPC 1 0 20K 19,2 PPIH 0 1
U1 snRNP associated U4/U6.U5
FBP11 108,8 PRPF40A 28 25 110K / hSnu66 90,3 SART1 26 5
S164 (fSAP94) 100,2 RBM25 8 9 65K / hSad1 65,4 USP39 4 3
17S U2 snRNP B proteins
U2A' 28,4 SNRPA1 20 10 hSmu-1 (fSAP57) 57,5 SMU1 16 12
U2B'' 25,5 SNRPB2 6 4 RED 65,6 IK 4 2
SF3a120 88,9 SF3A1 64 27 hPRP19/CDC5L complex
SF3a66 49,3 SF3A2 4 4 CCAP1 (hsp73) 70,4 HSPA8 26 23
SF3a60 58,9 SF3A3 34 22
A/B proteins
SF3b155 145,8 SF3B1 68 67 RBM39 (RNPC2, CAPER) 58,5 RBM39 34 35
SF3b145 100,2 SF3B2 42 35 p72/DDX17 80,3 DDX17 14 0
SF3b130 135,6 SF3B3 104 70 DDX9, DHX9 141 DHX9 11 6
SF3b49 44,4 SF3B4 11 11 p68 (DDX5) 69,2 DDX5 16 11
SF3b14a/p14 14,6  SF3B6 0 5
SF3b14b 12,4 PHF5A 0 4 SR proteins
SF3b10 10,1 SF3B5 SF2/ASF 27,8 SRSF1 26 33
9G8 27,4 SRSF7 16 12
17S U2 related SRp20 19,3 SFRS3 4 0
tat SF1 85,9 HTATSF1 0 0 SC35 25,5 SFRS2 1 3
hPRP43 90,9 DHX15 7 15 SRSF11 53,5 SRSF11 6 5
SPF45 45,0 RBM17 1 2
SPF30 26,7  SMNDC1 5 4 SR related proteins
U2AF65 53,5 U2AF2 25 20 SRm300 300 SRRM2 11 17
U2AF35 27,9 U2AF1 6 5
SPF31 29,8 DNAJC8 4 9 hnRNP
hPRP5 (DDX46) 117,4 Prp5 28 43 hnRNP A0 30,9 HNRNPA0 2 2
SR140 118,3 U2SURP 2 5 hnRNP A1 38,7 HNRNPA1 18 17
CHERP 103,7 CHERP 1 2 hnRNP A3 39,6 HNRNPA3 4 6
PUF60 59,9 PUF60 26 27 hnRNP AB 36,2 HNRPAB 0 1
SF3b125 103 DDX42 12 4 hnRNP A2/B1 37,4 HNRPA2B1 18 16
hnRNP C 33,7 HNRNPC 4 5
A proteins hnRNP D 38,4 HNRNPD 1 2
THRAP3 (TRAP150) 108,7 THRAP3 hnRNP H1 49,2 HNRNPH1 1 0
BUB3 37,2 BUB3 29 26 hnRNP K 51 HNRNPK 1 3
FLJ10839, CCAR1 132,8 CCAR1 0 0 hnRNP L 64,1 HNRNPL 0 1
RBM10 103,5 RBM10 13 0 hnRNP U 90,5 HNRNPU 2 3
SF1 68,3 SF1 11 11 PCBP1 37,5 PCBP1 22 23
RBM5/LUCA15 92,2 RBM5 0 0
ZNF207 50,8 ZNF207 19 13 Miscellaneous proteins
SF4 (F23858) 72,5 SUGP1 1 1 Luc7-like 2 46,5 LUC7L2 4 3






the exon complex minor it could potentially affect the association and binding of 
auxiliary factors that could play a role in the splice site selection during the assembly 
of the spliceosome. However, additional experiments are needed to show that these 
factors are reproducibly affected. 
4.2.6.2 Formation of ZDHHC16, ENOSF1 and TMEM14C exon complexes in K562 
nuclear extract 
After showing that the K562 nuclear extract supports cross exon complex formation 
on the MINX exon RNA, I next tested for complex formation in K562 nuclear extract 
with ZDHHC16. ENOSF1 and TMEM14C exon RNAs, including versions where 
either the canonical or the cryptic branch point adenosines was mutated. As shown 
in figure 5.26, formation of an A-like complex was detected after 2.5 minutes in the 
wild-type and mutant K562 extract with the MINX exon RNA, but was much less 







Figure 4.26 - Native gel electrophoresis of cross exon complexes assembled on different RNAs. 32P RNAs 
shown above were incubated in K562 nuclear extract, either wild-type (A) or containing SF3b1K700E (B), for the 
indicated times. After addition of heparin to 0.15µg/µl, complexes were separated on a 1.5% agarose gel. Bands 
were visualized with a PhosphorImager and their identity is indicated on the left. The MINX exon RNA was used 
as a positive control. 
The native gel electrophoresis of cross exon complexes assembled in K562 nuclear 
extract obtained from cell lines expressing only wild-type SF3b1 (Figure 5.26a) or 
wild-type and SF3b1K700E (Figure 5.26b) shows that the general efficiency of 
complex assembly decreased when compared to complex formation in HeLa S10 
nuclear extract (compare with figure 5.24). The overall decrease in complex 
formation is even more pronounced in the extract containing mutated SF3b1 than it 
is in the wild-type K562 nuclear extract. For the three RNAs of interest, complex 
assembly does occur, but with a very low efficiency. The most efficient complex 
assembly occurs on TMEM14C_wt and TMEM14C_-6. This observation is in line 
with the previous result that in HeLa nuclear extract TMEM14C derived RNAs 
showed the largest amount of complex formation. This experiment shows that the 
presence of SF3b1K700E in the nuclear extract impairs the formation of spliceosomal 
complexes in general. 
 
4.2.7 TMEM14C complexes assembled in HeLa S10 nuclear extract 
Due to the extremely low efficiency of complex assembly in K562 nuclear extract, I 
initially used HeLa cell nuclear extract to investigate the differences between 
complexes assembled on the different branch point mutations.  The TMEM14C RNA 
was used as a substrate, because the complex assembly appeared to be slightly 
more efficient than with the ZDHHC16 and ENOSF1 RNA substrates. Analysis of 
complex formation on native agarose gels showed that the RNA substrate 
containing a mutation of the cryptic branch point adenosine (T14_-17) displays a 
decreased level of complex assembly when compared to the other to substrates, 
i.e. wild-type (T14_wt) and mutated canonical branch point (T14_-6) (Figure 5.27a). 
This result was unexpected, since the cryptic branch point of TMEM14C should be 
irrelevant for splicing in nuclear extract containing only wild-type SF3b1. In order to 
further investigate potential reasons for the decreased complex assembly, I isolated 






Five milliliter splice reactions were performed in the presence of 1nM radiolabeled 
exon RNA. Afterwards the assembled complexes were purified using MS2-selection 
and then separated by gradient centrifugation. The gradient peaks were then 
analyzed for their RNA content by SYBR gold staining and the protein composition 
was evaluated by MS. 
 
Figure 4.27- Assembly of A-like exon complexes using TMEM14 variants in HeLa S10 nuclear extract. (A) 
32P RNAs shown above were incubated in HeLa nuclear extract for the indicated times and, after addition of 
heparin to 0.15µg/µl, separated on a 1.5% agarose gel. Bands were visualized with a PhosphorImager and their 
identity is indicated on the left. (B) MS2-purified complexes were analyzed on a 10-30% (v/v) glycerol gradients 
prepared with 75mM KCl. Gradients were fractionated by hand and CPM values were determined by Cherenkow 
counting. (C) RNA composition of purified cross-exon A-like complexes. 
The gradient centrifugation confirms the previous result from the native gel. That is, 
the substitution of the canonical branch point causes a smaller decrease in the 
amount of exon complex assembly than the substitution of the cryptic branch point 
nucleotide (Figure 5.27b). On the level of snRNA, no difference can be found. All 
purified cross exon complexes contained roughly equimolar amounts of U1 and U2 
snRNA (Figure 5.27c). The RNA composition and the position in the gradient both 
indicate that the complex formed is indeed a cross exon A-like complex. The peak 








Table 4.6 - Proteins identified by LC-MS/MS in A-like exon complexes isolated on different TMEM14C 
RNA constructs from HeLa nuclear extract. Total peptide counts for each individual protein is shown. The 
proteins are gouped according to function or association within the spliceosome. Common contaminants such 
as ribosomal proteins are omitted. 
 
The MS analysis of the three isolated TMEM14C exon complexes shows only minor 
differences between the three complexes. All three complexes contain the U1 
snRNP and U2 snRNP associated proteins, which one would expect to find in a 
cross-exon A-like complex. The only apparent differences are the absence of SF1, 
DDX9 and several additional A complex proteins in the exon complex assembled 
on the RNA containing a mutated cryptic branch point (T14_-17). However due to 
the low peptide counts, in some cases it is not clear if there is a difference in the 
amount of a certain protein present. 
4.2.8 Transition of MINX exon complexes into B-like complexes in the presence of 
SF3b1K700E 
Next, I wanted to investigate if the presence of SF3b1K700E has a negative impact 
on the ability of the exon complexes to transition into a B-like complex. For this, I 
performed complex assembly with the MINX exon RNA in K562-derived nuclear 
extracts containing either only SF3b1wt or SF3b1wt and SF3b1K700E. Formation of the 
A-like and B-like complexes was evaluated using native gel electrophoresis. After 
kDa
human                         
gene name T14_wt T14-6 T14_-17
kDa
human                         
gene name T14_wt T14-6 T14_-17
Sm proteins A proteins
B/B' 24,6 SNRPB 8 14 6 BUB3 37,2 BUB3 8 11 3
D1 13,3 SNRPD1 2 1 2 SF1 68,3 SF1 15 21 0
D2 13,5 SNRPD2 5 10 3 RBM5/LUCA15 92,2 RBM5 2 3 0
D3 13,9 SNRPD3 5 6 3 ZNF207 50,8 ZNF207 5 9 2
E 10,8 SNRPE 0 1 3 SF4 (F23858) 72,5 SUGP1 3 6 2
U1 snRNP U5
U1-70K 51,6 SNRNP70 7 9 5 200K / hBrr2 244,5 SNRNP200 5 2 5
U1-A 31,3 SNRPA 5 3 6
U1-C 17,4 SNRPC 1 0 0 hPRP19/CDC5L complex
CCAP1 (hsp73) 70,4 HSPA8 9 20 32
U1 snRNP associated
FBP11 108,8 PRPF40A 14 23 7 A/B proteins
S164 (fSAP94) 100,2 RBM25 10 10 9 RBM39 (RNPC2, CAPER) 58,5 RBM39 11 18 10
p72/DDX17 80,3 DDX17 0 0 3
17S U2 snRNP DDX9, DHX9 141 DHX9 8 16 0
U2A' 28,4 SNRPA1 6 7 10 NFAR 95,4 ILF3 2 1 0
U2B'' 25,5 SNRPB2 5 6 0 p68 (DDX5) 69,2 DDX5 5 6 0
SF3a120 88,9 SF3A1 16 26 17 SR proteins
SF3a66 49,3 SF3A2 4 5 0 SF2/ASF 27,8 SRSF1 17 21 11
SF3a60 58,9 SF3A3 11 11 6 9G8 27,4 SRSF7 8 5 0
SC35 25,5 SFRS2 2 1 0
SF3b155 145,8 SF3B1 39 51 25 SRSF11 53,5 SRSF11 2 0 0
SF3b145 100,2 SF3B2 17 30 13
SF3b130 135,6 SF3B3 53 69 46 SR related proteins
SF3b49 44,4 SF3B4 3 10 2 SRm300 300 SRRM2 13 15 14
SF3b14a/p14 14,6  SF3B6 5 9 10
SF3b14b 12,4 PHF5A 1 2 3 hnRNP
SF3b10 10,1 SF3B5 hnRNP A0 30,9 HNRNPA0 2 1 0
hnRNP A1 38,7 HNRNPA1 5 10 2
17S U2 related hnRNP AB 36,2 HNRPAB 0 1 0
tat SF1 85,9 HTATSF1 5 8 0 hnRNP A2/B1 37,4 HNRPA2B1 5 8 16
hPRP43 90,9 DHX15 5 5 2 hnRNP D 38,4 HNRNPD 0 1 0
SPF45 45,0 RBM17 2 0 0 hnRNP K 51 HNRNPK 1 0 0
SPF30 26,7  SMNDC1 1 1 0 hnRNP Q 69,6 SYNCRIP 0 1 0
U2AF65 53,5 U2AF2 7 10 3 hnRNP R 70,9 HNRNPR 2 1 0
U2AF35 27,9 U2AF1 3 5 3 hnRNP U 90,5 HNRNPU 2 2 2
SPF31 29,8 DNAJC8 7 6 2
hPRP5 (DDX46) 117,4 Prp5 20 43 22 Miscellaneous proteins
SR140 118,3 U2SURP 3 1 0 Luc7-like 2 46,5 LUC7L2 4 7 0
CHERP 103,7 CHERP 3 2 0
PUF60 59,9 PUF60 20 20 11






allowing A-like complexes to form, I added the 5’ SS oligonucleotide to investigate 
if the transition from the A-like complex into a B-like complex is hindered. For this, 
a 100-fold molar excess of 5’SS oligonucleotide over the radiolabeled MINX exon 
RNA was added to the reaction after 5 minutes and incubated at 30°C for an 
additional 5 minutes. 
 
Figure 4.28- A-like to B-like transition of MINX exon complexes after oligo treatment. Exon complexes 
were assembled in three different nuclear extracts and incubated for the time indicated above the gel. Lanes 
labeled with “OL” were treated with the 5’ splice site oligonucleotide. Assembled complexes were visualized 
using PhosphorImager screens and their identity is indicated on the left side. 
The assembly of cross exon A-like complexes is observed in all nuclear extracts that 
were tested (Figure 5.28). After addition of a 5’SS oligonucleotide the formation of 
a B-like complex can be observed in all three nuclear extracts. The transition to the 
B-like complex occurs with a similar efficiency in both K562 derived nuclear extracts. 
The HeLa S10 control extract shows a higher amount of A-like complex formation 
and subsequently also an increased total amount of B-like complex. However, the 
relative amount of exon B-like complex formed remains similar independent of the 
nuclear extract used. This suggests that the K700E mutation does not inhibit tri-
snRNP recruitment. However, it is presently not clear whether the A-like complexes 
generated contain substantial amounts of the mutant SF3b1 protein. In the future, 






complexes formed, will give insight into whether the SF3b1K700E protein is 
abundantly present within the complex. 
4.2.9 Consequences of the K700E mutation on the proteome of the K562 cell 
In parallel to the investigation of direct impacts of the SF3b1 amino acid substitution 
on the splicing of specific pre-mRNAs I also wanted to check, if the mutation leads 
to changes in the proteome of the cell. Several studies could show that SF3b1 and 
its misregulation leads to widespread changes within the cell, that affect multiple, 
not directly splicing related, processes. In order to evaluate changes in the proteome 
of the K562 cells expressing the mutated protein, TMT-labeling experiments were 
performed in cooperation with Dr. Kuan-Ting Pan in the department of Bioanalytical 
Mass Spectrometry at our Institute. The samples used for the analysis were labeled 
with isobaric molecules and quantitatively analyzed by mass spectrometry. 
A comparison of the cells containing the SF3b1K700E with the wild-type K562 cells 
revealed quantitative differences in the amounts of many proteins. The presence of 
SF3b1K700E affects the expression of over 2000 proteins that are involved in a variety 
of cellular processes (Figure 5.29). 
 
Figure 4.29 – Expression of multiple proteins changes as a result of SF3b1K700E expression. Many proteins 
are up or downregulated in their abundance as a direct or indirect consequence of SF3b1K700E expression. 
Significantly changed proteins were grouped according to their biological function.  
Amongst others, notable changes were seen in the down-regulation of some 
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tri-snRNP associated protein USP39. The amount of USP39 detected in the 
SF3b1K700E cells is reduced by approximately 50%. The second most down 
regulated protein is the alternative splicing factor TRA2B (-45%). Several other 
spliceosome associated proteins are also found among those proteins 
downregulated in the cells expressing mutated SF3b1 in addition to the wild-type 
isoform. These include GPKOW (-40%), SUGP2 (-35%), SF3A2 (-30%) and 
U2SURP (-25%). Splicing associated proteins were also upregulated, including 
CLNS1A (+70%), RBM10 (+50%), AQR (+35%) as well as the hnRNPs A1 and UL1 
(+47% and +41%). Taken together the proteome analysis showed widespread 
changes in the cellular proteome as a consequence of the amino acid substitution 
in SF3b1, including changes in the levels of multiple splicing and splicing regulation 
associated proteins. However, most changes were moderate and might reflect the 



















5.1 Pladienolide B stalled A complexes 
Pladienolide B is a natural small molecule macrolide compound that inhibits cancer 
cell growth and stalls splicing by binding to SF3b1 (Kotake et al., 2007). The binding 
of Pladienolide B is thought to block the HEAT domain of SF3b1 in an open 
conformation and prevents the correct binding of the branch point adenosine (Cretu 
et al., 2018). Pladienolide B and the bound branch point adenosine appears to 
compete for accommodation by the same region of the SF3b1 protein. In the current 
model, if the branch point adenosine is bound correctly, the HEAT domain switches 
to a closed conformation, stabilizing the formed U2/branch point helix during A 
complex formation (Cretu et al., 2018). However, the exact mechanism by which 
Pladienolide B stalls the splicing of pre-mRNA still remains to be elucidated.  
5.1.1 Pladienolide B blocks docking of the tri-snRNP to the spliceosomal A 
complex 
The interactions of Pladienolide B with the HEAT domain of SF3b1 were proposed 
to arrest the protein in an open conformation  (Cretu et al., 2018) and thereby might 
interfere with the stable interaction between U2 and the branch point sequence. In 
a first set of experiments, I set out to dissect the consequences that Pladienolide B 
has on the composition and structure of the spliceosome. To do so, I initially 
investigated at which stage the presence of Pladienolide B stalls the spliceosome 
assembly by analyzing cross-intron spliceosome complexes. First, using native 
agarose gel electrophoresis I checked at which stage the spliceosome assembly is 
stalled in the presence of different Pladienolide B concentrations and also how 
stable the formed complexes are by performing a heparin titration. Heparin disrupts 
weak and non-specific interactions between proteins in a concentration-dependent 
manner. At a Pladienolide B concentration of 250nM splicing catalysis was inhibited 
completely and only A complexes were detected on native agarose gels. This 
observation is consistent with previous investigations of the influence of Pladienolide 
B on splicing (Effenberger et al., 2014b; Kotake et al., 2007). By performing a 
heparin titration, I could show that the A complex formed in the presence of 
Pladienolide B is less stable compared to the wild-type A complex. The A complex 






the uninhibited A complex remains stable up to a heparin concentration of 0.6 µg/µl. 
The decreased stability of Pladienolide B stalled A complexes could indicate 
destabilizing effect of Pladienolide B on the U2/BPS interaction. This could directly 
affect splice site selection processes, by favoring strong branch point sequences 
over weaker ones, leading to changes in cellular splicing patterns in the presence 
of the inhibitor. This idea is supported by in vivo observations, which show that 
Pladienolide B modulates pre-mRNA splicing rather than inhibiting it completely. 
The resulting changes in the alternative splicing patterns, in particular those 
affecting cell proliferation, could also explain its anti-tumor activity (Effenberger et 
al., 2014a). 
When the assembly of spliceosomal complexes in the presence and absence of 
Pladienolide B was analyzed by gradient centrifugation, a less stringent method to 
evaluate complex formation, I could show that the presence of Pladienolide B 
prevents even the initial docking of the tri-snRNP. This means that the presence of 
Pladienolide B prevents the formation of a pre-B complex, where the tri-snRNP is 
only loosely bound (Boesler et al., 2016). Similar observations were made when I 
evaluated the influence of Pladienolide B on the formation of cross exon complexes. 
The A-like cross exon complex is formed even in the presence of high 
concentrations of Pladienolide B (250 nM), but it could not be converted into a B-
like cross exon complex with the tri-snRNP stably bound. Thus, like other SF3b1 
inhibitors, including SSA and the pladienolide B derivate E7107, splicing is inhibited 
at a very early assembly stage, after U2 binding. The initial docking of the tri-snRNP 
during formation of the pre-B complex involves the formation of the U2/U6 helix II 
(Boesler et al., 2016), which consists of base pairing between the 5’ end of U2 and 
3’ end of U6. The recent cryo-EM structures of the human pre-B complex show that 
the main interface between U2 and the tri-snRNP forms via interactions between 
SF3b and the U6 LSm-ring at the very end of U6 and the U4 Sm-ring (Charenton et 
al., 2019; Zhan et al., 2018). During the B complex formation, SF3b proteins, 
especially SF3b3, also play an important role in the bridging of U2 and U5. If now 
the SF3b1 protein, which is a scaffolding protein upon which most other SF3b 
proteins and various other spliceosomal proteins bind, is prevented from obtaining 
its correct structure due to the binding of Pladienolide B, then this could prevent the 






5.1.2 Pladienolide B remains bound to SF3b1 throughout A complex formation 
Even though Pladienolide B stalled A complexes were less stable, it was still 
possible to purify them using the established MS2 affinity purification of the AG 
Lührmann. To evaluate if Pladienolide B remains present in the spliceosomal 
complexes throughout the MS2 purification procedure I performed chase 
experiments with SF3b depleted nuclear extracts. The results of these experiments 
were consistent with the idea that Pladienolide B remains bound within the formed 
A complexes, since purified A complexes assembled in the presence of Pladienolide 
B remained inhibited after adding nuclear extract lacking the inhibitor, if reassembly 
of spliceosomes was prevented. However, it could also be that the presence of 
Pladienolide B in the early stages irreversibly damages the building blocks of the A 
complex making progression of splicing impossible even if Pladienolide B itself is 
not present anymore. Thus, the observations made in the chase experiments do not 
definitively prove that Pladienolide B remains present in the spliceosomal A 
complex. To confirm these experiments with radiolabeled or fluorescence labeled 
Pladienolide B would have to be conducted.  
5.1.3 Changes in the protein composition of purified Pladienolide B stalled A 
complexes 
Mass spectrometry of the wild-type and the Pladienolide B stalled A complexes 
showed that the presence of Pladienolide B does not affect the abundance of 
proteins associated with the stable binding of the U2 snRNP to the branch point 
region, such as the SF3a and SF3b complexes. This observation is consistent with 
the data indicating that the presence of Pladienolide B does not impair the formation 
of the 17S U2 particle itself, which means the U2 particles are not dissociated upon 
addition of the inhibitor. If Pladienolide B had an effect during the formation of the 
17S U2 particle itself, one would expect the formation of the A complex to be 
inhibited as well, which is not the case. Previous studies showed that the 
Pladienolide derivative E7107, also had no effect on the protein composition of the 
17S U2 snRNP (Folco et al., 2011). Unexpectedly, hPrp5, which is important for the 
stable U2 binding during A complex formation (see below), was not detected in the 
wild-type A complexes; normally, low amounts of hPrp5 are detected (see for 
example table 5.1- MINX vs. ZDHHC16 A complex) in the A complex. hPrp5 was 






in the wild-type complexes either, it remains unclear whether it is specifically absent 
in the Pladienolide B A complexes or was just not detected in this particular 
experiment. Experiments with other inhibitors stalling spliceosome assembly at the 
stage of an A complex, such as the previously mentioned E7107, did not cause a 
reduction in the amount of hPrp5 detected in the 17S U2 snRNP (Folco et al., 2011).  
On the other hand, mass spectrometry revealed for the first time that there are 
differences in certain proteins associated with the wild-type versus Pladienolide B A 
complexes. One intriguing difference is the accumulation of DDX42 (SF3b125) in 
Pladienolide B stalled A complexes. DDX42 is a DEAD-box, ATP-dependent RNA 
helicase, with a currently unclear role in pre-mRNA splicing. It is found in submolar 
amounts in purified SF3b but very little is found in purified 17S U2 particles (Will and 
Lührmann, 2002) and it is normally also not found in the human A complex 
(Agafonov et al., 2011). While the exact function of DDX42 in the process of splicing 
remains unclear, it was originally proposed to play a role in the formation of the 17S 
U2 snRNP (Will and Lührmann, 2002). DDX42 has been shown to be involved in 
both the unwinding of double-stranded RNA and also the annealing of single 
stranded RNA molecules, even if the involved RNA molecules are partially 
obstructed by RNA binding proteins (Uhlmann-Schiffler, 2006). In addition DDX42 
was recently implicated to be involved in the process of apoptosis (Sohn and Chay, 
2019) and was also proposed as a cellular sensor for double stranded RNA 
molecules (Lin et al., 2008).  
The presence of DDX42 in the stalled A complex could indicate that certain 
maturation steps or conformational changes that under normal circumstances lead 
to the loss of DDX42 prior to the formation of the A complex do not occur in the 
presence of Pladienolide B. Although the binding of Pladienolide B was shown not 
to change the three dimensional structure of the SF3b complex (Cretu et al., 2016), 
it is possible that its binding prevents subsequent structural changes, during the 
formation of the 17S U2 particle or the A complex from occurring and that these 
normally lead to the release of DDX42. In the future, it will be interesting to see if 
17S U2 particles purified in the presence of Pladienolide B bind more DDX42 than 
particles isolated in the absence of Pladienolide B. In summary, the accumulation 






inhibitor related impairment of the DDX42 release, but it can only be speculated if 
the persistence of the helicase has any functional implications for the spliceosome 
itself, or if it is just a side effect of the stalling brought about by the presence of 
Pladienolide B. 
A second interesting difference between the two analyzed A complexes is the 
absence of SPF30 in the Pladienolide B stalled A complex. SPF30 is a Tudor-
domain containing protein and is essential for the formation of B complexes – 
Immunodepletion of SPF30 shows stalling of spliceosome assembly at the stage of 
an A complex, meaning that it is required for the integration of the tri-snRNP into the 
complex (Meister et al., 2001; Rappsilber et al., 2001). SPF30 is present in the 17S 
U2 snRNP (Rappsilber et al., 2001; Will et al., 2001) and also interacts with hPrp3 
(a U4/U6 and tri-snRNP associated protein) (Little and Jurica, 2008; Meister et al., 
2001). This means the SPF30 protein most likely bridges the U2 snRNP and the tri-
snRNP in the spliceosome and thereby helps the latter to be recruited to the A 
complex. While SPF30 is found in the A complex and small amounts can still be 
detected in the pre-B complex, it is no longer present in the spliceosomal B complex 
(Agafonov et al., 2011; Boesler et al., 2016). This would indicate that SPF30 aids in 
the recruitment of the tri-snRNP but is then released upon binding and stable 
integration. One currently unanswered question is if the presence of Pladienolide B 
leads to the dissociation of SPF30 from the 17S U2 particle already, or if this takes 
place only during A complex formation.  
Not only Pladienolide B, but also many other natural inhibitors of splicing stall the 
assembly of complexes at the stage of an A complex (Effenberger et al., 2017). 
While little is known about the protein composition of the complexes that assemble 
in the presence of Spliceostatin A, E7107 and other SF3b1 inhibitors (Corrionero et 
al., 2011; Folco et al., 2011), all of these compounds appear to interfere with the 
recruitment and integration of the tri-snRNP. In the future it would be interesting to 
compare the protein composition of A complexes stalled with different compounds, 
because if the changes observed are similar, it would indicate a common 






5.1.4 Pladienolide B and the structure of the human A complex 
Pladienolide B binds to SF3b1 and could prevent structural changes in the protein, 
which are required for the stabilization of the U2/ BPS interactions. Currently it is 
assumed that the stable integration of the U2 particle that has to occur during the 
transition from the E to the A complex, revolves around the proposed clamping 
mechanism of the SF3b1 HEAT domain. However, due to the absence of a 
published high resolution structure of the human A complex and thus the poor 
resolution of the U2 snRNP, and SF3b1 in particular, this proposed mechanism has 
yet to be confirmed. Very recently, a cryo-EM structure of the yeast A complex was 
published (Plaschka et al., 2018); however, the resolution in the region of the U2 
snRNP was limited to 6-10 Å and so the precise structure of the SF3b1 HEAT 
domain was unclear. However, the high resolution structure of the Bact complex 
shows that the HEAT domain adopts a closed conformation, compared to the 
structure in the SF3b complex (Cretu et al., 2018). The HEAT domain forms a 
superhelical solenoid structure and the U2/ BPS helix is clamped between its N- and 
C-terminal HEAT repeat (Haselbach et al., 2018; Zhan et al., 2018). Although the 
resolution is not as high as in Bact, the SF3b1 HEAT domain seems to adopt a closed 
conformation in the human B complex as well (Bertram et al., 2017a; Zhan et al., 
2018). 
One aim of my work was therefore to perform a structural analysis of the human A 
complex in the presence and absence of Pladienolide B. I chose to perform cryo-
EM with the hope to obtain structures of the A complex at a resolution that would 
allow me to see conformational changes due to the presence of Pladienolide B. For 
this, the standard MS2-purification protocol of the department was optimized for the 
purification of A complexes. During these investigations, multiple salt concentrations 
were tested for both initial spliceosome assembly conditions, as well as for the 
subsequent gradient centrifugations. Interestingly, neither changes in the salt 
concentration of the reaction (65 mM KCl to 37.5 mM KCl) nor changes in the salt 
concentration used during the subsequent gradient centrifugation (150 mM to 37.5 
mM KCl) affected the ability of the nuclear extract to form A complexes, nor did it 
change the protein composition of the purified complex (data not shown). The salt 
conditions did change the sedimentation pattern of the complex, with lower salt 






in the sedimentation value would indicate a changed complex morphology. 
However, the analysis of the purified spliceosomes by negative stain EM, revealed 
massive aggregation of the individual spliceosomes. The aggregated spliceosomes 
themselves were not visibly changed from the entities purified at higher salt 
concentrations. Using different quenching conditions after cross-linking particles 
with glutaraldehyde also did not improve the EM images. All of our cryo-EM 
preparations, however, failed to produce datasets that yielded usable 2D classes. 
The failure to obtain datasets that ultimately produce a three dimensional structure 
of the human A complex can be due to various reasons. One possible explanation 
are errors in the sample preparations that, while not visible on the biochemical level, 
might destroy the particle prior to data acquisition. Initial experiments could show 
that the A complex is a fairly sensitive complex and that incorrect blotting conditions 
lead to a flattened particle that does not yield 2D classes. Alternatively it is possible 
that the A complex itself is a highly flexible particle that naturally exists in many 
different conformations at the same time. In this case, much larger data sets would 
be required to compute a three dimensional structure of sufficient quality. As an 
alternative to cryo-EM, biochemical methods might in the future also reveal 
structural differences between the wild-type and the Pladienolide B stalled A 
complex. For example, cross-liking studies could give further insight into potential 
changes in the interactome of the complexes due to the presence of the inhibitor. 
 
5.2 Cancer related mutations of SF3b1 
The cancer-linked hotspot mutations found in SF3b1 predominantly cluster within 
the HEAT domain of the protein with most found in HEAT repeats 2-9 (Bonnal et al., 
2012), SF3b1 amino acids mutated in cancer cells are important for the tertiary 
structure of SF3b1 (Cretu et al., 2016); thus these mutations have been proposed 
to alter the structure of the HEAT domain. The SF3b1 HEAT domain is a crucial 
interaction platform within the SF3b subcomplex and the larger 17S U2 snRNP 
(Cretu et al., 2016). For example, PHF5A contacts the concave surface of the HEAT 
domain both at the N- and C-terminus of the superhelix and it together with SF3b1 
forms the binding pocket for the BPS adenosine. Given that mutations of SF3b1 are 






et al., 2015), I wanted to investigate the consequences of these mutations on the 
structure and function of the 17S U2 snRNP. To do so, I focused on the K700E 
amino acid substitution, which is the one of the most common cancer-linked 
mutations found in SF3b1 (Yoshida and Ogawa, 2014). The K700 amino acid is 
located in HEAT repeat seven, in close proximity to where the pre-mRNA emerges 
from the inner area of the HEAT domain (Kastner et al., 2019). In addition the HEAT 
repeat seven is a part of the interaction surface between SF3b1 and U2AF65 (Cretu 
et al., 2016).  
Multiple models have been proposed to explain the changes in splice site selection 
observed upon emergence of the K700E mutation; they are largely based on the 
transcriptomic data obtained from patients and in vivo experiments. One possible 
mechanism is based on the observation that the mutation of the K700E amino acid 
is located right at the “hinge” between two HEAT-repeats of SF3b1. This substitution 
could lead to a change in the three-dimensional structure of the protein, forcing it 
into a more open conformation, as compared to the wild-type SF3b1. This open 
conformation could impair SF3b1 interactions with the canonical branch sites on the 
pre-mRNA and instead promote the recognition of the cryptic branch site, which on 
average has a slightly higher affinity for the U2 snRNA than its canonical 
counterpart. Alternatively, the presence of the mutation could change the positioning 
of the pre-mRNA within the spliceosome thus changing its interaction with the 
spliceosomal components. Here the spliceosome assembly on cryptic splice sites is 
possible in the presence of the mutation, whereas in case of the wild-type SF3b1 
protein steric obstacles prevent the assembly of splicing-competent spliceosomes. 
The discussed theories provide possible explanations for the mechanism of action 
of SF3b1 mutations; however, because the currently available data represents only 
endpoint observations, the actual changes in splicing leading to the K700E-
connected phenotypes still remain to be elucidated. 
5.2.1 The SF3b1 K700E mutation alters the composition of the 17S U2 snRNP 
A better understanding of how cancer-related mutations affect the normal function 
of SF3b and the U2 snRNP is important for improving our understanding of the onset 
of MDS and cancer. It may also be useful for developing better therapeutic 






K562 cell line expressing SF3b1K700E from one allele. The nuclear extract obtained 
from this cell line was active in splicing and contained wild-type amounts of 17S U2 
particles suggesting that the presence of mutated SF3b1 protein does not interfere 
with the formation of 17S U2 particles. The sedimentation behavior on a sucrose or 
glycerol gradient was unchanged. This suggests that the incorporation of the 
mutation into the 17S U2 particle does not cause major compositional or structural 
changes in the U2. After confirming that the 17S U2 snRNPs forms normally, I 
affinity purified particles containing the wild-type or mutated SF3b1 via the N-
terminal FLAG tag of SF3b1. The purification of FLAG-tagged 17S U2 particles was 
efficient (~80% of the bound particles) and mass spectrometry could confirm that 
the particle was not contaminated with significant amounts of untagged particles. In 
addition, the mass spectrometry analysis revealed that the majority of the U2-
associated proteins are equally abundant in the wild-type and K700E particles. All 
commonly found proteins, such as the SF3a and SF3b proteins as well as others, 
like SPF45, hPrp43, SPF30 and U2 SURP, were found in equal amounts based on 
the number of peptides sequenced. Only two proteins were less abundant in the 
mutant 17S U2 snRNPs, hPrp5 and hTAT-SF1. A substantial reduction in hPrp5 and 
only a moderate reduction in hTAT-SF1 was also confirmed by western-blotting. 
hTAT-SF1 is a transcription elongation factor that is also involved in pre-mRNA 
splicing (Miller et al., 2011). RNAi knockdown of hTAT-SF1 changes alternative 
splicing patterns, but the mechanism by which splicing is affected is not clear. In 
humans hTAT-SF1 interacts with the 17S U2 snRNP (Will and Lührmann, 2002). A 
recent study showed that it interacts with the ULM motives of SF3b1 in its N-terminal 
region (Loerch et al., 2019). This is consistent with my protein-protein crosslinking 
studies and indicates that the reduced association of hTAT-SF1 is not a direct effect 
of a change in the structure of the HEAT domain due to the SF3b1 mutation. In 
yeast, the hTAT-SF1 homolog Cus2 plays an important role in determining the 
structure of the U2 snRNA, which can have competing conformations, and has been 
implicated in the surveillance of U2 structure (Perriman and Ares, 2000). 
Mutagenesis and genetic depletion studies indicate that ATP hydrolysis by Prp5 is 
needed to displace Cus2 and thereby ensure the proper U2 structure for stable 






U2 snRNP was only mildly affected and it is not clear if this change has a functional 
consequence for the U2/BPS interaction when SF3b1 is mutated. 
Prp5 is an ATP-dependent DEAD-box RNA helicase, essential for splicing of pre-
mRNAs in both human and yeast spliceosomes. For the human Prp5 (DDX46) 
protein very little is known, but it is necessary for the stable integration of the BPS 
helix and the formation of the spliceosomal A complex and (Will and Lührmann, 
2002). The exact function of Prp5 in the splicing process in higher eukaryotes is 
currently unknown. Knock-down experiments in human cell lines could show that 
the reduction of Prp5 abundance causes a nearly complete cell cycle arrest and the 
depletion of Prp5 from nuclear extracts stalls pre-mRNA splicing in vitro (Will and 
Lührmann, 2002). Early studies in yeast indicate that Prp5 facilitates structural 
changes in U2 needed for the stable binding to the BPS. The absence of hPrp5 in 
the purified 17S U2 particles could be explained by a change in its interaction, either 
due to the binding of hPrp5 being less stable or completely prohibited. Both 
mechanisms would point towards structural changes as an underlying reason for 
the observed phenotype. Currently, it is not known exactly where hPrp5 binds to the 
human 17S U2 snRNP. My cross-linking experiments indicate that hPrp5 might 
contact multiple proteins within the particle, although the presence of cross-links 
only indicates physical proximity and not necessarily direct protein-protein contacts. 
Experiments performed in yeast showed that yPrp5 binds to the HEAT domains 1-
6 and 9-12 (Tang et al., 2016). This observation most likely translates to the human 
17S U2 particle because the cross-links between human SF3b1 and hPrp5 were 
found in similar regions. However, the yeast Prp5 protein lacks an N-terminal RS-
domain found in humans, and thus the human protein might form additional 
interaction networks not identified in yeast. Nonetheless, the reduced binding of 
hPrp5 to the 17S U2 snRNP could result from changes in the conformation of the 
HEAT domain due to the K700E mutation. This can be due to both direct hPrp5-
SF3b1 interactions or also indirectly through other protein-protein interactions 






5.2.2 Mechanisms whereby reduced Prp5 binding due to SF3b1 mutations can 
affect BPS selection 
Studies with the yeast Prp5 (yPrp5) gave further insight into the function of Prp5 
during spliceosome assembly and potential mechanisms for the selection of cryptic 
splice sites after mutations in the protein. Interestingly, the presence of the SF3b1 
myelodysplastic syndrome associated mutations in yeast spliceosomes also leads 
to the emergence of splicing on cryptic branch point sequences, without causing 
splicing of divergent 5’ or 3’ splice sites (Carrocci et al., 2017). 
The observations made in yeast mirror some of the observations I could make in the 
human system. The introduction of the cancer associated mutations in the 
homologous residues of the S. cerevisiae SF3b1 protein (denoted Hsh155) leads to 
reduced interactions between yPrp5 and ySF3b1 (Carrocci et al., 2017; Tang et al., 
2016). Currently, there is no known mechanism how the presence of these 
mutations leads to the emergence of cryptic splicing, however, multiple models 
exist.  
One model connecting the reduced interactions between SF3b1 and Prp5 with the 
usage of cryptic branch sites, explains the influence of the mutations on branch point 
usage by separating the actions of Prp5 and SF3b1 during spliceosome assembly. 
In this model, the mutations of SF3b1 decrease the stability of the interaction with 
the consensus branch site sequences, while Prp5 acts during a second proofreading 
step at later stages (Carrocci et al., 2017). This Prp5 independent mechanism 
mainly relies on structural changes in SF3b1 and resulting less stable binding of U2 
as the cause for the changes in the selection of the branch site (Carrocci et al., 
2017). Prp5 catalyzes a conformational change in U2 that allows stable U2 binding. 
The reduced interaction with Prp5 could hinder this structural change. Another 
function of Prp5 in the spliceosome is the bridging of the U1 and the U2 particle 
during the formation of early spliceosomal complexes (Shao et al., 2012; Xu et al., 
2004). U1 binding has been shown to stabilize the U2/BPS interaction. Potentially 
the reduced interactions between SF3b1 and Prp5 would also destabilize the 
interaction of U2 during A complex assembly by disrupting the bridge to the U1 






An alternative proposed mechanism describes the selection of cryptic splice sites 
as a consequence of altered proof-reading of the initial branch site selection due to 
the changed interaction between ySF3b1 and yPrp5 (Tang et al., 2016). In this 
model, the fidelity of for the branch point selection is directly proportional to the 
strength of the ySF3b1-yPrp5 interaction. Studies could also show that the 
dissociation speed and ATPase activity of the helicase directly correlates with the 
“quality” of the BPS used, with better branch point sequences, causing faster 
dissociation of yPrp5. If the U2/BPS interaction passes the quality control step, 
yPrp5 would dissociate and thereby allow the association of the tri-snRNP particle 
and progression of splicing (Tang et al., 2016). This would mean that the impaired 
interaction between ySF3b1 containing the MDS associated mutations and yPrp5 
would lead to a reduced rate of U2/ BPS interaction, and conversion to the B 
complex. Thus, the slowed reaction would increase the time for finding cryptic splice 
sites (Carrocci et al., 2017; Tang et al., 2016). This observation is in line with the 
observations made in vivo in human cells expressing the MDS mutations of SF3b1 
that the branch points used in the presence of the cancer related mutations of SF3b1 
are not the preferred BPS used in the absence of SF3b1 mutations. The cryptic 
apparently are not optimal although they often have a higher complementary to the 
U2 snRNA (Darman et al., 2015).  
My experiments demonstrate that the presence of the K700E mutation does 
negatively affects the interaction between SF3b1 and Prp5 in the human U2 snRNP. 
In addition, previous studies of the consequences of the mutations on the 
transcriptome of the affected cells showed that the mutations lead to the utilization 
of cryptic branch sites (Darman et al., 2015). However, the branch point sequences 
used in human spliceosomes are very degenerate compared to the yeast consensus 
sequence. This means that proofreading of the correct U2 RNA-BPS interactions by 
Prp5 may be absent in higher eukaryotes. Nonetheless, Prp5 may control for correct 
RNA-protein interactions. However, a change in proof reading is unlikely to be the 
only factor causing the selection of cryptic splice sites.  
Future experiments, which will require substantial upscaling of K562 nuclear extract 
preparation, will be targeted at understanding how the consequences of the K700E 






mRNA splicing. A first goal would be to perform cryo-EM to resolve the three 
dimensional structure of both the wild-type and the K700E U2 snRNP at a high 
enough resolution to see the consequences of the amino acid substitution on the 
three-dimensional structure. However, it has been difficult to date to generate a high 
resolution 17S U2 structure, due to conformational flexibility. An alternative to this 
approach would be the cross-linking of proteins in the wild-type and SF3b1K700E 17S 
U2 snRNP and a detailed comparison of the cross-links to identify potential 
differences. Secondly, to gain further insight into the function of U2 containing the 
SF3b1K700E mutation, it will be interesting to see how in vitro splicing is affected using 
U2-depleted nuclear extract. It will also be of great importance to investigate in vitro 
which factors exactly impact the selection of branch points in the human system. 
However, because the K700E mutation also affects the Prp5 interaction with U2, it 
may be difficult to separate effects caused by Prp5 and those directly due to the 
SF3b1K700E mutation. 
5.2.3 Pre-mRNA splicing and splicing complex formation in the presence of 
SF3b1K700E 
The expression of SF3b1K700E causes widespread changes in the splicing of pre-
mRNA in the cell (Darman et al., 2015). To investigate the consequences of this 
mutation, I investigated the in vitro splicing pre-mRNAs that are alternatively spliced 
in vivo using nuclear extracts obtained from a SF3b1K700E expressing K562 cell line. 
These pre-mRNAs, which were used as mini-genes for in vivo studies included 
ZDHHC16, ENOSF1 and TMEM14C (Darman et al., 2015). Unfortunately, the 
tested pre-mRNAs failed to splice under in vitro conditions; only formation of an A 
complex was observed in HeLa nuclear extract. Interestingly, no significant changes 
in the proteins commonly found in the A complex formed on MINX pre-mRNA where 
detected with the alternatively spliced pre-mRNA constructs. Only lower amounts of 
tri-snRNP associated proteins were found. This indicates that while normal 
formation of an A complex appears to take place; the transition towards later 
spliceosomal complexes (pre-B/ B complex) is impaired on the tested pre-mRNA 
constructs. Interestingly two other proteins, not directly associated with the A 
complex, show a significant difference between the MINX pre-mRNA control and 






are significantly more abundant in A complexes formed on ZDHHC16 and 
ZDHHC16_-30 pre-mRNA than on MINX. 
Matrin-3 is a nuclear matrix protein that binds RNA (Castello et al., 2012; Uemura 
et al., 2017). It is a known regulator of alternative splicing and interacts with multiple 
splicing factors; however its exact function in the splicing process remains poorly 
understood (Coelho et al., 2015). CCAR2 is a component of the DBIRD-complex, 
which binds to RNA polymerase II and has been linked to alternative splicing and 
pre-mRNA transcription regulation (Close et al., 2012). In addition to these two 
proteins, the ZDHHC16 pre-mRNAs also bind more hnRNPs than the MINX pre-
mRNA, while the amount of SR-proteins recruited remains at a similar level. The 
former is likely the result of the much longer RNA sequence of the ZDHHC16 versus 
MINX pre-mRNA (312 nt vs. 1073 nt). 
It is not clear why the spliceosome assembly on the ZDHHC16 pre-mRNA stalls at 
the A complex stage under in vitro conditions. The in vitro system could lack 
essential factors required for later assembly steps and for the splicing of these 
specific constructs. Although an A complex forms it is not clear if it is functionally 
competent for subsequent splicing steps. Long introns are typically poorly spliced in 
HeLa nuclear extract and may reflect the need for cross-exon assembly instead of 
cross-intron assembly.  
5.2.4 Cross-exon complex formation in the presence of SF3b1K700E 
To circumvent this problem, I thus switched to investigating cross-exon complexes 
on the alternatively spliced pre-mRNAs. All genes have a long intron preceding the 
cryptic 3’ splice site, making the cross-exon assembly the most likely path of 
spliceosome assembly in vivo. It is important to note, that on average, the cryptic 
branch point sequence is stronger (have a more complementarity to the U2 snRNA) 
compared to the canonical sequence (Deboever et al., 2015). 
The investigation of A-like exon complex assembly revealed multiple interesting 
observations. First, the presence of SF3b1K700E does not appear to interfere with the 
formation of A-like cross exon complexes on MINX exon RNA. Second, the 
constructs designed with the 3’ end of introns containing cryptic splice sites, form 






observation held true independent of the nuclear extract used. Mutation of canonical 
branch point adenosines did not appear to impact the formation of the cross-exon A 
complexes indicating that alternative or cryptic branch sites are used instead. The 
observation that mutations of single nucleotides within the branch point sequence 
do not interfere with the assembly of early cross-intron spliceosomal complexes has 
been made before (Reed and Maniatis, 1988), but it is interesting to observe that 
cross-exon complexes also still assemble. In some cases, the mutation of the 
canonical branch point even appears to increase the amount of complex formed. 
This would suggest that the binding of U2 to the cryptic site is more stable or that 
simultaneous binding to both sites may interfere with or destabilize U2 snRNP 
binding.  
Studies in vivo assaying for splicing and alternative 3’ splice site usage of the 
ZDHHC16, ENOSF1 and TMEM14C introns that I investigated here, showed that 
mutation of the canonical branch site inhibited splicing. However, splicing and the 
utilization of a cryptic BS and 3’SS was observed if the cells expressed a mutated 
SF3b1 protein (Darman et al., 2015). Thus, one reason for using version of these 
pre-mRNAs or exon RNAs with a mutated canonical or cryptic branch site was to 
specifically purify splicing complexes containing solely the SF3b1K700E. Cross-exon 
A-like formation in vitro was not dependent on the presence of SF3b1K700E when the 
canonical BPS was mutated. This discrepancy with the in vivo results with 
ZDHHC16, ENOSF1 and TMEM14C substrates indicates that the cross-exon 
complex form on the cryptic BPS even when SF3b1K700E is absent. 
Complex assembly most likely takes place on both potential branch point 
sequences; independent of the presence of SF3b1K700E, and the actual selection of 
the 3’ SS must therefore take place at a later stage. One way to explain this would 
be that both the canonical and the cryptic splice site fulfill the requirements for the 
initial association of the U2 snRNP, but then at a later stage the A complex formed 
on the cryptic splice site fails to convert into a later spliceosomal complex, perhaps 
because Prp5 proof-reading leads to the discard of these complexes or simply 






5.2.5 Future studies 
One aim of my studies was to determine if the presence of the SF3b1K700E mutant 
affects the structure and composition of early splicing complexes. Immunoblotting 
of MS2-affinity purified cross-intron A complexes formed in K562 nuclear extract 
containing both wild-type and mutated SF3b1 showed that the tagged, mutant 
protein is indeed present in the assembled A complexes. Future studies will involve 
scaling up the production of the K562 nuclear wild-type and mutant cells to generate 
large amounts of nuclear extract. This will potentially allow the purification of 
sufficient amounts of both 17S U2 snRNPs and splicing complexes containing either 
the wild-type or solely the mutant SF3b1 protein. Initial attempts at using the N-
terminal FLAG-tag of SF3b1 for the purification of spliceosomal components have 
shown that while the efficient purification of the 17S U2 particle is possible, the yield 
of purified A complex is significantly lower. This makes the upscaling of the reactions 
used for affinity purifications absolutely required to investigate the function of 
SF3b1K700E in later spliceosomal complexes. Similar studies, including protein-
protein and RNA-protein cross-linking and mass spectrometry analysis, can 
potentially be performed with the cross-exon complex formed on the various exon 
RNAs with cryptic 3’ SS and branch point sequences, although it is not presently 
clear if sufficient amounts of the FLAG-tagged wild-type or mutated SF3b1 is 
present in the A-like exon complexes. These studies could provide novel insights 
into the effects of the cancer-related mutations in SF3b1 on SF3b function and may 
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2D two dimensional 
32P radioactive isotope of phosphorus 
3D three dimensional 
3'SS 3 prime splice site 




AA anacardic acid  
AML acute myeloid leukemia 
APS ammonium persulfate 
ATP adenosine tri-phosphate 
BBP branch point binding protein 
bp base pair/ base pairs 
BP branch point 
BPA branch point adenosine 
BPS branch point sequence 
C cytosine 
CMML chronic myelomonocytic leukemia 
cntrl control 
Da Dalton 
ddH2O bidistilled water 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA desoxyribonucleic acid 
DTE dithioerythritol 
DTT dithiothreitol 
E.coli Escherichia coli 
ECL enhanced chemiluminescence 
EDTA ethylenediaminetetraacetic acid 
EJC exon junction complex 
EM electron microscopy 
ENOSF1 Enolase Superfamily Member 1 
ESE exonic splice enhancers 




HEK293T Human embryonic kidney 293 cells  






hnRNP heterogeneous ribonucleoprotein particle 
IMEM Improved Minimum Essential Medium 
ISE intronic splice silencers 
ISS intronic splice enhancers 
kDa kilodalton 
l liter 
LB lysogeny broth 
LDS lithium dodecylsulfate 
M molar 





mRNA messenger RNA 
MS2-MBP  MS2 loop binding - maltose binding protein fusion protein 
NaOAc sodium acetate 
NE nuclear extract 
nM nanomolar 
nm  nanometer 
nt nucleotide 
OD optical density 
PA poly acrylamide 
PAGE poly acrylamide gel electrophoresis 
PCI Phenol-Chloroform-Isoamyl extraction 
PCI Phenol-Chloroform-Isoamyl alcohol  
PEI polyethyleneimine 
PK proteinase K 
PlaB Pladienolide B 
pre-mRNA  premature messenger RNA 
pY poly pyrmidine 
RC Röder C buffer 
rcf relative centrifugal force 
RD Röder D buffer 
RNA ribonucleic acid 
RNP ribonucleoprotein particle 
rpm rounds per minute 
RT room temperature 
SDS sodium dodecyl sulfate 
snRNA small nuclear RNA 
snRNP small nuclear ribonucleoprotein 
SOC Super Optimal broth with Catabolite repression 
T thymine 
TEAB triethylammonium bicarbonate 
TEMED tetramethylethylenediamine 






TMT tandem mass tag 
Tris Tris-(hydroxymethyl)aminomethane  
U uracil 
V volt 
v/v volume per volume 
w/v weight per volume 
Y pyrimidine nucleotide 
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